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Chemical Carcinogens: A Review of the
Science and Its Associated Principles
By the U.S. Interagency Staff Group on Carcinogens*
In order to articulate a view ofchemical carcinogenesis that scientists generally hold in common today
and to draw upon this understanding to compose guiding principles that can be used as a bases for the
efforts ofthe regulatory agencies toestablish guidelines forassessingcarcinogenic risktomeetthe specific
requirements of the legislative acts they are charged to implement, the Office of Science and Technology
Policy, Executive Office, the White House drew on the expertise of a number of regulatory agencies to
elucidate present scientific views in critical areas ofthe major disciplines important to the process ofrisk
assessment.
The document is composed of two major sections, Principles and the State-of-the-Science. The latter
consists of subsections on the mechanisms of carcinogenesis, short-term and long-term testing, and epi-
demiology, which are important components in the risk assessment step of hazard identification. These
subsections are followed by one on exposure assessment, and a final section which includes analyses of
dose-response (hazard) assessment and risk characterization.
The principles are derived from considerations in each of the subsections. Because of present gaps in
understanding, the principles contain judgmental (science policy) decisions on major unresolved issues
as well as statements of what is generally accepted as fact. These judgments are basically assumptions
which are responsible for much ofthe uncertainty in the process ofrisk assessment. There was an attempt
to clearly distinguish policy and fact. The subsections of the State-of-the-Science portion provide the
underlying support to the principles articulated, and to read the "Principles" section without a full
appreciation of the State-of-the-Science section is to invite oversimplification and misinterpretation.
Finally, suggestions are made for future research efforts which will improve the process of risk as-
sessment.
Introduction understanding, the principles contain judgmental (sci-
Background
Over the years, agencies and programs have been
established to deal with hazardous substances, with re-
cent focus on the deleterious long-term effects, such as
cancer. Adetailed analysis oflegislative acts concerning
toxic substances (Table 1) reveals an evolution of
thought, in that each reflects the scientific views that
existed at the time of enactment. Consequently, these
acts are not uniform in their view of disease, the role
chemical substances might play in its incidence, and
what ought to be done about potential toxic substances
and potential carcinogens.
Purpose of This Report
The purpose of this document is to articulate a view
ofchemical carcinogenesis that scientists generally hold
in common today and to draw upon this understanding
to compose, as was done here by senior scientists from
a number of federal agencies, a series of general prin-
ciples that can be used to establish guidelines for as-
sessing carcinogenic risk. Because of present gaps in
ence policy) decisions on unresolved issues as well as
statements ofwhat is generally accepted as fact. There
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Donald Barnes, Office of Pesticides and Toxic Substances, Environ-
mental Protection Agency; Margaret Chu, Carcinogen Assessment
Group, Office of Research and Development, Environmental Protec-
tion Agency; Colin Church, Health Sciences, Consumer Product
Safety Commission; W. GaryFlamm, Office ofToxicological Sciences,
CenterforFoodSafetyandAppliedNutrition, FoodandDrugAdmin-
istration; Allen Heim, Office of the Commissioner, Food and Drug
Administration; Richard Hill, Office of Pesticides and Toxic Sub-
stances, Environmental Protection Agency; David Hoel, Biometry
and Risk Assessment Branch, National Institute of Environmental
Health Sciences, National Institutes ofHealth; Michael Hogan, Biom-
etry and Risk Assessment Branch, National Institute of Environ-
mental Health Sciences, National Institutes of Health; Zdenka Hor-
akova, Food Safety and Inspection Service, Department of
Agriculture; John Martonik, Health Standards Program, Occupa-
tional Safety and Health Administration, Department ofLabor; John
A. Moore, Office of Pesticides and Toxic Substances, Environmental
Protection Agency; Peter Preuss, Health Sciences, Consumer Prod-
uct Safety Commission; Robert Scheuplein, Office of Toxicological
Sciences, Center for Food Safety and Applied Nutrition, Food and
Drug Administration; Raymond Tennant, National Toxicology Pro-
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Table 1. Federal laws related to exposures to toxic substances.
Legislation
Food, Drug and Cosmetics Act (1906, 1938, amended 1958,
1960, 1962, 1968, 1976)
Federal Insecticide, Fungicide and Rodenticide Act
(1948, amended 1972, 1975, 1978)
Dangerous Cargo Act (1952)
Atomic Energy Act (1954)
Federal Hazardous Substances Act (1960, amended 1981)
Federal Meat Inspection Act (1967) Poultry Products
Inspection Act (1968)
Egg Products Inspection Act (1970)
Occupational Safety and Health Act (1970)
Poison Prevention Packaging Act (1970, amended 1981)
Clean Air Act (1970, amended 1974, 1977)
Hazardous Materials Transportation Act (1972)
Clean Water Act (formerly Federal Water Control Act)
(1972, amended 1977, 1978)
Marine Protection, Research and Sanctuaries Act (1972)
Consumer Product Safety Act (1972, amended 1981)
Lead-based Paint Poison Prevention Act (1973, amended
1976)
Safe Drinking Water Act (1974, amended 1977)
Resource Conservation and Recovery Act (1976)
Toxic Substances Control Act (1976)
Federal Mine Safety and Health Act (1977)
Comprehensive Environmental Response, Compensation,
and Liability Act (1981)
Agencya
FDA
EPA
Area of concern
Food, drugs, cosmetics, food additives, color
additives, new drugs, animal and feed additives, and
medical devices
Pesticides
DOT, USCG Water shipment oftoxic materials
NRC
CPSC
USDA
OSHA, NIOSH
CPSC
EPA
DOT
EPA
EPA
CPSC
CPSC, DHEW
(DHHS), HUD
EPA
EPA
EPA
DOL, NIOSH
EPA
Radioactive substances
Toxic household products
Food, feed, color additives and pesticide residues
Workplace toxic chemicals
Packaging of hazardous household products
Air pollutants
Transport of hazardous materials
Water pollutants
Ocean dumping
Hazardous consumer products
Use of lead paint in federally assisted housing
Drinking water contaminants
Solid waste, including hazardous wastes
Hazardous chemicals not covered by other laws,
includes pre-market review
Toxic substances in coal and other mines
Hazardous substances, pollutants and contaminants
aAbbreviations used: CPSC, Consumer Product SafetyCommission; DOL, Department ofLabor; DOT, Department ofTransportation; EPA,
Environmental Protection Agency; FDA, Food and Drug Administration; DHEW, Department of Health, Education and Welfare (many
functions assumed by (DHHS); DHHS, Department of Health and Human Services; HUD, Department of Housing and Urban Development;
NIOSH, National Institute forOccupational Safetyand Health; NRC, NuclearRegulatory Commission; OSHA, Occupational Safety and Health
Administration; USCG, United States Coast Guard; USDA, United States Department ofAgriculture.
has been, however, an attempt to distinguish clearly
between the different types of information presented
(and also provide to all interested parties specific ref-
erence to the analysis upon which they are based).
The principles can serve as the basis for consistent
regulatory cancer guidelines that the federal agencies
can tailor to meet the requirements of the legislative
actsthey arecharged toimplement. Similardocuments,
Institutes of Health; Angelo Turturro, National Center for Toxico-
logical Research, Food and Drug Administration; Elizabeth Weis-
burger, Division of Cancer Etiology, National Cancer Institute, Na-
tional Institutes of Health; Paul White, Health Sciences, Consumer
Product Safety Commission; AlvinYoung, Office ofScience andTech-
nology Policy, Executive Office of the President, The White House.
A number of people were members at different times in the delib-
erations for various tenures. They included: AndrewJovanovich, Of-
fice of Pesticides and Toxic Substances, Environmental Protection
Agency; Carl Leventhal, Office of Science and Technology Policy,
Executive Office ofthe President, The White House; Denis Prager,
Office ofScience andTechnologyPolicy, Executive Office ofthe Pres-
ident, The White House; John Todhunter, Office of Pesticides and
Toxic Substances, Environmental Protection Agency. This document
was edited by R. W. Hart, A. Turturro, and E. K. Weisburger.
with varyingdegrees ofspecificity, have beenproduced
inthepast; e.g., inthelate 1970sandearly 1980sseveral
agencies of the federal government produced state-
ments directed toward providing a consistent basis for
a general federal cancer policy. This document should
be seen then, in the broad view, as part of an ongoing
process, on behalf of the federal government, that
strives to periodically update and review current un-
derstanding ofcarcinogenesis and the scientific process
of how this understanding is utilized.
This document is the result of the combined efforts
of senior scientists from the following Federal health-
related units, operatinginthe Interagency StaffGroup,
under the direction of the Office of Science and Tech-
nology Policy (OSTP): Center for Food Safety and Ap-
plied Nutrition (CFSAN) (formerly Bureau of Foods),
Food and DrugAdministration (FDA); ConsumerProd-
uct Safety Commission (CPSC); Environmental Protec-
tion Agency (EPA); Office of the Commissioner (OC),
FDA; Food Safety and Inspection Service (FSIS) ofthe
United States Department ofAgriculture (USDA); Na-
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tional Cancer Institute (NCI), National Institutes of
Health (NIH); National Center for Toxicological Re-
search (NCTR), FDA; National Institute of Environ-
mental Health Sciences (NIEHS), NIH; National Tox-
icologyProgram(NTP); Occupational SafetyandHealth
Administration (OSHA), Department of Labor (DOL).
Context of This Report
This documentis written in light ofadecision-making
process used bymany ofthe regulatory agencies, which
involves the assessment ofcarcinogenic risks posed by
chemical substances. The scientific inputs to these eval-
uations can be best appreciated by examining the de-
cision-making process in some detail.
Risk can be conceived of as being composed of two
aspects, each of which can be addressed by science:
hazard and exposure.* Although other definitions have
been used historically, this document conforms to pres-
ent usage, and "hazard" generally refers to the toxicity
of the substance (for some toxic endpoint) and is de-
duced from a wide array of data including: epidemiol-
ogical evaluation of long-term animal studies, short-
term tests, information on mechanisms, and the results
of structure/activity relationships. "Exposure" gener-
ally refers to the amount of the substance that people
come in contact with. The "risk," in a quantitative risk
assessment, is estimated by coupling the results ofthe
exposure and hazard assessments. As eitherthe hazard
or exposure approaches zero, the risk also approaches
zero.
As a first step in assessing the cancer risk associated
with the use of a particular chemical substance, the
qualitative evidence that a given chemical substance is
likely to be a human carcinogen must be evaluated. In
this step, as in the whole process, a number of as-
sumptions and approximations must be made in order
to deal with inherent limitations found in the existing
data bases. Then, estimates of human exposure, and
distribution ofexposures likelytobe encountered inthe
population are made. Next, one or more methods for
estimating the dose-response relationship at doses be-
low those generally used experimentally must also be
evaluated. Finally, the exposure assessment is com-
bined with the dose-response relationship to generate
an estimate of risk. The various ways in which these
steps are conducted and combined and their attendant
uncertainties treated, constitute what is generally re-
ferred to as "cancer risk assessment," although an as-
sessment can be terminated at different stages to es-
timate risk for different purposes.
Somelegislation calls foractioninthe presence ofany
risk. Other forms of legislation use the concept of un-
reasonable risk, defined, in some acts, as a condition in
which the risks outweigh the benefits: e.g., the Toxic
Substances Control Act (TSCA) and the Federal In-
secticide, Fungicide and Rodenticide Act (FIFRA). A
*The European community uses the term "risk" where we have
used the term "hazard" and vice versa.
spectrumofapprovedresponses, fromsimplyinforming
the public ofariskthrough restricted use to a complete
ban, may be available to bring the risks and benefits
into appropriate balance.
This document does not perform a risk assessment
nor does it suggest that one method of cancer risk as-
sessmentisbetterthananother; but, rather, itattempts
to review the science of chemical carcinogenesis and
develops from this review a set of general principles.
It is not a comprehensive treatise nor a document writ-
ten for the lay public, but is rather a semitechnical re-
view which tries to evaluate the impact of scientific
findings of the last decade on general assumptions or
principles important to risk assessment. This is based
upon the beliefofthe group that elucidation ofthe basic
mechanisms underlying cancer and the identification of
cancer-causing agents and conditions, when coupled to
research aimed at identifying and evaluating the prob-
lems createdbysuchagents, should provide the optimal
administrative bases for making sound and reasonable
judgments. Theseoverlappingapproachestoevaluating
the problems ofcancer, we believe, should form one of
the strongest foundations upon which a technologically
based society could base its decisions.
Content of This Report
This documentiscomposed oftwomajorcomponents.
Thefirst sectionpresentsaset ofgeneralprinciplesthat
maybeusedbyregulatoryagenciesastheyreviewtheir
own specific guidelines for performing cancer risk as-
sessments. The second majorsection, "State-of-the-Sci-
ence," addresses the current state of the science con-
cerning carcinogenesis and cancer risk assessment and
forms the underlying scientific base of the "Principles"
section.
Thegeneralprinciples, ashasbeensuggestedforsim-
ilar guidelines in the National Academy of Sciences
(NAS) report on Risk Assessment in the Federal Gov-
ernment (1), can be useful despite an inherent tendency
towards oversimplification and the mixing of scientific
knowledge with risk assessment science policy. Many
components of the risk assessment process lack defini-
tivescientificbases. Oftenachoicemustbemadeamong
several different scientifically plausible options. The
above-cited NAS report identified approximately 50
components where the uncertainty in the science re-
quires, in part, scientific judgments and science policy
decisions to go from one component to the next to reach
a decision. This document attempts to leave the major-
ity of these necessary scientific inferences to the sci-
entific regulatory agencies. However, some are so im-
portant and fundamental to all cancer risk-assessment
procedures, regardless of the source of hazard or the
different statutory provisions ofthe agencies, thatthey
are included in some of the principles. Where this has
occurred we have attempted to indicate, inthe wording
ofthe principle itself, that apublic health science policy
decision is embodied in it. For example, Principle 8
defers to the statement that it is reasonable to treat an
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animal carcinogen as if it were a human carcinogen.
Many scientists would agree that, while there is a sig-
nificant amount of evidence to support qualitative ani-
mal-to-human extrapolation for carcinogenesis, the evi-
dence falls short of establishing this proposition as a
scientific fact. (When determining the response of dif-
ferent species to chemicals, many chemicals appear to
be carcinogenic in one species or strain and not in an-
other, even when only rodents are being compared.)
Nonetheless, this principle has been accepted by all
health and regulatory agencies and is regarded widely
by scientists in industry and academia as a justifiable
and necessary inference. Despite this effort, it is not
possible to draw a sharp distinction in every instance
between the bases of the principles which are based
solely on science and thosewhich embodyachoice based
also on science policy. Several of the principles, e.g.,
Principles 8, 11, and 26, clearly reflect certain aspects
of science policy.
The second major section of this document is divided
into six sections. Each discusses the current information
inanareaofscienceinthe cancerriskassessmentprocess.
The first section, Current Views on the Mechanisms
of Carcinogenesis, highlights some of the recent ad-
vances in our understanding ofsome ofthe mechanisms
of carcinogenesis. A general consensus has evolved
which describes cancer as a multi-stage process involv-
ing a variety ofevents which can include metabolic con-
version, initiation, promotion, and proliferation. The
section highlights some advances in our understanding
that have implications in the way we assess cancer risk.
At the same time, the section also identifies some ofthe
vast amount ofinformation that remains to be collected
and analyzed.
The second section, Short-Term Tests for Potential
Carcinogens, examines short-term testing and the re-
lationship between genetic toxicity and carcinogenicity.
Tests forgenemutation, chromosomal aberration, DNA
damage and repair, and cellular (morphologic) trans-
formation have provided valuable information on the
potential for chemical substances to cause cancer. This
field is currently characterized by a great deal of activ-
ity, and the data generated must be carefully analyzed
and verified before use in cancer risk assessment.
The third section, Long-Term Carcinogen Bioassay,
contains an evaluation of long-term animal tests which
have been a major factor in past assessments of cancer
risk. A review of the usefulness in cancer risk assess-
ment ofthe datadeveloped viathisapproach tochemical
evaluation ismade, and potential limitations and pitfalls
of such data relative to extrapolation to human popu-
lations are discussed.
The fourth section, Current Views ofEpidemiological
Methods, examines the current state ofepidemiological
knowledge relating to human cancer. Data collected
during the past 50 years permit the analysis of trends
in cancer incidence/mortality and provide information
related to the various etiologies of cancer. Recent de-
velopments in cancer epidemiology are highlighted and
their potential impact on risk assessment pointed out.
Much of the discussion concentrates on the methods to
be used in such studies in attempting to overcome past,
often cited, limitations of this approach.
In addition to these sections which examine factors
associated with hazard assessment, a discussion of ex-
posure assessment is also given. As the fifth section,
Chemical Exposure Assessment, points out, the field of
exposure assessment has been marked by significant
progressinthe areas ofmonitoringdata, computermod-
eling, transformation and transport of chemicals, and
laboratory approaches to determining the behavior of
chemicals in the environment. At the same time uncer-
tainties remain, and any risk assessment will necessar-
ily be affected by these limitations.
The sixth section, Utilizing Scientific Data in As-
sessing Human Cancer Risk Associated with Chemical
Exposure, discusses hazard or dose response assess-
ment and gives a comprehensive framework for inte-
grating this with hazard and exposure elements as in-
puts into the qualitative and quantitative risk
assessment processes. It depends heavily on all the
other sections and attempts to make clear the various
approaches that are used in risk assessments, noting
both the limitations and advantages of each. Common
themes within are the uncertainty, the gaps in data,
andthequestions ofinterpretationassociated with some
aspects of the scientific information used in the risk
assessment process. A critical evaluation of this infor-
mation comprises the State-of-the-Science section and
led to the principles listed in the first part. These gen-
eral principles were developed to provide interim guid-
ance in areas of uncertainty until such time that addi-
tional scientific experimentation provides the required
information needed to improve estimations of risk in
human populations. As a note of caution, it should be
recognized that the State-of-the-Science section, taken
in toto, provides the underlying support for the Prin-
ciples section. To read the Principles section without a
full appreciation ofthe material in the State-of-the-Sci-
ence section is to invite oversimplification and misin-
terpretation.
Finally, a note is needed, chiefly addressed to spe-
cialists on the various topics that are briefly discussed.
Ifreports ofa broad nature are to be written at all, and
general reports are often necessary to present orga-
nized thought on subjects of vital interest, it is inevi-
table that those who write them must spend less time
on a topic than someone who concentrates almost ex-
clusively on one specific interest. Therefore, there are
certain to be areas which some authorities think are not
discussed enough, others which some feel go on ad in-
finitum. Also, since the sections are an attempt to pro-
vide a balanced account of what is generally accepted,
derived from a vast amount ofinformationinvolvingthe
work of thousands of individuals, citing relatively few,
some must be slighted.
Both problems are inevitable in a work of this type.
Hopefully, deficiencies in the choice oftopic for empha-
sis or failures to acknowledge contributions have not
been egregious.
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Principles
Preface
The principles contained herein were derived from
the information detailed by the members of the Inter-
agency Staff Group. This section attempts to provide,
in a nontechnical form, some important general state-
ments relevant to the evaluation ofthe role ofchemicals
in carcinogenesis. These statements are intended to
serve as a bridge connecting the basic science with mul-
tifaceted process of risk assessment.
Since there are gaps in the information available, dif-
ferences in evaluations and in scientific opinion may ex-
ist about certain ofthe points highlighted as principles.
However, these principles derive from a Weltan-
schauung utilizing a balanced approach with an appre-
ciation ofall elements ofthe problem, from hazard iden-
tification and estimation through exposure and risk
assessment. It is clearly understood that new infor-
mation and newly emerging concepts may modify some
ofthese statements. Indeed, an unstated "zeroth" prin-
ciple is that regulatory judgments should embody an
openness to advances in science and emerging scientific
understanding. As a consequence, it is necessary that
the process which led to this document be a continuing
one, with periodic updates as new advances in science
dictate. For the time being however, as a result of an
arduous cooperative effort, these statements, we be-
lieve, represent an up-to-date summary on a number of
important topics.
Principles Derived from the Mechanisms
of Carcinogenesis
Principle 1. Carcinogenesis is a multistage phe-
nomenonthat mayinvolve the genome both directly and
indirectly. These stages of carcinogenesis may be, to
varying degrees, influenced by a number of variables
such as age at exposure, diet, hormonal status, and
intra- and interspecies variability, which should be con-
sidered when trying to predict human response to po-
tentially carcinogenic agents (see pp. 209-212, 220-
224).
Principle 2. Appropriate in vitro and in vivo tests
can indicate that an agent has a certain action such as
genetic toxicity or promotion. Such information is val-
uable and may be useful in evaluating mechanism(s) of
cancer induction. However, in the evaluation ofhuman
risk, the attribution ofobserved findings ofcarcinogen-
icity to a particular biological effect must rest upon
sound evidence that the effect is responsible for the
cancerinduction. Itmustbe keptinmindthat achemical
may contribute to carcinogenesis in multiple ways (see
pp. 220-224).
Principle3. Atthepresent stage ofknowledge, me-
chanistic considerations such as DNA repair and other
biological responses, in general, do not prove the ex-
istence of, the absence of, or the location ofa threshold
for carcinogenesis. The presence or absence ofathresh-
old for one step of the carcinogenic process does not
necessarily determine the presence or absence of a
threshold for the whole process (see pp. 217-219).
Principle 4. The carcinogenic effects ofagents may
be influenced by nonphysiological responses (such as
extensive organ damage, radical disruption ofhormonal
function, saturation of metabolic pathways, formation
ofstones in the urinary tract, saturation ofDNA repair
withafunctionallossofthesystem) inducedinthemodel
systems. Testing regimes inducing these responses
should be evaluated for their relevance to the human
response to an agent, and evidence from such a study,
whether positive or negative, must be carefully re-
viewed (see pp. 217-220).
Principles from Tests of Cancer Induction
Principle 5. Short-term tests, such as assays for
point mutations, chromosomal aberrations, DNA dam-
age, and in vitro transformation are useful in screening
for potential carcinogens, reaching a judgment on the
carcinogenicity ofachemical, and providinginformation
on carcinogenic mechanisms (see pp. 227-230).
Principle 6. Short-term tests are presently limited
in their ability to predict the presence or absence of
carcinogenicity and cannot supplant data from long-
term animal studies or epidemiological investigations,
since the tests do not necessarily screen for all potential
means ofcancer induction and do not necessarily mimic
all reactions that would occur in vivo. Additional re-
search is required to improve existingtests and develop
ones that identify chemicals which act by genetic mech-
anisms not yet determined or which act by other, non-
genetic mechanisms (see pp. 227, 232-233).
Principle 7. Short-term tests should be carefully
selected to ensure they have been adequately validated.
Several tests with different endpoints may be required
to characterize a chemical's response (see pp. 230-232).
Principle 8. In the evaluation oflong-term test re-
sults, the term "carcinogen" should be used in a broad
sense, i.e., a substance which is capable under appro-
priate test conditions (Principles 10-13) of increasing
the incidence of neoplasms (combining benign and ma-
lignant when scientifically defensible) or decreasing the
time it takes for them to develop. Careful consideration
to the relevant issues cited in Principles 4, 9, and 14
should be given prior to a determination that a chemical
is an animal carcinogen (see pp. 234-235).
Deference should be given to the IARC principle:
"that in the absence of adequate data in humans, it is
reasonable, for practical purposes, to regard chemicals
for which there is sufficient evidence ofcarcinogenicity
in animals as if they presented a carcinogenic risk to
humans." However, thispresumptionisevaluated along
with otherrelevantinformation (Principle 25) inmaking
a final judgment concerning human carcinogenicity and
should not foreclose further inquiry into the human rel-
evance of animal carcinogens (see pp. 253-254).
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Principle 9. Some experimental animal models or-
dinarily have high incidences of certain tumors. The
evaluation of tumor data from such animals can pose
special problems. For example, the interpretation of
cancer incidence in some strains ofrats with testicular
or mammary tumors or in some strains of mice with
lung or liver tumors must be approached carefully in
the light of other biological evidence bearing on poten-
tial carcinogenicity (see pp. 240-241).
Principle 10. Protocols for long-term tests should
be designed to achieve an appropriate balance between
the two essential characteristics of a biological assay:
adequatebiologicalandstatisticalsensitivity(alowfalse
negative rate) and adequate biological and statistical
specificity (a low false positive rate). The absence of
biases in selection and allocation of animals between
control and treatment groups as regards diet, husban-
dry, necropsy, pathology, and from insufficient quality
control, is crucial (see pp. 234-238, 241-243).
Principle11. Itisappropriate touse testdosesthat
generally exceed human exposure levels in order to
overcome the inherent insensitivity of the traditional
design of the long-term animal test. The highest dose
should be selected after an adequate prechronic study
and after evaluating otherrelevant information, as nec-
essary, to determine the highest dose consistent with
predicted minimal target organtoxicity and normal life-
span, except as a consequence ofthe possible induction
ofcancer (see pp. 236-239).
Principle 12. The diagnosis ofpathologic lesions is
complicated and requiresjudgment and appropriate ex-
perience. Diagnoses candiffer, dependingonthetissues
and species involved and can change with time as tech-
niques improve and data on bioassays accumulate. Ac-
curate interpretation oftumor data is contingent upon
careful attention to gross observation, tissue sampling,
slide preparation and histologic examination. Diagnosis
of tumors should be guided by evidence of their histo-
genic origin and stage ofprogression (see pp. 240-241).
Principle 13. Appropriate statistical analysis
should be performed on data from long-term studies to
help determine whether the effects are treatment re-
lated or possibly due to chance. These should include a
statistical test for trend and a test based on pairwise
comparisons, including appropriate correction for dif-
ferences in survival. The weight to be given to the level
ofstatisticalsignificance (thep-value)andtootheravail-
able pieces ofinformationis amatterofoverallscientific
judgment (see pp. 241-243).
Principle 14. Decisions on carcinogenicity ofchem-
icals in animals should be based on consideration ofrel-
evant biological and biochemical data. Use of back-
ground or recent historical control incidence of tissue
specific tumors can be an aid, in addition to concurrent
controls, in the evaluation of tumor data. Care should
be exercised when combining different control groups.
Evidence of probable reproducibility is important.
This evidence can consist of independent confirmation
of the original findings or may be derived from inter-
group comparisons of tumor incidence data, between
dose groups, sexes, strains orspecies. Evidence ofdose
response increases confidence that the effect is treat-
ment-related; similarly, lack of an observed dose re-
sponse may reduce the likelihood that the effect is as-
sociated with the treatment.
Confidence is increased when: (1) the incidence oftu-
mors is markedly elevated in the treated groups com-
pared to controls; (2) tumor incidence is significantly
increased at multiple anatomical sites; and (3) tumor
latency is significantly reduced. In addition to tumor
incidence at specific sites, the stage in the development
ofneoplasia should be evaluated. Forexample, the find-
ing that the majority of neoplastic lesions at a specific
site is more advanced in a treated group compared to
its control may provide additional evidence of a treat-
ment related effect. Conversely, the finding that the
control group lesions are more advanced might argue
thatamarginalelevation oftumorincidenceisnottreat-
ment-related. The incidence of preneoplastic lesions in
treatment or control groups may, in certain instances,
provide evidence for the biological plausibility ofa neo-
plastic response and contribute to the interpretation of
a bioassay. Identification of effects from prechronic
studies on the target organ(s) can aid in the evaluation
of long-term studies. Information on the activity of
chemicals at the physiological, cellular and molecular
level may be important to the evaluation ofcarcinogen-
icity data on a case-by-case basis (see pp. 238-243).
Principles for Epidemiology
Principle 15. The major strength ofthe epidemiol-
ogical method is that it is the only means of assessing
directly the carcinogenic risk of environmental agents
in humans. However, the observational (nonexperi-
mental) nature ofmost epidemiological studies, as well
as the frequent paucity of relevant data, can impose
serious limitations on the method (see pp. 243-244).
Principle 16. Descriptive epidemiological studies
(based on the measurement ofdisease rates for various
populations), including correlational studies (in which
the rate ofdisease in a population is compared with the
spatial or temporal distribution of suspected risk fac-
tors), are useful to generate and refine hypotheses, or
provide supporting evidence in evaluating relationships
detected by other means, but rarely, if ever, provide
information allowing a causal inference (see pp. 244-
245).
Principle 17. Well designed, conducted, and eval-
uated analytic epidemiological investigations of either
the case-control or cohort variety can provide the basis
for causal inferences especialiy useful for public health
decisions (see pp. 245-246).
Principle 18. Elements in interpreting the likely
causality of epidemiological observations include the
magnitude of the risk estimates (strength of associa-
tions); the possibility oftheir being due to chance (sta-
tistical significance); the rigor of the study design to
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avoid various kinds of bias, including those related to
selection, confounding, classification and measurement;
dose-response relationships; the temporal relationships
between exposure and disease; the specificity of the
associations; their biological plausibility; and the re-
producibility of the findings (see p. 244).
Principle 19. A high-quality negative epidemiol-
ogical study, while useful, cannot prove the absence of
an association between chemical exposure and human
cancer. Within the scope of the study, specifically for
the populations studied (including concomitant expo-
sures), for the levels and durations of exposure to the
agents evaluated and for the time assessed following
exposure, a likely range can be determined for the es-
timates ofrisk and the statistical likelihood ofthe study
to detect an effect can be assessed (see p. 247).
Principles for Exposure Assessment
Principle 20. It is desirable that exposure routes
employed in animal health effects studies are compa-
rable to human exposure routes both for the simplifi-
cation of risk assessment and because there may be
important route-dependent differences in molecular,
biochemical, and physical parameters in organs (see pp.
209-212).
Principle 21. At present, a single generally appli-
cable procedure for a complete exposure assessment
does not exist. Therefore, in the near term, it is ex-
pected that integrated exposure assessments (utilizing
monitoring data, results from physical and chemical
models, and considerations of all routes of exposure
through all media) will be conducted on a case-by-case
basis (see pp. 248-251).
Principle 22. The depth and accuracy of an expo-
sure assessment should be tailored to provide the de-
gree ofknowledge required to support analytical needs.
A preliminary assessment using available crude data
can often shed light on the upper or lower bounds of
potential risks (see pp. 248-251).
Principle 23. An exposure assessment should de-
scribe the strengths, limitations anduncertainties ofthe
available data and models and should indicate the as-
sumptions made to derive the exposure estimates (see
pp. 251-252).
Principle 24. In general, an array or range of ex-
posure values is preferable to a single numerical esti-
mate (see pp. 251-252).
Principles for Risk Assessment
Principle 25. Decisions on the carcinogenicity of
chemicals in humans should be based on considerations
of relevant data, whether they are indicative of a pos-
itive or negative response, and should use sound bio-
logical and statisticalprinciples. Thisweight ofevidence
approach should include consideration of all relevant
factors and should give appropriate weight to each on
a case-by-case basis. Examples of the types of infor-
mation that should be taken into account include: find-
ings from long-term animal studies (see Principle 14);
results from epidemiological studies (see Principles 16-
19); results from in vivo and in vitro short-term tests
(see Principles 5 and 6); and data from studies ofmech-
anism, including factors such as structure-activity re-
lationships, and known similarities and differences in
metabolic and kinetic profiles for different species (see
Principles 1-4 and pp. 253-254).
Principle 26. No single mathematical procedure is
recognized as the most appropriate for low-dose ex-
trapolation in carcinogenesis. When relevant biological
evidence on mechanism ofaction (e.g., pharmacokinet-
ics, target organ dose) exists, the models or procedures
employed should be consistent with the evidence. How-
ever, when data and information are limited, and when
much uncertainty exists regarding the mechanisms of
carcinogenic action, models or procedures which incor-
porate low-dose linearity are preferred when compati-
ble with the limited information (see pp. 255-258).
Principle 27. The quantification of the various
sources of uncertainty involved in cancer risk assess-
ment can be as important as the projection of the risk
estimate itself. The sources that might be addressed
include the statistical uncertainty associated with the
givenrisk estimate (often expressed as upperand lower
confidence bounds); the variability introduced by the
selection of a particular low-dose extrapolation proce-
dure (often expressed as an envelope of risk estimates
fromavarietyofplausiblemodels);whenriskestimation
is based on laboratory-generated data, the biological
variability associated with the use of a particular test
organism and its scaling or extrapolation to man (see
pp. 257-258).
Principle28. An estimate ofcancerriskforhumans
exposed to an agent can be no more accurate than an
exposure assessment that it utilizes. Lack of adequate
exposure data is frequently a major limiting factor in
evaluation of carcinogenic risks for humans (see Prin-
ciples 20-24 and p. 254).
Principle29. While severalconsiderations oftenen-
ter the risk assessment process, it is important to try
to maintain a clear distinction among facts (statements
supported by data), consensus (statements generally
held in the scientific community), assumptions (state-
ments made to fill data gaps), and science policy deci-
sions (statements made to resolve points ofcurrent con-
troversy) (see pp. 257-258).
Principle 30. Differences in human susceptibility,
and variable and extreme exposures to chemicals sug-
gest the likelihood that there are subpopulations that
are at greater than average risk. Consideration should
be given to the identification of high risk populations
(see pp. 209-212, 251).
Principle 31. Because of the uncertainties associ-
ated with risk assessment, a full evaluation of risk to
humans should include a qualitative consideration ofthe
basic strengths and weaknesses ofthe available hazard
and exposure data, in addition to any numerical esti-
mations that are made (see pp. 257-258).
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State-of-the-Science
This segment contains the details about the topics
emphasized in Part I, and, as such, is a summary ofthe
current science in a number of fields important to ade-
quate risk assessment. Special emphasis has been
placed on those areas considered to be particularly rel-
evant to estimation of hazard and risk.
There are six sections: one on the mechanisms of can-
cer induction is followed by two on testing, one each for
short-term and long-term testing. These disciplines im-
portant tounderstandingand estimates are rounded out
by a chapter concerning estimation of human hazard,
i.e., epidemiology. Following, there is a chapter on ex-
posure assessment, a critical problem in assessing hu-
man risk. The last section discusses hazard or dose-
response assessment and risk characterization as well
as drawing on all the other chapters to discuss risk
assessment as a whole. It is clear that the limited space
available in this review does not allow a totally com-
prehensive treatise on the various subjects involved,
and specialists in the various fields may disagree with
the importance ofcertain aspects ofthe discussion. The
focus has been on a balanced presentation of what is
consensus in the various fields discussed as they inter-
sect with the need to understand the effects ofchemical
agents.
Current Views on the Mechanisms of
Carcinogenesis*
Introduction
PHILOSOPHICAL PERSPECTIVES. Underlying the elu-
cidation of mechanisms in carcinogenesis is the search
for causality in this biological phenomenon in order to
better evaluate and control it. Since science is contin-
ually advancing, ourunderstandingmustbe periodically
re-evaluated in light ofnew, generally agreed uponfind-
ings. Such a review is especially important in rapidly
advancing, highly specialized and interdisciplinary
areas that are ofsignificance topublic health. The mech-
anisms underlying induction of cancer represent such
an area and are re-examined here in light ofthe findings
of the last few years.
This section first places the understanding of the
mechanisms of cancer induction in a historical perspec-
tive and provides a synopsis of some current commonly
held beliefs. The bulk ofthe text follows, which focuses
on the interaction ofcancer-related agents with factors
both external and internal to an organism and the con-
sequences ofsuch interactions atthemolecular, cellular,
tissue and organismic levels relative to the development
of cancer. The sequence ofevents presented is not writ-
ten to advance any specific mechanism of cancer induc-
*Although the full committee participated in the framing of this
section, primary responsibility was assumed by Drs. R.W. Hart and
A. Turturro.
tion, but simply to organize the presentation ofthe re-
sponse ofvarious levels ofbiological organizationto can-
cer-related agents. It should also be appreciated that
the data presented have been obtained from studies
using various research model systems (e.g., cell-free,
cellular, whole animal) to isolate various components of
the process. They have also been derived from various
strains and species treated under a great variety of
experimental conditions. This comprehensive approach
to the study of cancer is generally accepted for many
reasons, primarily the belief that, while biological sys-
tems vary, the degree of similarity at the level oftheir
basic processes is greater than at higher levels of in-
tegration.
HISTORICAL PERSPECTIVES. Studies in paleopath-
ologyhaveindicatedthatcancers occurredinprehistoric
times (2). The frequency of occurrence of the disease
(its incidence) is hard to quantitate in antiquity, how-
ever, over approximately the last century, a relatively
well-documented period, total cancer incidence percap-
ita has increased (3). The increase in the mean life span
as aresultofprevention andtreatmentofotherdiseases
is a significant factor in this increase in incidence, how-
ever exposure to carcinogens (e.g., by smoking) is also
important (3). Less cleararethe effects ofotherfactors,
e.g., increasing urbanization (3,4), which would result
in reducing exposure to certain agents (e.g., mycotox-
ins, mutagens in raw sewage), while increasing expo-
sure to others (e.g., asbestos, benzene). The study of
the process of carcinogenesis is at least 300 years old,
with studies during the first 200 years being primarily
descriptive. The influence of occupation and lifestyles
in cancer occurrence was first observed by Ramazzini
in 1700, who noted that nuns exhibited a higher fre-
quency of breast cancer than other women (5). Subse-
quently, in 1761 Hill associated the use oftobacco snuff
with cancer of the nasal passage (6), and in 1775 Pott
noted the occurrence of soot-related scrotal cancer in
chimney sweeps (7). Based upon observations in de-
veloping systems, Weismann, in 1881, suggested an as-
sociation between the "germplasm" (the reproductive
or life principle) and cancer (8), one of the first exper-
imentally based theories concerning the mechanism of
cancer induction. In 1895 Rehn published evidence that
aromatic amines were associated with bladder cancer
(9), while Unna, in 1894, and Dubreuilh, in 1896, as-
sociated sunlight exposure with skin cancer (10,11). In
the following 50 years, with the development of appro-
priate models, numerous agents were found to induce
cancer in experimental animals. Over the last 30 years,
there has been an increased emphasis on understanding
the mechanisms ofcarcinogenesis and, recently, on the
role of factors such as diet in the enhancement or in-
hibition oftumor formation (3,12-14). Consequently, in
the last decade, more progress has been made in un-
derstanding the overall mechanisms of carcinogenesis
than at any other time in history.
CurrentBeliefs
Fromthe mass ofdata on carcinogenesis, aconsensus
has emerged on a number ofimportant scientific issues.
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First, cancer can be induced by radiation, biological,
"physical" and/or chemical agents.
Second, on a biochemical and molecular level, there
are important similarities among mammalian species.
Third, an estimate ofthe potency ofcarcinogens may
never be exact and may vary with lifestyle, habits, age,
sex, individual genetic differences, ethnic background,
test strain and/or species, diet, dose rate, route of
administration, vehicle or solvent used (if any) as well
as the presence or absence of other agents, and the
environmental conditions prior to, during, or after ex-
posure.
Fourth, cancer development is a multistage process
that may involve the genome, both indirectly (fre-
quently termed epigenetic events) and directly, which
may include the participation of chemicals or viruses,
and which may be modulated by higherorderfunctions,
i.e., at the organ and organismic level.
Fifth, numerous factors may alter the frequency of
cancerinductionbyalteringone ormoreofthese stages.
Sixth, the genesis of a cancer appears to require an
alteration in the ability of a cell to elaborate its appro-
priate genetic program, i.e., in its information process-
ing capacity, with the subsequent fixation and propa-
gation of that alteration.
Seventh, we still lack an in-depth understanding of
the mechanisms and stages of cancer induction and
expression.
Eighth, only by understanding the stages of tumo-
rigenesis and carcinogenesis, the substances and pro-
cesses which modulate them, and how these may differ
amongcells, organs, individuals, strains andspecieswill
we ultimately understand the role ofsubstances, radia-
tions, viruses and/or life-style factors in human cancer.
Preabsorption Modification ofCarcinogens
Human exposure to carcinogens usually occurs by
dermal contact, inhalation, ingestion, or a combination
ofthese routes ofexposure. Depending on route of ex-
posure, anagent canbe altered as aresult ofinteraction
with interactions that are in association with, but not
actually part of, an organism. These factors include: (1)
direct transformation of chemicals by environmental
factors [e.g., solar radiation interacting with an agent
on the surface of the skin (15)]; (2) interaction with
cellular secretions [e.g., certain inhaled carcinogens
being "coated" with lung secretions (16)]; and (3) met-
abolic conversions by microorganisms [e.g., gut micro-
flora acting on ingested agents (17-24)]. An illustration
ofthe impact that these factors can have is exemplified
by the role of the gut microflora in the metabolism of
xenobiotics. It has been suggested that the potential
for metabolism in the gastrointestinal tract is similar to
that of the liver (20). However, hepatic metabolism of
nonnutrients is predominantly oxidative and synthetic
(conjugations), while reactions by intestinal microflora
are mostly ofa hydrolytic and reductive nature (20). It
also appears that intestinal microbial metabolism is
most important for polar compounds that are not well
absorbed from the gut and for those that are excreted,
free or conjugated, in the bile (20). Examples of this
includethemetabolismofcycasintoacarcinogenicagly-
cone (19) and enzymatic reduction of a number of azo
dyesbynumerous generaofanaerobicgutbacteria(24).
Intestinal microfloral metabolism can give rise to com-
petition or cooperation between mammalian and micro-
bial enzyme systems in sequential reactions in the cells
and in the enterohepatic circulation.
Intra-andinterspecies comparisonsofmicrofloralme-
tabolism of xenobiotics have been rare. In one study,
rat, monkey, and human intestinal microflora exhibited
the capacity to reduce several benzidine and benzidine
congener-based dyes to potentially carcinogenic aro-
matic amines under test conditions (17). Since there is
a similarity between the biological effects ofthese dyes
and the effects ofbenzidine on humans (25), this study
suggested that, for these dyes at least, gut microfloral
metabolism may play a significant role in the etiology
of urinary bladder cancer. Diet composition has also
been shown to affect microbial metabolism. Diets with
high pectin content can alter the metabolic activities of
bacteria in the gut, thus directly effecting hepatic cov-
alentbindingofcarcinogens (26). Furtherstudiesinthis
area, especially in regard to the relation between gut
microflorain animalswithdifferent feedinghabits (e.g.,
carnivore, herbivore, and omnivore) and the animal's
susceptibility to certain classes of carcinogens, would
be ofinterest. Species and individual differences in mi-
crofloral composition could quantitatively and qualita-
tively alter the nature ofthe agent to which the animal
isultimately exposed and, thus, thebiologicalresponse.
Organismic and Cellular Metabolism
ACTIVATION, DETOXIFICATION, AND REACTIVA-
TION. Carcinogens include biological agents, such as
some viruses (27), radiations, such as X-rays and ultra-
violet light (28), "physical agents," such as plastic sur-
faces and wounding (29), chemical agents, both organic
and inorganic (30), and combinations thereof. Chemical
carcinogens occur in a number of chemical classes in-
cluding polycycic aromatic hydrocarbons and their de-
rivatives, aromatic amines, azo dyes, nitrosamines, ni-
trosamides, halogenated hydrocarbons, alkylating
agents, and metals, their salts and metal complexes, as
well as in plant and microbial products (30). Ordinarily,
notallchemicalsbelongingtoanyclassarecarcinogenic,
norare allthose compounds within aclass which exhibit
carcinogenicityequallypotent. Carcinogensmaybenat-
urally occurring(31,32), as in food (33), mayresult from
industrial processes (32,34,35), or may represent the
consequencesofsocialactivities (36). Withtheexception
of a few direct-acting agents, the organic carcinogens
(37) and, possibly, some of the metal complexes (38)
require metabolic activation in order to exert their can-
cer-inducing properties. In general, by whatever route
chemicals enter the body, the enzymes involved in bio-
transformation of a chemical to carcinogenically active
(as well as to a number of carcinogenically inactive)
metabolites are part of the same mechanisms respon-
sible for detoxication of drugs. Included in this inter-
pretation of the detoxication mechanism is the parti-
tioning of a compound and its metabolites into various
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body compartments and the effects of differing physi-
ology (blood pH, blood flow to various organs, etc.) on
the distribution of the compound and its metabolites.
For example, the prolonged retention ofacidic urine in
dog and man, compared to the rat, can result in a very
different profile of aromatic amine metabolites than in
the rat, due to the effect of a lower urine pH over a
longer time on N-hydroxyarylamine conjugates (39).
Realistic modeling can be very useful to understand the
mechanisms ofthe effects ofan agent. However, a de-
tailed analysis (e.g., pharmacokinetics) can become
quite involved, and the simplifying assumptions used in
deriving tractable equations may be inimical to realist-
ically modeling the in vivo situation. The data required
for modeling are often unavailable, and care should be
taken in defining the "effective dose" when the mech-
anism(s) of carcinogenic action is (are) unknown (40).
Alsoincluded inconsideringmetabolismisthetotalmet-
abolic potential of the organism. For instance, nasal
epithelium canactivate chemicalcarcinogens (41), acon-
sideration especiallyimportant tounderstandingthe ef-
fects of exposure by inhalation.
The enzyme systems involved in biotransformation
can be divided for convenience into two groups that
convert a compound into either a phase 1 or phase 2
metabolite. Phase 1 metabolites are primary oxidation
or reduction products, which are usually more water-
soluble than the parent compound and thus may gen-
erally be more easily eliminated from the body. These
metabolites may be then conjugated with various sol-
uble intracellular constituents, forming glucuronides or
sulfates, to become even more water-soluble and avail-
able for excretion from the body. These conjugated me-
tabolites constitute the phase 2 metabolites (42), which
are usually excreted. However, deconjugation prior to
excretion may release an active carcinogen at a site
distant from the site of conjugation (39,43).
The reactions that occur in the formation of either
phase 1 orphase 2 metabolites require specific enzymes
for their conversion (some of the better characterized
of which are listed in Table 2). Interactions between a
chemical carcinogen and these metabolizing systems
may form a large spectrum ofphase 1 and phase 2 me-
tabolites. A generaliy accepted mechanism for the re-
action of metabolically activated agents with the cell
has been proposed by Miller and Miller (37), namely,
thattheultimate carcinogenic forms oforganic chemical
carcinogens are electrophilic (electron deficient) reac-
tants that bind with target intracellular nucleophilic
(electron-rich) macromolecules such as DNA and pro-
teins. The reactive metabolites formed may also react
with other nucleophiles such as glutathione or water
(44,45). Through these latter processes, the effects of
agents can be neutralized by forming less biologically
reactive metabolites that are very polar and may be
more easily excreted. The efficiency of this neutraliza-
tion is an important factor in tumor induction. For ex-
ample, if detoxification by glutathione is efficient, the
effective local concentration ofthe active metabolites of
the agent isusuallyreduced, which results in decreased
binding to macromolecules. However, the electrophilic
properties of some chemicals may be enhanced by glu-
tathione conjugation (46) (although this is exceptional).
Thus, determining the details of chemical biotransfor-
mationisdesirablewhenassessingtheimpactofachem-
ical.
Understanding the metabolism of chemical carcino-
gens is often complicated by the diversity ofthe enzy-
maticreactions. Forexample, whileforaromaticamines
andrelated compounds, theN-hydroxyderivativesmay
be the only phase 1 metabolites needed for generation
of the nitrenium ion-species that bind with target in-
tracellular macromolecules (39,47), the common meta-
bolic activation ofnitrosamines and nitrosamides occurs
via the formation of diazo intermediates, which subse-
quently decompose to molecular nitrogen and active al-
kyl carbonium ions (30). To illustrate the complexity of
metabolism ofachemical carcinogen, most oftheknown
metabolicpathways and the phase 1 metabolites formed
from benzo(a)pyrene, one ofthe most ubiquitous ofen-
vironmental animal carcinogens, are shown in Figure
1. Many of these metabolites can be converted to dif-
ferent conjugates by phase 2 enzymes. Also, the en-
zymes cytochrome P-450 and epoxide hydrolase exhibit
high selectivity for a particularmolecularregion and its
local conformation (48). This results in arene oxides,
trans-dihydrodiols, and trans-dihydrodiol-epoxides
being formed as specific optically active isomers (en-
antiomers). These enantiomers exhibit markedly dif-
ferent biological activities (49).
Simply knowingthe identity ofthe major metabolites
of a compound may not always allow prediction of its
hazard. Forexample, metabolism ofpolycyclic aromatic
hydrocarbons to trans-dihydrodiols was long known,
but thought to be a pure detoxification process (50).
However, identification of the anti-isomer of the di-
hydrodiol-epoxide of benzo(a)pyrene, which is derived
from the trans-7,8-dihydrodiol (Fig. 1), as the electro-
philic metabolite of benzo(a)pyrene which binds DNA
(ultimate carcinogen) has proven that some trans-di-
hydrodiol metabolites can be enzymatically activated
(51,52). Additionally, detoxified metabolites formed in
the liver may be reactivated in other organs, e.g. the
bladder (39). The metabolic fate of a compound is a
function of a number of processes occurring together
(activation, deactivation, and reactivation), whose dy-
namic interaction results in the local concentration and
lifetime ofthe active metabolite(s). The combination of
whole animal, organ, and cellular processes results in a
local variable dose rate of active species with time.
These changes may be significant factors in producing
the biological effects seen with a particular agent.
MODULATION OF METABOLISM. Compound metabo-
lism is a function of the processes in tissues described
above, incombinationwiththecellular, organandwhole
animal distribution and excretory processes. This dy-
namic interaction can be modulated by a number offac-
tors. Such factors include enzyme inhibitors, enzyme
inducers, metabolite scavengers (see below), starva-
tion, age, sex, stress, tissue ablations, nutritional fac-
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Table 2. Some enzymes needed for phase 1 and phase 2 reactions.
Phase Enzyme(s) Catalysis
Phase 1 Enzyme systems containing cytochrome P-450 and Epoxidation of aromatic rings or olefinic double
the FAD-containing monooxygenase. This system bonds, hydroxylation of aromatic rings or alkyl
occurs mainly in the endoplasmic reticulum ofliver, chains; oxidative dealkylation and N-oxidation.
kidney, lung, and intestine. The enzymes may occur
in multiple forms and exhibit different or
overlapping substrate specificity.
Epoxide hydrolase Hydrolysis of arene oxides and alkene oxides into
trans-dihydrodiols
Dehydrogenases, flavin-containing cytochrome P-450 Reduction of nitroaromatics to nitrosoarenes,
reductases and xanthine oxidase N-hydroxyarylamines, and arylamines; reduction to
azo compounds to amines
Phase 2 Glutathione S-transferases (these enzymes are Conjugation between glutathione and a variety of
known to exist in multiple forms) electrophilic compounds such as arene oxides
UDP-glucuronyltransferases (also found in multiple Conjugation reactions between glucuronic acid with
forms) substrates such as phenol and bilirubin
Sulfotransferases Sulfate ester formation
N-acyltransferases and N,O-acyltransferases N-acetylation and N,O-acyltransfer of aromatic
amines and arylhydroxamic acids
12 1
10 3
9 P-450
7 a 5
Benzo(a)pyrene
(1.-Oxde]NR - [1,2-Oxide] b 1-Phenol - 1,8-Oulnone
[2,3-Oxide] 3-Phenol 3,6-Ouinone
(+)-4,5-Oxide E ,(--t-4,5-Dlhydrodiol
6-Phenol - 1.6-Oulnone + 3.6-Qulnone + 6,12-Quinone
EH (-)-t-9.1O-Dlhydrodlol
-s-o[9.10-OxIde-
NR 9-Phenol
7 7-Phenol -1 [(+)-7,8-OxldeI]
(-)-t-7,6-Dlhydrodlol
I P-450
(+)-t-7.8-Dlhydrodiol-
antl-9,IO-epoxide
H20 NADPH 7, NADH
7,8,9,10-Tetrols 7,8,9-Trlol
(-)-t-7.8-Dihydrodiol-
ayf-9,.1O-epoxide
NDPH H20
T 78DH -Tto
7,8,9-trlol 7,8,9,10-Tetrols
FIGURE 1. Metabolic pathways and metabolites ofbenzo(a)pyrene obtained from metabolism by rat liver microsomes. Abbreviations: P-450,
cytochrome P-450 containing enzymes together with cofactors; EH, epoxide hydrolase; NR, nonenzymatic rearrangement; t, trans.
tors, individualgeneticdifferences, andhormonal status
(45,53). Various synthetic chemical agents have been
shown to act asinhibitors, inducers, or scavengers (54),
and this diversity ofeffects has been suggested as well
for some commonly eaten foods, which contain natu-
rally-occurring inhibitors or inducers, and which also
appeartomodulatemetabolism(3,33). Briefly, there are
three general mechanisms accounting for the modula-
tion of metabolism by inhibitors or inducers (54). (1)
Stimulation of cellular metabolism results in an in-
creased deactivation and/or activation. For example, a
wide range ofcompounds including polycyclic aromatic
hydrocarbons, phenobarbital, flavones, halogenatedhy-
drocarbons, and indoles induce an increase in monooxy-
genase activity and changes in the relative proportions
ofthe different isozymes. Other enzymes, such as glu-
tathione S-transferases may simultaneously be en-
hanced. Affinity constants may be altered. As a con-
sequence of any and all these changes, the relative
proportions ofvarious metabolitesmaychange, thereby
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influencing the ratio of metabolic activation to deacti-
vation (55). (2) Interference with enzymatic activation
ofchemical carcinogens occurs to form the ultimate car-
cinogenic metabolite(s). For example, disulfiram is
thought to inhibit dimethylhydrazine-induced neoplasia
ofthe large bowel by directly reducing the rate ofcon-
version ofthe agent into a reactive metabolite (54). (3)
Scavenging (neutralization) ofthe reactive metabolites
is altered by nucleophiles, such as glutathione or other
defense systems, such as superoxide dismutase. For
example, starvation, other nutritional imbalances, or
compounds such as butylated hydroxyanisole may
drastically alter glutathione levels (56,57). Decreases in
glutathione levels may lead to a decreased proportion
ofthe reactive metabolite beingdetoxified. Conversely,
the increased levels of glutathione and glutathione
transferase produced by butylated hydroxyanisole may
indicate greater detoxification ofa reactive metabolite,
provided that the glutathione conjugate products are
not reactivated.
However, it is the balance between the activation,
detoxification and reactivation systems for a chemical
carcinogen, and theirinteraction overtime, ratherthan
the change in one of these processes per se, which is
important. If monooxygenase activity has been stimu-
lated, resulting in increased reactive metabolite for-
mation, a greater proportion of biologically available
carcinogen will result only if the detoxification mecha-
nisms cannot compensate. [Anexample ofcompensation
using another toxic endpoint involves low doses of ac-
etaminophen, whose reactive metabolite reacts with
glutathione, and which will not be hepatotoxic (58).
However, larger doses will deplete the glutathione pool
and result in hepatotoxicity.] Alternatively, if gluta-
thione levels are decreased, concentrations of electro-
philic metabolites may increase.
The use of various chemical modulators has contrib-
uted significantly to our understanding of the metabo-
lism and disposition of chemical carcinogens. With ex-
tended research into the mechanism of action of these
agents, the use of such modulators may, in the future,
aid in the treatment ofindividuals accidentally exposed
tohigh doses ofcertainchemicalcarcinogens. However,
at present, it would be premature to state that modu-
lators will be generally effective in preventing cancer
induction by some chemicals or that such agents could
everbe used as analternative toreducingorpreventing
exposure to identified carcinogens. An indication for
caution is the demonstration that co-administration of
aspirin, which modulates the metabolism ofN-[4-(5-ni-
tro-2-furyl)-2-thiazolyl]-formamide (FANFT) (a potent
rat urinary bladder carcinogen) will decrease the num-
berofbladder tumors induced by FANFT, however, at
the same time, it will increase the number of foresto-
mach tumors produced (59).
ORGAN AND SPECIES DIFFERENCES. Because the to-
tal enzyme level and substrate specificity of the phase
1 and phase 2 metabolizing enzymes exhibit organ, in-
dividual, and species differences (53), themetabolicpat-
terns ofboth activation and deactivation ofaparticular
agent could also differ markedly. An example ofthis is
the differences in the monooxygenase activities in nasal
epithelium in different species (60). Also, there exist
multiple forms of cytochrome P-450 enzymes, each of
which exhibits its own specificity toward the substrate
metabolized (45). Since glutathione S-transferases and
UDP-glucuronyltransferases also occur in multiple
forms (45), their particular form in different tissues,
strains, individuals orspecies mayalsovary. Moreover,
the activity of each metabolizing enzyme in a specific
tissue of the same strain could vary widely depending
on age, sex, nutritional factors, hormonal status, or
other factors (32). For these reasons, unless one knows
the rates of the activation-deactivation processes and
the participating isozymes responsible for these reac-
tions and their levels, it is impossible to predict quan-
titatively the metabolic activation of chemical carcino-
gens from an in vitro to an in vivo system, or from
laboratory animals to humans. Metabolic comparisons
between animal species and humans, when the meta-
bolic pathways are similar, could be useful for qualita-
tive assessments of the relevance of a specific animal
test system to human risk. Presently, however, a pauc-
ity of comparative metabolism data on either induced
or noninduced systems exists since most studies are
based on an ontogenetic rather than a molecular-evo-
lutionary approach (61). They, therefore, are oflimited
use for extrapolation of data between species and or-
gans. There is also expected to be, because of these
variabilities, a wide range of responses in different
members of a species, leading to individuals with dif-
ferent levels of sensitivity to agents.
Macromolecular Interactions
ALTERATIONS IN GENETIC INFORMATION. Modifica-
tion ofthe information content ofcells is believed to be
one ofthe eventsinvolved inthe onset ofcarcinogenesis
(62). Although macromolecules such as RNA (37), pro-
tein (63), and lipid-containing membranes (64) wili be
altered by many carcinogens, and may be important at
different stages incarcinogenesis, it isbelieved thatthe
primaryinitial site forcancerinductionisthe DNA. The
evidence for this hypothesis rests on a number of ob-
servations: (1) the great majority of biological carcino-
gens that have been examined interact with the DNA
of the host cell (65); (2) many, but not all, radiations
and chemical carcinogens are mutagens, and mutations
result from alterations in the DNA (66); (3) individuals
with certain genetic diseases which are characterized
by defective DNA repair, such as xeroderma pigmen-
tosum, are prone to cancer at a number of sites and
cells from these individuals have increased sensitivity
toseveralradiationsandchemicalmutagens (67-69); (4)
ultraviolet (254 nm) light-induced tumor formation in
the gynogenetic fish, Poeciliaformosa, is directly re-
lated to the amount of DNA damage remaining after
different levels ofphotoreactivation repair ofthe DNA
(70). Factors which influence the expression of cancer
cells may or may not act on the DNA during different
stages. These factors willbe referred tothroughout the
text, but especially in the subsequent sections on pro-
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motion, progression and multiple agents.
The changes in information content of DNA can take
many forms such as integration into DNA of viral in-
formation for biological carcinogens, chromosomal al-
terations with radiations, and changes in the base se-
quence after replication as a result ofadduct formation
with many chemical carcinogens.
Biological Carcinogens. Many viruses will induce
cancer in various organs of one or more species (71).
The most progress made recently in understanding the
mechanisms of viral carcinogenesis relevant to human
cancer involves onc genes, expression control elements,
dominant transforming genes, and human viruses.
Studies on oncogenic RNA viruses have provided the
background for detailed investigations of genes in the
cell with oncogenic potential and for development of
methodologies enabling identification and isolation of
dominanttransforming genes in humantumorcells (72-
85). This approach has helped identify genetic elements
that may be responsible for certain types of cancer. A
major class of RNA tumor viruses, known as retrovi-
ruses, has been particularly useful in providing new
insight into the cancerprocess. Retroviruses areunique
among animal viruses in theirmode oftransmission and
their intimate association with a wide variety of ver-
tebrate species (86), factors which may have allowed
them to become oncogenic in a number ofspecies. Cer-
tain members ofthis group, the acute transforming re-
troviruses, appear to have arisen by recombination of
the viral genome with cellular genes. The acquisition
by these viruses of cellular genes, termed onc (for on-
cogenic) genes (87), is associated with the ability of
these viruses to induce rapid neoplastic disease in new-
born animals and to transform cells in culture, an in
vitromodelforcarcinogenesis. Thesegenes(thenumber
isolated, at present about two dozen, is increasing) ap-
pear to be of major importance to the cells since some
have been conserved in widely divergent species (88).
The RNAtumorviruses containingthemcanbethought
of as vectors that carry isolated cellular-derived genes
critical for malignant neoplastic disease.
Thegenes inthe normalgenome ofacellwhichappear
to have given rise to the onc genes, presumably as a
result of viral infection, are termed proto-oncogenes.
There are human genes homologous to retrovirus onc
genes (89-93) and specific onc genes can be identified
in many different human cancer cells (94). Some onc
genes are rarely expressed, some are expressed chiefly
in specific kinds ofcells derived frommalignant tumors,
and some appear to be expressed only in cells ofcertain
lineage ordifferentiation states (95,96). The specific cel-
lular functions coded by most onc genes are unknown,
although a variety of activities have been found. For
example, the gene product of one family of oncogenes,
src, is a protein kinase, usually tyrosine-specific (97),
similar to the kinase often activated by binding of a
number of growth factors to their receptors. Interest-
ingly, phorbol tetradeconate acetate (TPA) (an impor-
taht model compound in tumor promotion) (see below),
may substitute for diacylglycerol and permanently ac-
tivate protein kinase C, a tyrosine-specific protein ki-
nase (98), which phosphorylates insulin and somato-
medin receptors (99). ras p21 protein seems to have a
guanosine triphosphatase activity (100). Sometimes,
only pieces of a cellular protein are coded, e.g., erbB
codes for the integral membrane and large interior por-
tions ofthe epidermal growth factor receptor (101) and
fgr seems to produce a hybrid protein resulting from
the recombination ofactin and part ofatyrosine specific
protein kinase (102). The onc gene of simian sarcoma
virus was probably derived from genetic material en-
coding platelet-derived growth factor (PDGF), which is
a growth factor in the type of tissue which becomes
cancerous as a result of this virus (103), while c-myc
seems to mediate the mitogenic response to platelet-
derived growth factor (104) by localizing in the nucleus,
perhaps by its DNA-binding properties (105). This is
especially interesting in that it has been shown that at
least two oncogenes, ras and myc, can work together
to transform primary fibroblasts in culture (106) (al-
though Ha-ras-1 can be effective alone ifit is mutated)
(107). When an onc gene is expressed at high levels, an
increase in gene dosage or expression has been corre-
lated with the transforming activity of the virus (90).
Alternatively, there is some evidence that the removal
of a suppressor or regulatory gene, with the possible
involvement of an oncogene as a second step, may be
important in human retinoblastoma (108), while erbA
(similar to carbonic anhydrase) blocks differentiation of
immature erythrocytes and potentiates the effects of
erbB (109). It appears that any step in the growth reg-
ulation of cells, from receptor through kinase and nu-
clear changes, can be affected by different oncogenes.
These dataalso suggestthatthereis atwo-partmodel
for transformation. The first part centers around the
stimulation of some growth factor, and the second, an
alteration in the cell nucleus. The first part may also
involve the interaction of a cell with other cells, as
growth factors can be elaborated (110), and the second
may be an intrinsic change in the cell itself. Although
this is a speculation and there are important gaps in
information, a general picture ofthe mechanism ofviral
carcinogenesis is starting to emerge which also may be
very important in understanding chemical carcinogen-
esis, since activated oncogenes are seen in chemically
induced rodent tumors, e.g., ras in rat nitrosomethy-
lurea-induced tumors (111).
Some normal cell onc genes can be activated when
linked with expression control elements (ECE) derived
from the retroviruses (72,112,113). The ECE regulate
the level ofexpression or gene dosage ofthe retrovirus
genome in an infected cell and can be used to "switch
on" expression of other genes. Recent studies suggest
that when the ECE is linked to an onc gene it activates
the gene's transforming potential by increasing the
gene's level of expression (112). In vivo, the same two
factors, onc and ECE, which appear to link by chance,
have been shown to be responsible for oncogenesis in
animals infected with certain retroviruses (112).
The viruses from which the acute transforming re-
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troviruses seem to have originated, the leukemia re-
troviruses, usually cause leukemias or lymphomas, but
can also cause a variety of other neoplastic diseases in
animals after long latent periods (86). When these vi-
ruses infect a large population of cells, viral genetic
information can integrate at many loci in the host gen-
ome. The stable integrated form ofthe virus (called the
provirus) is bracketed by the same ECE described
above. These ECE are virus specific and are generated
during the integration process (114). In some instances
these viruses will integrate at loci in the host chromo-
some adjacent to cellular onc genes and will cause neo-
plastic disease (115). Similar to the situation described
above forthe acute transforming retroviruses, this spe-
cific integration results in elevated levels ofexpression
of a specific cellular onc gene which becomes regulated
by the viral ECE. The long latent period required for
neoplastic disease induced by these viruses may be as-
sociated with the frequency of, or time to, specific in-
tegration in the host chromosome ofthe viral ECE ad-
jacent to a cellular onc gene.
Some radiations and chemical carcinogens might en-
hance either the frequency of initial integration of the
virus or subsequent rearrangement ofviral material by
inducing chromosomal translocations. In Burkitt's lym-
phoma, a characteristic portion of human chromosome
8 (carrying c-myc) is translocated to chromosome 14,
the site ofimmunoglobulinheavy chains (114-116). This
onc gene is the same one activated by aretrovirus tran-
scription control element in avian bursal lymphoma dis-
ease (117,118). Also, c-abl is translocated in chronic
myelocytic leukemia patients with a Philadelphia chro-
mosome (a translocation of the gene from chromosome
9to chromosome 22adjacent to animmunoglobulin light
chain cluster ofgenes) (116). Such translocations might
conceivably result in the juxtaposition of an onc gene
and an ECE, altering onc gene expression. The same
result might arise from direct genetic insult (via some
carcinogen) to the ECE which normally regulates
expression of the cellular onc gene.
Considerable study is now being focused on ECE. It
has been known for some time that certain nucleotide
sequences which bracket structural genes are associ-
ated with the initiation and termination ofgene expres-
sion (120). However, it was first shown with transform-
ing genes that a region termed "enhancer" must be
present in order for these start and stop signals to be
recognized (72,112,121,122). Although it is not yet
known how enhancers function, apparently they can be
located in a number of different positions surrounding
the structuralgene. Moreover, eventhoughthefewthat
have been examined bear little sequence homology, the
enhancer sequences fromretroviruses have been shown
to function to allow expression of a DNA tumor virus,
SV40 (122). Also, the sequences seem to be utilized in
normal differentiation, as shown by the evidence that
immunoglobulin heavy-chain class switching in a pre-B
cell line is accompanied by gene rearrangement (123),
and, in the development of Burkitt's lymphoma, the
activation ofthetranslocated c-mycgene seems to occur
byanenhancerintheheavy-chainimmunoglobulin locus
(124). It is possible that translocation into a region con-
trolled by an enhancer or mutations in gene enhancer
or activator sequences of cellular onc genes could par-
ticipate in expression of a transforming phenotype.
Another area of considerable study during the past
two years has been the direct isolation of dominant
transforming genes from human tumor cell lines (83-
85). A biological assay referred to as transfection was
used early in tumor virology to demonstrate that host
genomic DNA containing dominant viral onc genes
couldbetransferred tonormal cells (86). The earlystud-
ies were developed and refined by using cells trans-
formedwith acutetransformingretroviruses; theydem-
onstrated clearly that the integrated provirus could be
transferred as part ofthe cellular genomic DNA in spe-
cific cell lines capable of assimilating foreign DNA into
theirchromosomes. Byusingthistechnologyithasbeen
possible to transfer dominant transforming genes from
a variety of tumor cell lines from different species, in-
cluding human. These include genes from human lung
cancer, colon cancer, bladder cancer, and breast cancer
cell lines (83-85,125-127). By utilizing recombinant
DNA techniques, it has also been possible to identify
and isolate (in certain instances) these dominant trans-
forming genes from the transformed recipient cell and
to show that these isolated genes are of human origin
(83-85). In the molecular cloned state, the genes have
high oncogenic potential. It is of particular importance
that some ofthese genes (for example, genes associated
with human bladder, lung, and colon cancers) are re-
lated to a specific family of retroviral onc genes (128-
130). In the case of a human bladder cancer gene, a
single base change in normal human gene results in
expression ofits oncogenic potential (131-133). Also, in
the case ofchemically induced tumors, there is sugges-
tive evidence that the activation of an oncogene can
occur by a single base change (111). The study of RNA
tumor viruses has provided an initial understanding of
how viral onc genes cause cellular transformation. The
correlationwithhumanoncgenesprovides an enormous
leap in our understanding of causal factors in human
neoplastic disease.
Recently, retroviruses of the kind that cause leuke-
mia in animals have been isolated from humans. These
human leukemia viruses (HTLV) are known to be as-
sociated with several types of T-cell leukemias in man
(134,135). When they are transmitted to normal human
T-cells, they induce a morphology, behavior, and phen-
otype similar to those naturally occurring in trans-
formed cells isolated from individuals with T-cell leu-
kemia and lymphomas (136). This virus, the presence
of which correlates with clusters of the disease, thus
may represent a true human cancer virus (137,138).
Other viruses, such as herpes viruses, especially Ep-
stein-Barrvirus(EBV), hepatitis B virus, andpapilloma
viruses, have also been associated with human cancers
(139). Although these viruses do not fit all the presently
recognized criteria for a true human tumor virus, they
may nonetheless influence the development of certain
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human cancers. Thus, EBV appears to be a stimulus
for proliferation ofB-cells which may be an early event
in the development ofAfrican Burkitt lymphoma (140).
Herpes simplex, a DNA virus, is associated with cerv-
ical cancer (141), and hepatitis B virus to liver cancer
(142). Papilloma viruses cause benign skin growths
(warts) and some strains have recently been shown to
be associated with squamous cell carcinoma (143). Much
current work is focused on a possible similar role for
papilloma viruses in cancers of the genital tract and
accessory organs (144,145). How, and even whether,
these and other viruses play a role in various types of
cancer or interact with various "physical" and chemical
carcinogens is poorly understood; but the belief that
DNA is a critical target for the biological carcinogens
is strongly supported by current studies. New meth-
odology to prepare antibody-using chemically synthe-
sized peptides from nucleic acid sequences-makes it
possible to generate antibodies against severaldifferent
onc gene products (146) and to characterize the molec-
-ular properties of the transforming proteins in trans-
formed cells. This method should aid in developing a
better understanding of how chemicals and viruses in-
teract with one another.
Radiation. Radiations, both ionizing (the corpuscular
radiations and X- and gamma-ray photons) and nonion-
izing (ultraviolet light) radiations, have been shown to
act as carcinogens (28). Ionizing radiations are ubiqui-
tous, with cosmic rays and naturally occurring radioiso-
tope decay being examples of major sources of back-
ground radiation. UV is also ubiquitous, being a com-
ponent of sunlight.
Carcinogenesis by ionizing radiations is generally re-
lated to the spatial distributions within cells ofthe ion-
izations they produce (28) as well as total dose, dose
rate and fractionation, and targettissue (147). The dep-
osition of energy which results from the interaction of
radiation with biological media creates ions, free radi-
cals and excited molecules (147). The free radicals are
thought to be most important product since: hydroxyl
free radicals are involved in some of the biological ef-
fects ofradiation (148); chemicals that are cellular free-
radical scavengers inhibit the ability of ionizing radia-
tions to transform cells in vitro (149); and chemicals
involvedinprotectionfromfreeradicals (e.g., selenium,
which is important in the action of glutathione peroxi-
dase, an endogenous scavenger system) inhibit radia-
tion-induced transformation (147). (These data also in-
dicate a role for modulators ofmetabolism in radiation-
induced carcinogenesis, since enzyme systems may be
modified bymetabolic changes.) Free radicals willreact
with many cellular macromolecules, but the production
of DNA single-strand breaks, double-strand breaks,
chromosomal aberrations, and the production of muta-
tions by ionizing radiation, argue that the DNA is the
criticalcellulartargetforthebiological effects (although
the relationship ofany ofthese phenomena with carcin-
ogenesis is not definitive) (147). Although experimental
dosimetryismuchbetterdefinedforradiationcompared
to most chemical agents, the molecular lesion(s) signif-
icant for carcinogenesis is (are) unknown and may be
different for different radiations [one example ofa pos-
sibly significant lesion is the reaction of the hydroxyl
radical with the deoxyribose in DNA, which results in
DNA strand breakage (130), although many other le-
sions are formed]. The absence of "radiolabelled ad-
ducts," common for many chemical agents, has ham-
pered analysis.
UV photocarcinogenesis is wavelength-dependent,
with UVB (photons with a wavelength of280-320 nm)
being most effective on mouse skin (151). Although the
photoproducts produced by UV irradiation in cells are
myriad (152), reaction with the DNA has been shown
to be the critical factor in carcinogenesis. There are a
number of lines of evidence which suggest this. First,
in patients with actinic keratoses (a premalignant con-
dition)the DNArepaircapacityforUV-induceddamage
(UV excision repair) in lymphocytes was found to be
less than in matched controls (153). Also, individuals
with xeroderma pigementosum, who exhibit a predis-
positionforsunlight-related cutaneousmalignancies (al-
though having a number of genetic complementation
groups) generally are deficient in the ability to repair
damage inducedby UV (67). Byuse ofantibodies, DNA
has been shown to be altered immediately and directly
by UV irradiation (154). The persistence of UV pho-
toproducts after photoreactivation, a repairmechanism
which specifically corrects pyrimidine dimers in the
DNA induced by UV, is directly correlated with the
capacity ofUV-irradiated tissue to develop into tumors
(70). Finally, the action spectrum (relationship of in-
tensity of a biological response to frequency) of UVB
photons is the same for their carcinogenic action and
theproductionofpyrimidine dimersinmouseskin(155).
It is important when making estimations of risk for
chemical agents that we realize that many ofthe tenets
upon which these estimations are made are based upon
information from radiation carcinogenesis. For exam-
ple, the hypothesized mechanisms of the action of ra-
diation, while nottheprimaryconcern ofthisdocument,
haveserved, andcontinuetoserve, asthebasisforsome
of the primary models for chemical carcinogenesis
(156,157). Much evidence that damage to the cellular
DNA is a step in the induction of tumors comes from
studies using radiation. Similarly, various models for
high-dose to low-dose extrapolation have their origins
in studies using radiation and the best data for these
models have been obtained from such studies.
Chemical Carcinogens. The interaction of chemical
electrophiles with DNA, as discussed in the section on
metabolism, may lead to covalently bound adducts, in-
tercalations, strand breaks, phosphotriesters, cross-
links, apurinic sites, apyrimidinic sites, deaminations,
and/or hydrations, all ofwhich are forms ofDNA dam-
age that may alter genetic information (54,158-170).
Studies ofchemicalcarcinogenesishavefocussedoncov-
alent adducts. Examples of this are the observations
that: simple alkylatingagents canmethylate orethylate
any of the nitrogens or oxygens in either of the four
bases in the DNA as well as the sugar residues and
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phosphate backbone ofthe DNA (171); the epoxide de-
rivatives ofaflatoxin canattacktheN-7positionofguan-
ine (172) (as well as other sites); activated aromatic
amines attack the C-8 and N-2 position of guanine
(173,174); and the dihydrodiol-epoxide derivatives of
benzo(a)pyrene and certain other polynuclear aromatic
hydrocarbons attack the N-2 position of guanine and,
to a lesser extent, form adducts with adenine and cy-
tosine (175,176). Activated derivatives of these and
other carcinogens form similar lesions in the DNA of a
number of diverse tissues and species (176,177).
The biological significance of these alterations in the
DNA is not always clear, and different alterations may
have very different biological effects. Some alterations
may cause mutations (178,179). For example, modifi-
cation ofthe 0-6 position ofguanine will cause this base
tobemisread, duringDNAreplication, asadenine (180).
Also, the major guanine adduct of benzo(a)pyrene,
through a transversion, may be misread as a cytosine
or thymine in replication (181,182). Alterations in the
control ofDNAare possible. The amount ofmethylation
of DNA, which may be used in the control of genetic
expression (183), can also be altered by some agents.
Some of the carcinogenic metal complexes may work
through alteration of the enzyme that replicates DNA
(DNA polymerase) to cause alterations in the genome
through miscoding ofDNA bases after replication (this
will be discussed in detail in the section on fidelity/in-
fidelity ofreplication).
"Physical" Carcinogens. This class ofcarcinogens en-
compasses a number of very diverse phenomena in-
cluding skin abrasion, scar formation, implantation of
nonreactive materials (foreign bodies), schistosomiasis,
etc. (the term physical carcinogen also is sometimes
used to refer to radiation, i.e., a physical agent). Com-
mon factors of this class seem to be the need for the
development of a chronic fibrosis, or a least an inflam-
matory response, and the observation that chemical
properties, e.g., of a foreign body, are not important
(29). Aninterestingmechanism, with anumberofsteps,
proposed for foreign body carcinogenesis may be rel-
evant to the whole class. During tumorinduction, there
is an acute inflammatory response with an outgrowth
ofcapillaries as cells adhere tothe surface ofthe foreign
body. This response is induced by a number of sub-
stances (including mitotic stimuli similar in some ways
to growth factors), elaborated by cells in the vicinity of
the foreignbody. Fibroblasts increase innumber, which
leads to tissue deposition of collagen (fibrosis). After a
latent period, uncontrolled proliferation begins (184).
The initiation event seems to occur away from the for-
eign body surface, inducing an initiation cell through
changing the environment ofthe cells in the vicinity of
the foreign body (29). However, the inflammatory re-
sponse results in an active cellular proliferation of a
number ofvascular-derived cells (this step can also oc-
curintheinflammatory responsegeneratedbythe other
"physical" carcinogens). By its presence, the foreign
body causes the macrophages to become quiescent and
the reactive tissue to develop into a chronic fibrotic
state, so that there is surface-independent maturation
of the initiated cell (29). Asbestos, which is frequently
considered a member of this class, may induce cancer
by a different pathway since, unlike other "foreign bod-
ies," fragments of asbestos fiber are incorporated into
and activate macrophages, as well as slowly dissolve
components (185). However, the end result is a fibrosis,
i.e., asbestosis, which, though more diffuse, is similar
in many ways to fibrosis induced by the foreign bodies
(29). The size of the asbestos fiber and the possibility
of chemical effects because of fiber dissolution of ad-
sorbed molecules make direct comparison with foreign
body cancers difficult.
It is not clear how, if at all, this class of carcinogens
interacts with the genome. Speculations include: no in-
teraction with the genome, with the recruitment ofom-
nipresent previously initiated cells by a proliferative
stimulus into neoplasia; the environment of the inflam-
matory response, especially the production offree rad-
icals by macrophages, causes chromosomal damage and
rearrangement resulting in transformation; and a stim-
ulation ofproliferationmayresultinmutationasaresult
ofinfidelity ofreplication (see below); however there is
little information in the area.
General Statements. The interaction ofelectrophiles,
or the products ofirradiation, with DNA can play arole
in the induction of a tumorigenic phenotype through
either oftwo mechanisms: directly, by altering genetic
material through a somatic mutation (178) or indirectly,
by altering gene expression (183). Somatic mutation,
for example, can arise from the direct interaction of
DNA with electrophiles, free radicals derived from car-
cinogens, or with activated oxygen produced by metab-
olism of the agent. The alteration of gene expression
can arise from (1) a direct mutational event in a regu-
latorygene controllingexpression (e.g., basetransition)
(178,186); (2) changes in gene expression resulting from
an increased rate ofabnormal base incorporation due to
enhanced DNA synthesis, or abnormal methylation of
nucleicacid bases (183); or(3) induction ofgenetictrans-
positions or gaps in the DNA leading to an alteration
in gene expression (higher order alterations) (190). Di-
rect alterations in the informational content of cells
seem to be commonformany carcinogens. The potential
involvement ofanonc genewith eitherdirectorindirect
alteration of the genome has been discussed in a pre-
vious section.
Understanding the significance ofthese changes may
now be possible with the recent development of new
methods to determine the structural alterations caused
in DNA by chemical carcinogens and radiation (188).
This has occurred as aresult ofrecent advances in spec-
troscopic and spectrometric instrumentation, especially
inthe areas ofnuclearmagneticresonance spectroscopy
and mass spectrometry. Significant progress has also
been made in understanding the effect of carcinogens
upon DNA's higher-order structure (189-191). For ex-
ample, recent studies have demonstrated that while
methylating and ethylating agents do not induce major
steric changes in DNA, aromatic amines induce "base
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displacement" (192). Additionally, the carcinogen 2-ace-
tylaminofluorene appears to induce a flip from a con-
ventional right-handed DNA helix to the left-handed Z
form (175,192), which may induce changes in gene reg-
ulation (191). Such changes, while not induced by all
chemical carcinogens could, if they occur in vivo, sug-
gestmechanisms bywhichchemicalsinducemajorsteric
alterations in the structure ofDNA. The biological con-
sequences of such changes, however, are uncertain.
Even newer techniques are being developed, such as
radioimmunoassays usingmonoclonalantibodies against
specific forms of DNA damage (193) and reversed la-
belingmethods that are able to detect a single damaged
base per cell (194), that may eventually allow routine
estimation of DNA damage in humans and better es-
timation of its biological effects.
Modulation ofAltered Genetic Information
Formany carcinogens, itisnecessaryforcellularpro-
liferation to occurbefore the damage inducedbyagiven
agent is expressed. Forinstance, a cell replication must
occur within 48 hr to express X-ray-induced transfor-
mation in cell culture (195). Replication must also occur
invivo inliver(196). Onewaytothinkabouttheprocess
isthatacellisfirst"primed"foralterationbyinteraction
with acarcinogen; cellreplication thenresults in atleast
one daughter-initiated cell, i.e., a cell irreversibly al-
tered so that it can interact with the proper stimulus
to form a malignant cell.
The alteration of genetic information that produces
the initiated cell is modulated by a number of factors.
Two of the most important are: the amount of DNA
damage (adducts, strand-breaks, etc.) that is removed
from the "primed" cell and its daughters (DNA repair)
and the accuracy ofDNA synthesis (fidelity/infidelity of
replication), both as a result of damage to the genome
and as a result of changes in cellular parameters (ion
concentrations, etc.).
DNA REPAIR. DNA damage is believed to be one of
theprimaryfactorsinchemicalcarcinogenesis. Thebulk
of evidence for this assertion comes from studies im-
plicating UV and ionizing radiation as etiologic agents
in cancer induction (198). For example, as discussed
above, individuals with xeroderma pigmentosum who
are defective in repair of UV-induced and some forms
ofchemically induced DNA damage (68) exhibit a high
incidence oflight-related cancers (199). More generally,
the available data are equivocal as to whether there is
an increased risk of development of cancer of the in-
ternal organs (69,200). Problems with interpretation of
these observations include: chemically-induced and UV-
induced damage may induce cancer by different means;
organ-specific differences existforcancerinduction; and
the time to tumor may differ significantly between or-
gans and death of the individual due to complications
arising from the skin tumor prior to the onset ofcancer
in an internal organ or tissue. Also, however, the da-
tabases may have been too small to support any con-
clusion and a larger study may resolve any problems.
Because oftheimportance ofDNAdamage, anumber
ofshorttermbioassay systems that measureit, directly
or indirectly, have been developed to screen for poten-
tial carcinogens. One ofthe most important modulators
of the amount of DNA damage an agent causes, DNA
repair, has been studied in numerous in vitro and in
vivo biological systems (201).
From these studies, various pathways for repair of
numerous forms of DNA damage have been identified
(Table 3) (202-251). Many ofthe processes ofrepair in
mammalian cells are similar to those described in bac-
teria, and thus it is assumed that these systems have
been conserved during the course of evolution. It has
been speculated that the primary role ofthese systems
in evolution was to protect the genetic information of
the species from both endogenous and naturally occur-
ring exogenous DNA-damaging agents, especially long
enough for the organism to replicate (249). All species
examined thus far possess at least one form of DNA
repair (219).
Since the nature of DNA lesions formed by agents
which are genetically toxic and the methods of their
repair are so similar across species, the use of prokar-
yotes to screen for this particular form of genetic tox-
icity seems reasonable. However, the greater complex-
ity of the mammalian systems requires that care must
be exercised in the interpretation ofbacterial data. For
example, chromatin structure in mammalian cells ap-
pears to make some regions of the DNA more acces-
sible, and others less accessible, to adduct formation
and repair (250-252). Furthermore, significant differ-
ences intherepairefficienciesbetweentissues (253) and
species (254-264) have been observed. In terms ofgen-
eral understanding of the significance of these differ-
ences, it is known that among the placental mammals
there is a good correlation between the maximum
achievable lifespan of a species and the ability of pri-
mary fibroblast cell cultures from these species to per-
form unscheduled DNA synthesis following UV expo-
sure (262,264). It is not known whether there is any
such relationship for DNA damage induced by chemical
electrophiles. Also, in animals, the organization ofcells
into tissues presents other complicating factors. One
example, based ontissueinteractions, involvesthe com-
plex effects of xenobiotic liver metabolism on the acti-
vated agent concentrations in other tissues. Another
involves tissues that are less active mitoticallythan oth-
ers. The longer cells are given to perform DNA repair
prior to DNA replication, the less likely it is that a
transformation event will occur (199,261). Still another
example may be the maintenance of many cells in sta-
tionary phase (Go) in a tissue. Those cells could be trig-
gered into DNA replication, and run the risk of muta-
genesis, by an agent delivered in adose sufficientlyhigh
to induce cell killing (see below, section on hyperplasia)
(267). Since the latter possibility has been used to ex-
plaintheapparentthreshold effectsseeninvariouslong-
termlow-dose vs. high-dosecarcinogenesis experiments
using nitrosamines (by presuming that the high dose
induces cell killingandresultant divisionleadsto effects
thatareonlyseenwithahighdose)(265), understanding
factors such as these are important in assessing risk.
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Table 3. Mammalian DNA repair mechanisms.
Reaction
Nucleotide excision repair
Base excision repair
Strand break repair
Photoreactivation
Recombination repair
(post-replication repair)
Replication bypass
(post-replication repair)
Inducible DNA
repair systems
Action
Removes bulky, noncoding lesions from the DNA in a manner similar to
but not identical with bacterial nucleotide excision repair
Permits reinsertion of the proper base into the gap left in the DNA by
the action of enzymes that effect the excision ofinappropriate bases
from DNA as the free base (DNA glycosylases), avoiding scission ofthe
DNA backbone, as well as a system similar to the bacterial one
requiring strand scission. Included are direct demethylation by transfer
of a methyl group to an acceptor protein and AP site repair (direct
repair of a removed base)
Rejoins single- and double-strand breaks with the addition offew or no
additional nucleotides through the action of a sealing enzyme
Light-activated mechanism specific for the breakage ofthe UV-induced
covalent bond attaching two pyrimidines in a cyclobutane-type ring
System once believed to occur in mammalian systems but now
controversial, by which bulky, noncoding lesions are transferred to
DNA synthesized after damage
Process that may function in mammalian cells as an alternative to
recombination repair in which the bulky lesions are bypassed and the
gap created filled
Still speculative (for mammalian systems) repair system in which DNA
damage triggers the induction of enzyme systems to remove the damage
Other complicating whole-animal effects include diet,
age, and hormonal status, all ofwhich impact on DNA
repair (266-268).
Many biochemical mechanisms are involved in the re-
pair of DNA damage, and many factors may modify
their effectiveness. One mechanism is a nuclear enzyme
system which polymerizes activated ADP-ribose resi-
dues to form poly(ADP-ribose) (269). The biological
function ofADP-ribosylation is notclear; howeverthere
is a relationship between it, DNA damage, and DNA
repair, which may involve the capacity of the system,
demonstrated in vitro, to utilize damaged DNA (270).
This system also seems to influence the production of
sister chromatid exchanges (271) and has some rela-
tionship to mutagenesis and carcinogenesis, although
not a simple one (270). Another mechanism, recently
brought to light by the identification of a series of en-
zymes [collectively referred to as the DNAglycosylases
(214-218,272-278)] active inbase excision repair(Table
3), has indicated that there is much greater specificity
for the various kinds of DNA damage than was previ-
ouslythought. Over adozen ofthese enzymes havebeen
isolated from bacterial and mammalian systems, each
involved intherepairofaspecificform ofDNAdamage.
The apparent lack of nonspecific DNA damage recog-
nition enzymes in adult mammalian tissues and the high
degree of specificity of those repair systems that have
been studied suggest that there is specific repair of
many forms of DNA damage, including those induced
by man-made substances. Another recently discovered
mechanisminvolves aninducibleantimutagenesisrepair
system in bacteria (279). An inducible system, consid-
ered part of post-replication repair, was also found in
mammalian cells (243,244). Low doses of certain mu-
tagenic agents appear to induce a response in the liver
that enhances the repair of damage subsequently in-
duced by those agents. For example, in rat liver, an
inducible protein transfers the intact methyl group,
added to the guanine base by the potent carcinogen
dimethylnitrosamine, from the DNA to a cysteine res-
idue. Prestimulation of the animal with small doses of
the compound can enhance this inducible repair system
by as much as threefold (221).
As an example ofthe relation between knowledge of
mechanisms and resolution of science policy questions,
one canconsidertherelationshipofDNArepairsystems
and a threshold phenomena incarcinogenesis. In simple
terms, the threshold concept maintains that there is a
levelofexposure to anagentbelowwhichthereiseither
no observable effect and/or no adverse biological effect,
usually as a result of some reserve (280). The practical
manifestation of this concept is a dose-response curve
which does not appreciably differ from zero response at
some nonzero dose. The concept is used to evaluate
many toxic phenomena, but has been a source of con-
troversy in the evaluation of carcinogenicity. The ex-
istence of DNA repair systems has been used by some
authors to support speculation that a threshold exists
for the biological effects of chemical carcinogens, by
suggesting that low levels of DNA damage could be
totally removed, thereby removing the effects of a low
dose ofcarcinogenic agent. Such an extrapolation is not
supported by present data, as is shown below.
The following analysis will concentrate on the ques-
tion of a threshold for DNA damage and it must clearly
be recognized that DNA damage is only one part of a
complex chain ofevents leadingto carcinogenesis which
maybe effected inmultiple waysby anagent. Athresh-
old, or lack of threshold, for DNA damage does not
necessarily determine a threshold, or lack ofthreshold,
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for carcinogenesis.
First, no DNA repair system reduces DNA damage
to zero. Consistent with this observation is the obser-
vation that DNA damage accumulates in postmitotic
tissue, as afunction ofage even inthe absence ofknown
chemical exposure (282). The repair proficient systems
found in dividing Escherichia coli, when fully induced,
can reduce mutagenesis by up to 5000-fold, but the mu-
tation rate in exposed cultures is still 10 times that
which is produced spontaneously (283). The fragmen-
tarydatafrommammalian cells suggests thattheremay
be an inducible system (282), but it would be unreason-
able to assume that replicating eukaryotic cells would
be at less risk than prokaryotic cells from low doses of
a mutagen. Second, not all DNA repair systems are
error-free. While the data on inducible error-prone by-
pass mechanisms in mammalian systems are meager
(282), virus reactivation, whichislikenedtoamutagenic
effect, has been well established in eukaryotes
(245,282). This suggests that mammalian cells also pos-
sess an error-prone bypass system. Third, major vari-
ations in DNA repair efficiency occur between cells,
tissues, strains and species exposed to similar doses of
the same carcinogen (254-268). This heterogeneity lim-
its generalizations about the effectiveness ofrepair sys-
tems, constitutive or inducible, relative to the com-
pleteness of repair or the notion of a "safe" threshold.
Tissue differences in repair might result in a dose-re-
sponse relationship indicating a threshold for repair in
one tissue, but arelationship indicating no threshold for
repair in another, thereby providing little hope for uni-
form protection within an organism. In tissue or cell
culture, repair appears to vary between cells. Thus,
even if biochemical analyses, which normally measure
the average repair capacity of a heterogenous popula-
tion ofcells, demonstrate that a tissue or cell culture is
repair proficient, the possibility ofrepair deficient sub-
populations cannot be disregarded.
It is clear that DNA repair will not produce a thresh-
old for DNA damage. However, it is not clear what the
significance is of the DNA damage which results from
exposure to exogenous agents. Since some damage re-
sults from normal metabolism and, probably, exposure
to chemicals infoodstuffs (33) overthelife ofthe animal,
the importance of the additional burden induced by a
carcinogen above this background is hard to determine.
As noted above, since DNA damage is only a part of
the complex process leading tothe production ofcancer,
this determination probably can only be made when a
clear understanding ofthe mechanism(s) ofcarcinogen-
esis is achieved.
FIDELITY/INFIDELITY OF DNA REPLICATION. An-
other modulator ofthe alteration ofgenetic information
is the fidelity of DNA replication. Although it is not
proven that the role of DNA replication in initiation is
to stabilize incorporation ofthe effects ofDNA damage
in the genome ("fixation") (283), it remains the most
attractive possibility. The fidelity of DNA replication
(284) will help determine the integrity ofgenetic infor-
mation in the initiated cell.
Before one considers the ways fidelity can be altered,
it is important to understand the consequences oferror
accumulation in DNAin nondividing somatic cells (249).
In dividingcells, one is concerned with replicative error
propagation; that is, the transmission ofmistakes from
one generation to the next. Mechanisms that enhance
the frequency ofsuch mistakes could involve alterations
inthe DNA synthetic apparatus and havebeenreferred
to as intrinsic mutagenesis (285). In nondividing cells,
one is concerned about the effect of accumulated un-
repaired DNA damage on cell function. When consid-
ering mechanisms in carcinogenesis, attention is nor-
mally limited to either dividing cells or to resting cells
destined to undergo at least one further division cycle.
With our present understanding, a cell which fails to
undergo further division is not usually considered piv-
otal with respect to neoplasia. However ifamitotic cells
become, through some mechanism, able to divide, or if
nondividing cells are involved in the control ofdividing
cell populations, the accumulation of damage in them
can be significant. For instance, nondividing neurons
control the level of thyroxine, and it has been shown
that this hormone is an important factorin X-ray trans-
formation ofcells (286). Therefore, although usually not
appreciated, the effects of agents on nondividing cells
should not be ignored.
In dividing cells, a repaired or inadequately repaired
DNA lesion, such as an adduct, when present on the
DNA template at the time of replication, could result
in a genetic alteration, e.g., base substitution, such as
replacing aguanine with acytosine. However, damaged
DNA need not always cause significant base substitu-
tions during DNA replication. First, parental cells con-
taining the damaged DNA may fail to divide and thus
be progressively diluted during cellular proliferation.
Second, due to the redundancy of the genetic code, as
well as other factors, approximately 25% of incorrect
base substitutions may not result in amino acid substi-
tutions. On the other hand, a number of modifications
ofthe DNA template or ofthe DNA polymerases have
been shown to cause incorrect substitutions during
copyingbyDNApolymerasesinvitro (287,288). Ifthese
modifications are not corrected by subsequent DNA re-
pair, it is a reasonable expectation that the unrepaired
lesions will in time result in either mutations or ces-
sation ofcell reproduction (263). Alkylating agents and
carcinogens have been shown to induce misincorpora-
tion in vitro by modification of DNA templates and by
removal ofpurines from the DNA (289-294). Also, the
induction of an error-prone repair pathway (SOS) may
cause problems since the underlying concept ofthis re-
pair pathway is that it can alleviate potentially lethal
damage only at the expense ofinducingmutations (279).
Even if the template is undamaged, other factors
which can be altered by carcinogens, both directly and/
or indirectly, may cause the template to be copied in-
correctly. Somefactorsthathavebeenfoundtodiminish
the fidelity of DNA synthesis in vitro in two different
systems (289) and may have to be considered in vivo
are: (1)ratioofincorrecttocorrectnucleotidesubstrates
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(294-300); (2) type of incorrect nucleotide substrates
(296-300); (3) different metal activators for DNA po-
lymerase (288,291,295); (4) nonactivating metal muta-
gens and/or carcinogens (288); (5) depurination oftem-
plate (293).
During replication, the fidelity of DNA synthesis is
altered by changes in the reaction conditions. The error
rate ofmammalian DNA polymerases in vitro has been
shown to be dependent on the ratio of correct to incor-
rect nucleotides with both polynucleotide and natural
DNA templates (295,296). There is evidence that alter-
ations in cellular nucleotide pool sizes and content are
mutagenic (297-299), and the cellular homeostatic
mechanisms for precise maintenance of deoxyribonu-
cleotide concentrations maybe altered byvarious chem-
icals. Furthermore, agents may directly alter some of
the nucleotides in the pools available for replication,
leading to possible misincorporation (300,301).
Lindahl and Nyberg (302) estimated that the in vivo
rate constant forthermal depurination is approximately
3 x 10-" see-1, suggesting that as many as 10,000
purines may be lost from the genome of a mammalian
cell per generation time (20 hr). Furthermore, this rate
constant may be significantly increased after alteration
ofbases by alkylating agents (302). The intensity ofthis
formation of damage suggests that during replication,
thecellularmechanisms forcorrectingdepurinated sites
on DNA might not be able to repair every site before
the polymerase complex involved in replication encoun-
ters a damage site. Thus, replication over a damaged
site may be a secondary result of cellular interaction
with a carcinogen. Lastly, mutagenic/carcinogenic met-
als canaffectthefidelityofDNAsynthesisinvitro(289).
Thus, various agents that do not damage DNA directly
orenhance theproduction ofmetabolitesthatcaninduce
such damage may exert their effect by altering the fi-
delity of DNA replication. Methods to assess or screen
for such agents in mammalian cells are generally lack-
ing. The end result ofthese processes is that adaughter
cell can have an irreversible alteration in genetic infor-
mation (283), even though the cell which interacts di-
rectly with the agent does not. This altered cell may be
similar to normal cells in many respects, but may be
capable ofgiving rise to a cancer, i.e., be initiated, and
may lead to carcinogenesis if, during the lifespan ofthe
animal, it encounters an appropriate stimulus.
As previously noted, it is not clear what role DNA
synthesis has in initiation, though it has been shown
that manipulation of the rate of cellular proliferation
can modify tumor incidence. This has been demon-
strated: (1) in partial hepatectomy for animals treated
with methylnitrosourea, dimethylnitrosamine (283),
benzo(a)pyrene and radioactive particles that localize in
the liver (303); (2) with chemical treatment combined
with dietchanges, drugs ornatural physiological agents
such as hormones or bile acids which alter proliferation
rates (283), e.g., retinoids, which stabilize the differ-
entiatednondividing state ofepithelial cells amongtheir
other biological effects, have been used to inhibit mam-
mary and colon carcinogenesis (304,305); (3) in stimu-
lated hyperplasiaresultingfrom atoxic effect (306); and
(4) regeneration in skin using skin abrasion (307) (much
ofthese data are hard to evaluate however because the
treatments induce a chronic inflammatory response and
it is not clear whether one is studying the effects of
proliferation or the inflammatory response).
Cytotoxicity could be a stimulus for cellular prolif-
eration which may result in hyperplasia (308) (usually
termed restorative orreactive hyperplasia). A chemical
which may work through such a mechanism is carbon
tetrachloride, which is carcinogenic in mice but which
haslittle orno activityintestswhichmeasure alteration
ofthe genome (the compound was positive in yeast, but
only at doses which were almost lethal, casting doubt
on the relevance of the result) (309). Replication may
actto "fix" changesincells previously"primed"bysome
unknown stimulus or it may result in replication errors
through some ofthe mechanisms suggested above. The
possibility that hyperplasia can lead to carcinogenesis
has led to the speculation that a cytotoxic mechanism
is of primary importance in the carcinogenic effect of
all carcinogens which do not appear to act directly on
the DNA that are tested at a high dose (310), with a
suggestion that a dose which does not lead to cytotox-
icity would have no toxic effect. This hypothesis over-
looks the obvious problem that cytotoxicity is by no
means the only way an agent which does not appear to
act directly on DNA can alter either replication or gene
expression. Certain compounds can stimulate hyperpla-
sia without significant cytotoxicity (311). Furthermore,
it has been shown many times that neither the induced
hyperplasia (312) nor the irritant properties resulting
from promoters, such as PMA (313), are sufficient to
explain the promotion effect. Thus, a cytotoxic action
should be considered simply as an additional possible
mechanism ofcarcinogenesis and not equated to an ex-
planation for carcinogenesis for all nondirectly acting
agents tested at high dose.
Whatever mechanism(s) is (are) important in the for-
mation ofinitiated cells, it is clearthat cells irreversibly
altered in a heritable fashion are induced during this
process and that these are the progenitors of further
new cell populations during the carcinogenic process.
The properties of these cell populations are discussed
in the next section.
CancerFormation
How initiated cells with altered genetic information
result in a cancer seems to be the least understood area
of carcinogenesis. The process can be divided into two
operational stages, promotion and progression. Pro-
motion will be used to describe the process(es), usually
initiallyreversibleintestsystems, butlaterirreversible
(314), that results in cellular proliferation and termi-
nates when one or more neoplastic cells, i.e., cells with
the ability to grow autonomously, is (are) formed.1Neo-
plasticprogressionwillrefertothe nextstep(s) inwhich
cells become able to form tumors and become malignant
with some potential to metastasize.
PROMOTION. A promoter is experimentally defined as
an agent whichresults in anincrease in cancerinduction
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after long-term application subsequent to treatment of
an animal with an initiator. Under otherwise identical
conditions, neither initiator nor promoter alone induces
many tumors, nor does a regimen with reversed order
(treatment with promoter followed by an initiator)
(312). Ataparticulardoselevel andtreatment schedule,
a carcinogen that does not require supplemental pro-
moteractivityistermed complete. Manyorallcomplete
carcinogens act as both an initiator and promoter in
their interaction with the organism, and some act as
initiator or promoter for different tissues in the same
organism atthe sametime(315,316). Also, thepromoter
action ofacomplete carcinogen maynot actbythe same
mechanism as promoters used in initiator-promoter
paradigms (313). Separation ofthese two aspects ofcar-
cinogenic action is frequently difficult. However the
term remains a convenient description for one part of
an experimentally isolated complex process. For the
most part, the phenomenon of tumor promotion has
been most carefully delineated in skin and liver carcin-
ogenesis. It remains to be established more firmly with
cancer at other sites, though there is suggestive work
in colon, breast, kidney, central nervous system (283),
and bladder (311,317) carcinogenesis. At present, given
the lack ofinformation onmechanisms ofcarcinogenesis
in humans and the myriad interactions oftissue and the
biological effects of promoters demonstrated in exper-
imental systems, it is premature to designate agents as
acting through only a promotion-type mechanism, al-
though anumber ofagents seem to have some promoter
action.
This experimental definition will not clearly differ-
entiatebetweenpromotionandprogression, sinceitmea-
sures onlythe production ofamalignanttumor. Inprac-
tice, however, laboratory studies ofpromoter action are
usually ended after afocal mass ofcells (e.g., papilloma,
nodule) is observed (311). The appearance of the first
neoplastic cells has been proposed as a definition ofthe
end of promotion (283). This definition is useful, since
it emphasizes the frequently seen reversible effects of
promotion, i.e., regression of the direct results of a
promoter (e.g., papilloma) with termination of its use,
while clearly indicating that the role a promoter has in
carcinogenesis is to induce a presumably irreversible
event, aneoplastic cell. Asimilardefinitionis suggested
by the separation of promotion into two stages, based
on work in skin promotion in mouse (314). Stage one is
partiallyreversible, while stagetwo, whichrequirescell
proliferation, is initially reversible and then becomes
irreversible. When induced, many of the focal masses
are reversible, especially in skin and liver (283). How
these nonneoplastic masses originate is not completely
known, but they seem to arise through the differential
stimulation of cells altered by the initiator to respond
to the promoter (283). Of the persistent masses, in all
systems in which they are induced, almost all do not
become neoplastic (196).
Promoters are usually thought of as exogenous com-
pounds. Many ofthem are plantproducts (311,318) such
as certain of the phorbol esters, e.g., 12-0-tetradeca-
noylphorbol-13-acetate (TPA) or phorbol tetradeconate
acetate, which is also known as phorbol myristate ace-
tate (PMA). However, there is also evidence that cer-
tain compounds normally present in the body (endog-
enous) may also be promoters (319,320). Promotion by
such endogenous compounds may be difficult to dem-
onstrate, since production ofthe compound in the body
mustusuallybealtered (whichnormallyhasmanyphys-
iological ramifications) to observe an effect, as opposed
to exogenous compounds, whose levels are controlled
by direct application to a tissue. Another type ofinter-
action that seems to have promoter action occurs in
foreign-body tumorigenesis (197). Although it has been
claimed that a single event determines the sarcoma
which results from the implantation (183), it is clear
thatthereis astepwhere preneoplastic cells ofprobable
vascular origin (produced in a surface-contact indepen-
dent step) require a surface-contact dependent step to
become neoplastic (183). Like otherpromoters, removal
of a foreign body before the last step will, as a rule,
prevent the sarcoma from developing. Thus some sur-
faces, aswellas exogenous and endogenouscompounds,
seem to be able to act as promoters.
Despite recent significant progress, the mechanism
ofaction ofPMA, themodelpromoter, is notcompletely
clear. There is good evidence PMA binds to a receptor
(321,322), that activates protein kinase C (101,323) or
that may activate the kinase permanently through sim-
ilarity to diacylglycerol (98), similar to a number of
growth factors. Other promoters also interact with a
cell receptor (311,324), e.g., estrogens, suggested to be
promoters of mammary and liver tumorigenesis (325),
are known to produce their main biological actions
through receptors (326).
PMA produces profound biological effects in vivo, in-
cluding edema, erythema, inflammation, and cellular
proliferation (a property which allows the promoter to
participate in "fixation" if given within a short enough
time after the initiator dose). But these same effects
canbe produced byagents that are notpromoters (311).
Bystimulating specific separate effects ofPMAin other
ways, onecandefine, asnoted above, atleasttwo stages
in promotion (314,327,328), supporting the hypotheses
that cancer is a multistep process and that more than
one aspect of PMA may be important in promotion. In
vitro, promoters have been shown to induce an array
of diverse morphological and biochemical changes
(311,325,329). An important one may be the interaction
ofPMA and otherpromoters with cells to generate free
radicals (330-332). A similar stimulation is seen with
the use ofeither ionizing radiation or activated oxygen
(332), agents which damage the DNA. The capacity to
stimulate radicals seems tobe correlated with promoter
potency to generate tumors (330) and varies in a dose-
dependent manner for the strong promoter PMA (332).
PMAcan alsocause dedifferentiation orinhibitterminal
differentiation (334), stimulate cellular differentiation
(335), alter macrophages (336), induce chromosomal al-
terations (337) and sister chromatid exchanges (SCE)
(338), and induce virus synthesis (339). It is not known
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which, if any, of these effects are central to the role of
promoters in carcinogenesis, since evidence for all
models of promotion is indirect. However, the effects
on chromosomes may be especially relevant.
PMA can induce chromosomal anomalies such as
SCE, although the concentrations (100 ng/mL) required
forthis effect are quite high (338). The activated oxygen
species produced by the promoters, perhaps through an
interaction with membrane components, can induce
chromosomal damage and a soluble substance which in-
duces chromosomal abnormalities (a clastogen) in
nearby cells (337). However, the promotional effects of
PMA are reversible unless it is given for a fairly long
time while a chromosomal change, such as an aberra-
tion, is almost certainly not reversible. This suggests
that a chromosomal alteration could be an event, in-
duced by prolonged exposure to the promoter, which
terminates thereversible period inpromotion (191,312).
This suggestion is consistent with the observation that
papillomas, which emerge in a common response to pro-
moter action in skin carcinogenesis during the stage
when it is reversible, are primarily associated with a
diploid karyotype, whereas malignant tumors usually
havekaryotypic alterations (340,341). Theselectionpro-
cess for cellular characteristics important to neoplasia
may occur during the entire promotion process [indeed,
selectionmaybeimportant evenduringinitiation (283)].
Also, the need for prolonged exposure, leading to a
relatively large cumulated dose, may be why such high
doses have to be given to observe the effect in short-
term experiments in vitro.
Chromosomal changes, although not proven to be re-
sponsible for growth independence of neoplastic cells,
are implicated in transformation (342). For example,
SK-L7 human lymphoid cells markedly increase their
cloning efficiency in soft agar and decrease their dou-
bling time from 30 hr to 14 hr upon introduction of an
additional chromosome 15 (343-345). More directly, a
clastogenic effect is produced bycells from anindividual
with Bloom's syndrome, a clinical entity in which there
is usually a high cancer incidence (337). Specific chro-
mosomal transpositions, as seen in the case ofBurkitt's
lymphoma, can be associated with changes in the reg-
ulation of gene expression and also could be associated
withphenotypicchanges such asdifferencesinantigenic
expression and unresponsiveness to regulators of cell
growth. (It must be remembered, however, that this
analysis is drawing general conclusions about malig-
nancy from the pathogenesis ofrare diseases in persons
with a limited life span, which may not be appropriate.)
The hypothesis that achromosomal change is a causal
factor in cancer induced by promoters is attractive, es-
pecially when viewed with the evidence concerning the
effects oftransposition in oncogenes; however, few data
directly support this contention (199). Although there
is a lack ofmethods to measure such changes readily in
vertebrates, this hypothesis is interesting since such
genetic alterations are much more drastic than localized
changes in base sequences, may be either site-specific
or non-site-specific, do occur at different frequencies,
appear to affect the stability ofneighboring genes, and
are virtually irreversible. In rapidly multiplying bac-
terial cells, conventional mutagens do not enhance the
frequency of transposition (346); however, factors that
triggertranspositions orgovern theirrate ofmovement
are not yet understood well enough to determine
whethermutagens enhance transposition in mammalian
cells in vivo. Large-scale changes, such as rearrange-
ments and deletions, rather than the small changes re-
pairable by excision repair that can be detected in the
usual tests for mutagenicity may be more important to
predicting human cancer (199). It appears that localized
lesions in DNA can be carcinogenic (55,347); it is not
clear whether such lesions might act either indepen-
dently or through induction of direct or indirect induc-
tion of major genetic alterations or through a combi-
nation of both factors (348).
Evidenceisstartingtoaccumulatethatbothoncogene
activation and treatment by some promoters have some
aspects in common, i.e., the activation of some growth
factor-like stimulus. Interesting in this regard is the
discovery that metallothionein gene induction by heavy
metal ions (such as cadmium) and glucocorticoid recep-
torsbothworkbyactivationof"enhancer-like" elements
(349), which leads to the speculation that the direct
interaction of certain metal complexes with DNA may
have effects similar to hormone or growth-factor in-
duction forgene expression. In some cases, the primary
stimulus seems to need some second factor, another
oncogene involving a nuclear protein in the case of on-
cogenes, or Phase II promoters, involving replication,
to cause transformation. In this light, chromosomal
changes might be seen as merely a possible, but not
obligatory, method to accomplish the same end, with
the final, chromosomal change equivalent to the second
oncogene activation or the effect of proliferation and
other changes in the case of the PMA stimulation.
Cancers in humans from causes such as exposure to
cigarette smoke or exposure to benzidine in the work-
place have a very long latent period. It is not clear
whether this long period is the time from exposure to
the production of a neoplastic cell (promotion) or the
timenecessarytogofromaneoplasticcelltoamalignant
tumor (progression). Evidence that the carcinogenic
risk of cigarette smoking declines with the length of
time after smoking stops (350), suggests that most of
the latent period is partially "reversible" and therefore
probably occupied by a phenomenon similar to promo-
tion.
This is also suggested by a recent model for the de-
velopment ofBurkitt's lymphoma, which seems to be a
virally produced cancer (351). According to this model,
a lymphoma clone develops in one or more steps from
B lymphocytes that have acquired neoplastic charac-
teristics due to EBV transformation, and the fully ma-
lignant phenotype occurs only when the lymphoblastoid
cells acquire a specific chromosomal translocation that
involves the immunoglobin locus. The long latency pe-
riod seen in the disease has been suggested to arise
from the need for a promoter-like stimulus that may
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cause proliferation andinterfere withthedifferentiation
ofthe long-lived initiated B cells (341).
Since neitherinitiator norpromoteralone is sufficient
to cause tumors and since promotion appears to be in-
volved in the carcinogenic process, especially in time to
tumor induction, low-level exposure to certain carcin-
ogens may only become significant after subsequent ex-
posure to promoters. This bears on the question of a
threshold for tumor promoters. Although it has been
stated that promoters have a threshold (310), there is
little good evidence for this. Studies of the dose-re-
sponse curves for promoters, e.g., PMA (352), have
clearly been inadequate for the purpose of defining a
threshold, as is usually acknowledged by the authors
involved. Also, thereis aquestion ofinterpretation. For
instance, recent workhas shown thatbladder stone for-
mation by high doses of melamine is correlated to the
carcinogenic effect ofthis agent in rats (353). (The sig-
nificance ofthis observation forcarcinogenesis has been
brought into question by the discovery that mice, with
similar propensity to develop stones and induce tumo-
rigenesis bybladderimplantation, have little melamine-
induced bladder cancer.) This has been taken by some
authors as indicating a threshold for "promotion." Al-
ternatively, thedoseusedintheassaycanbeconsidered
to have induced a significant pathological effect (other
than tumorigenesis) that was important in generating
the cancer seen. Similar considerations are appropriate
for agents which induce other functional pathological
effects only in high dose, e.g., immunosuppression. It
must be remembered, though, that agents whichinduce
these pathological effects may have other actions [e.g.,
azathioprine ismutagenic aswell asimmunosuppressive
(309)], whichcould contribute tocarcinogenesis atlower
doses. Also, it must be kept in mind that the tendency
to induce a pathological effect may vary with the well
documented variations in individual human response to
agents. Important factors in tumor promotion such as
dose, dosing schedule, tissue specificity, interaction
with initiating stimulus, etc. create substantial uncer-
tainty about any general statements regarding thresh-
olds.
Generally, animal bioassay studies, because of their
design and the conditions under which they are con-
ducted, fail to distinguish between initiating or pro-
moting activity or between a direct or indirect action
by the agent on the genome. Although it may be useful
togroupcompoundswithsomecriteria; e.g., mutagenic,
or having a particular biological effect in a particular
strain, one should be careful about implying that some-
thing is known about the mechanism of action. The
grouping, since it is not based on knowledge of carcin-
ogenic mechanism in vivo, may have no relationship to
the multiple routes by which carcinogenesis could be
induced in a particular instance (354). It is difficult to
be clear about what is the target of a particular agent
when the mechanism of effect of any agent is still un-
known. However, itis stillimportant to define the kinds
of promoters and to examine the patterns of exposure
to them to help elucidate mechanism.
SPECIFICITY/ANTIPRoMoTIoN. Tumor promoters
often display tissue specificity, having primary effects
on only one oralimited numberoftissues inaparticular
species. For example, estrogens seem to be promoters
in breast (319) and liver (320) in animal models. Mouse
skin and bladder are also specifically responsive to cer-
tain promoters (311). An interesting sidelight to this
aspectofpromotionisthatthePDGF-likematerialstim-
ulated by the sis oncogene is active specifically for the
tissue which develops the sarcoma produced by the vi-
rus (102). Since some promoters seem to be simulating
growth factors, and many growth factors tend to be
fairly tissue-specific, this may be an important source
for the tissue specificity seen.
The potential for any tissue to give rise to a tumor
after initiation may be partly determined by inherent
biological processes; treatment to prevent disease may
be designedtointerferewiththoseprocesses, especially
with endogenous tumor promotion. Such inherent pro-
cessesmaybealteredbydiet, stress, orotherconditions
such as individual genetic differences or altering phys-
iological function. For example, a number of experi-
mental animal studies suggest that a high fat diet can
promote carcinogenesis in breast and colon, while epi-
demiological studies show a positive relationship be-
tween dietary fat and breast cancerin some populations
(355). However, to confirm that a low fat diet will de-
creasethesetypesofcancer(13), additionalstudiesneed
to be conducted in countries with a wide genetic diver-
sity where a high proportion ofthe population's caloric
intake comes from fats. It must be kept in mind that
the total carcinogenic response should be considered.
Forinstance, therearecertainpopulations, withcertain
lifestyles and diets, such as the Japanese, which have
alowincidenceofonecancer, suchascoloncancer, when
compared with other cultures (e.g., Americans). How-
ever, they frequently have a high incidence of some
othertype ofcancer, such as stomach cancer, which has
a low incidence in other populations (3).
Studies have also revealed several compounds, called
antipromoters, that inhibit responses to PMA in vitro
(148) and prevent tumor promotion in vivo (356). An-
tipromoters are effective during different phases ofthe
multistep process of promotion. Although "pure" pro-
motion has not been conclusively demonstrated in hu-
mans, the existence of antipromoters in other systems
has been used to suggest that it may be possible to
design cancer prevention methodology based on the in-
terference of promotion with a putative antipromoter
in humans. Clinical studies are currently underway to
test the therapeutic efficacy of some antipromoters,
e.g., synthetic retinoids (357).
While cell culture methods offer possibilities for
screening for tumor promoters and antipromoters, it
will first be necessary to determine which functions al-
tered invitro by promoters are critical to the promotion
process and which are secondary. The species andtissue
specificityoftumorpromotersmake itlikelythat a num-
ber of different cell types will be required for any
screening procedure.
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NEOPLASTIC PROGRESSION. The progression of a
neoplastic cell into a malignant tumor, which does not
occur to every neoplastic cell, is the last major stage of
cancer formation and is probably accomplished through
a number of steps. Many cancers have more than the
normalnumbers ofchromosomes andexhibitpoorlycon-
trolled and sometimes higher rates of growth, inva-
siveness and anaerobic glycolysis, factors that may be
important to their survival in the animal.
The route bywhich aneoplastic cellbecomes a cancer
may entail a sequence of interactions between tumor
cells and both specific and nonspecific host defenses
(358), as well as a series ofevents that result in the cell
acquiring more ofthe characteristics ofcells in a malig-
nant neoplasm (283). These selection processes are mu-
tuallynonexclusive andmayinvolve karyotypic changes
(359). The factors that are important in neoplastic pro-
gression, especially inthe premalignant stage afterneo-
plastic cells emerge and before a malignant neoplasm is
formed, may be similar to those in tumor dormancy, a
phenomenon in which tumor cells reappear many years
afterapparently successfultreatment. The majormech-
anisms of tumor dormancy seem to be (1) inhibition of
cell division and (2) cell division accompanied by cell
lysis. Mitotic control can be exercised by macrophages
(360), soluble factors such as lymphokines (361) and in-
terferon (362), nutrient depletion (363), or a hormonal
requirement for growth (364). Continuing cell division
in a tumor, the major characteristic of a neoplasm, can
continue without much effect ifdaughter cells are lysed
about as fast as they are produced. This can result from
immunological lysis, nutritional deprivation, or very
slowtumorcellproduction. Any orallthese factors may
lose their effectiveness during the selection processed
for malignancy described above, perhaps in a number
of steps.
An interesting model for the mechanism of progres-
sion of a neoplasm to malignancy is the one proposed
byGersten, Fidler, and Hart (360,365). After aprimary
tumor is established, there is tumor vascularization, by
an angiogenic factor (363), with invasion ofsurrounding
tissue and blood vessels. This invasion seems to be ac-
complished through tissue damage by a number of dif-
ferent enzymes, such as collagenase (361) and cathepsin
B (362), although the role of tumor cell motility is not
clear(365). Thewidespread disseminationofcancercells
occursbythelymphatic (carcinomas) andhematogenous
(mesenchymal tumors) routes. During lymphatic
spread, the regional lymph node is involved in the host
immune responses to neoplasia (368). During hematog-
enous spread, release of tumor emboli in the blood-
stream results in most tumor cells being destroyed by
interactionwith anumberofblood elements (369). How-
ever, the more that are released, the greater chance of
survival to form metastases. Arrest and subsequent
growth ofcirculating tumor cells or implantation in an-
othersite seemtobe afunctionoftissue andmetastasis,
and there are some data that the site is selected by the
membrane properties ofthe metastatic cells (370). Met-
astatic cells then leave the blood vessel and form mi-
crometastases which induce blood vessel proliferation
leading to metastatic growth (365).
Progression seems to be modulated by a number of
factors. Important among these is the immunological
system. Manytumorsinducedbyradiation andchemical
agentsareantigenicallydistinct(371-373). Toovercome
the immunological defenses ofan immunocompetent in-
dividual, the tumor could (1) simply not be immuno-
genic, e.g., contain only antigens expressed normally
inthebody, or(2) suppresstheimmunologicalresponse.
Lack of immunogenicity seems to be very common in
spontaneous tumors in animals (373,374). This also
seems to be the case for humans since, at present, only
cells from presumably viral-induced tumors such as
Burkitt's lymphoma (375) may be considered to be truly
immunogenic (although there is evidence of some spe-
cific antigens associated with cells from human tumors
grown in culture, e.g., colorectal tumor cells (376,377).
A tumor could also induce immunodeficiency, either
general or selective. Immunosuppression could be ac-
complished by a variety of mechanisms, including pro-
ductionofcirculatingimmunecomplexes(378)(toinhibit
antibody response) or a rise in suppressor T-cells (379)
(to inhibit T-cell response). Production of an immuno-
deficiency seems to be important for highly immuno-
genic tumors, such as UV-induced tumors, which are
decisively affected by suppressor T-cells in the forma-
tion of primary tumors (379), and viral tumors, which
are profoundly influenced by immunocompetence
(139,380). The immunodeficiency associated with UV-
induced tumors is a selective one, perhaps because ofa
UV-induced deficit in antigen processing by a macro-
phage-like cell that subsequently produces the T-cell
response (379).
Clinically, the term "immunodeficiency" usually re-
fers to a more general type of immunodeficiency that
canoccurduringthelaterstagesofcarcinogenesis (381).
This may be of importance mainly in metastasis, since
it has been shown that immunosuppressive treatments
and agents greatly increase the incidence ofdistant me-
tastases in rats with highly immunogenic tumors
[though the effect is reversed for tumors with low im-
munogenicity (382)]. Its role may be wider, however,
since it has been suggested, from evidence about lym-
phoma in immunosuppressed individuals, that the im-
mune system may be important in the selection of a
particularchromosomalalteration, i.e., maybeinvolved
in promotion (139).
Implicit in this analysis is the fact that factors that
can alter modulators of progression can also alter pro-
gression. Forexample, factors suchasstressthatresult
in a mild immunodeficiency may also mimic the effects
of immunosuppression in production of lymphoma. A
cancer is a product of a long series of events, and it is
a reasonable assumption that modulators may interact
in a positive or negative fashion with this sequence at
any point.
An interesting approach to this complex problemwas
the development of a general model for the temporal
development oftumors, rooted in evolutionary theory.
224CHEMICAL CARCINOGENS
Based upon the observation of tumor heterogeneity,
even when derived from a single clone, the "shifting
balance" theory, which emphasizes that many genes,
with multiple pleiotropic effects mediate the expression
of tumor genotype, was applied to tumor evolution
(383). This "micro-evolution" maintains the flexibility
for rapid population adjustment to conditions because
of a wide variety of phenotypes. "Macro-evolution" oc-
curs when a new niche is available, after survival of a
"catastrophe" forthe cancercells (resultingfromclinical
treatment or immunological attack), or when a new
adaptive level emerges from previous micro-evolution-
ary changes. The implications of this theory are intri-
guing and suggest that cancer prevention may be more
effective than cure.
Multiple Agents
Since people are exposed to many different agents at
the different times in different sequences, the effect of
multiple agents on carcinogenesis is of major concern.
However, there is little information of general import
in the field. Models for interaction are generally limited
by lack ofinformation on dose-response curves for car-
cinogens in the area ofinterest (384). The great number
ofpermutations ofpossible agents and doses makes un-
derstandinginteraction ofmultiple agents verydifficult.
In general, the action of two or more agents can be
additive (ifthe agents are given in a dose range where
the biological response is a linear function of dose) or
multiplicative (if the response is a simple exponential
response to dose), synergistic (greater than expected)
or antagonistic (less than expected) (384,385).
One obvious example of synergism is the tumor ini-
tiator-promoterinteraction described above. Tumorin-
cidence is much less when either agent is given sepa-
rately than when the two agents are given inthe proper
order. Anotherpossibleexampleistherelationbetween
cigarette smoking and asbestos exposure in carcinogen-
esis. The effectofbothcarcinogensismuch greaterthan
a simple additive model would predict and is closer to
multiplicative (386). Although the mechanism for this
phenomenon is not known, there are several possibili-
ties: (1) asbestos increases the uptake of the carcino-
genic substances in cigarette smoke [as shown when
benzo(a)pyrene is used as a model compound (387)]; (2)
asbestos stimulates metabolism of carcinogen(s) in
smoke (which has been shown for benzo(a)pyrene, one
component ofsmoke) (388); (3) asbestos works as a pro-
moter with cigarette smoking the initiator (389); or (4)
some combination of the above mechanisms (390).
One example of antagonism is the interaction of 3'-
methyl-4-dimethylaminoazobenzene (an azo dye) and
certain polycyclic aromatic hydrocarbons (PAH), such
as 3-methylcholanthrene (MCA) (391,392). Some car-
cinogenic PAH, by stimulating metabolism, inhibit azo
dye carcinogenesis. Although the study and under-
standing of the interaction(s) of multiple agents is not
easy, it becomes much more difficult (conceptually as
well as experimentally) when it is not clear whether
more than one agent is involved. An example is the
interaction ofimmunosuppressive agents and EBV. Al-
though immunosuppressive agents are presumed not to
induce tumors, their use may allow the expression of
EBV induced carcinogenesis, as has been suggested for
renal transplant patients who have a substantially
raised incidence oftumors, especially lymphomas (139).
Since EBV is ubiquitous, exposure to an immunosup-
pressive might result in an increased number oftumors
in a bioassay (i.e., be carcinogenic), although in fact it
is simply allowing expression oftumors that arise from
aviral infection. Other agents may alterthe modulators
at any stage in carcinogenesis and result in either more
intense effects of a ubiquitous agent or the expression
of a tumor derived from long-lived, irrevers-
ibly initiated cells.
These examples illustrate just a few of the possibil-
ities ofinteraction. Some agents may stimulate metab-
olism, interact chemically with other agents, or be so
cytotoxic that tumors induced by another agent are
killed. Other agents may alter modulators of different
stages of carcinogenesis or stimulate the expression of
tumors that would normally not be expressed in the
lifetime of the animal. At present, in the absence of a
well established and comprehensive theory of carcino-
genesis, the complexinteraction ofagentsisbestunder-
stood by elucidating the action ofeach compound. Then
the effects of each compound on the organism can be
evaluated and their interaction estimated.
Summary
Although the study of the phenomenology of cancer
was initiated many years ago, analysis of the mecha-
nismsinvolvedincarcinogenesiswas startedmuchmore
recently, and the level ofactivity has risen significantly
in the last decade. This review has attempted to place
much of the data concerning cancer into a broad per-
spective. Exposure to a carcinogen begins at the inter-
face of an animal with its environment, and an agent
can be modified by factors associated with an organism
at that interface. An example ofthis is the reduction of
benzidine-based azo dyes to carcinogenic benzidine by
gastrointestinal microflora. Since the microflora can
vary with species as well as with food habits, this pro-
vides one source ofvariation in the activation ofagents.
There is a wide variety ofprocesses that are involved
in the activation and detoxification ofmost agents. The
complexityofthese processes isillustratedbythemajor
products ofthe metabolism ofbenzo(a)pyrene, a carcin-
ogen which needs activation. Lifestyle, exogenous
agents, diet, age, etc., can act on several levels to alter
the balance ofactivation and deactivation. Examples of
this arethe stimulationofcellularmetabolismproducing
morereactivespecies, theinhibition ofaparticularpath-
way resulting in a smaller amount of reactive moiety,
andthealterationofcellscavengersthatabsorbreactive
metabolites produced by metabolism, and lower the
overallconcentration ofreactive moiety. Activation and
deactivation are functions of species, tissue, and even
individuals, providing another source ofvariation in re-
sponse to a carcinogen.
The interactions of carcinogens with DNA, which
seemtobeimportantforthecarcinogenicactionofmany
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initiators and complete carcinogens, varyacross the dif-
ferent classes of carcinogens. Biological carcinogens,
such as the acute transforming retroviruses, seem to
insert genetic information which allows the expression
of certain cellular onc genes whose products are im-
portant for transformation. Some of these products
seem to have effects like certain growth factors. The
discovery that the dominant transforming genes ofcer-
tain human cancer-derived cells are similar to certain
classes ofonc genes derived from the acute transform-
ing retroviruses has been a breakthrough in under-
standing certain causal factors in human neoplasia. Ra-
diations damage DNA, but, with the exception of
ultraviolet light (UV), the irradiation products are not
very well characterized, and the role of the damage is
not clear. It has been shown that a particular DNA
damage is involved in the carcinogenic action of UV
light, but how this occurs is also not clear. The specific
damage that many chemical carcinogens produce in
DNA is much better characterized, but which lesions
are important in carcinogenesis and how a lesion can
interact to produce a cancer are not known. "Physical"
carcinogens include a number of very different agents
and processes which seem to have in common the pro-
duction of a chronic fibrotic reaction.
Twomodulators ofDNAdamage are DNArepairand
fidelity of replication, which help to determine the ef-
fects of a carcinogenic stimulus that survives through
replication in initiated cells. Recent work on DNA re-
pair has suggested the importance of the ADP-ribosy-
lation system and has determined that there is a set of
enzymes, the DNA glycosylases, that confer specificity
in base excision repair for different types ofDNA dam-
age. Also, post-replication repair has been found to be
more complex than thought previously, which may help
explain how a specific lesion influences DNA. Since
DNA repair is modified by many factors and is tissue-
andspecies-specific, thisprovides anothersource ofvar-
iation in the final response ofthe organism to a carcin-
ogen. An example ofhow knowledge about mechanisms
impacts on risk assessment is the question ofhow DNA
repair is related to biological thresholds for effects of
carcinogens. Statements that DNA repair results in a
threshold for carcinogenesis cannot be substantiated.
The fidelity of DNA replication can be altered by a
damagedtemplate or, moreindirectly, through changes
in the reaction conditions that result in miscoding. Any
ofthe reaction conditions could be altered by a carcin-
ogen or by a change in physiological state induced by a
carcinogen, providing a route by which the DNA could
be altered without the formation of direct binding be-
tween the DNA and a carcinogen derivative.
Cancer is a phenomenon with many steps. In an ex-
perimental paradigm, two major stages can be dem-
onstrated: initiation, the induction ofan irreversible al-
teration of genetic information, and promotion, a
reversible process terminated by the final irreversible
alteration ofinitiated cells into neoplastic cells. Each of
these stages canbe subdivided. The progression ofneo-
plastic cells into a cancer, which has not been easy to
separate experimentally from promotion, is the final
step in careinogenesis.
Promotion can occur with both exogenous and en-
dogenous compounds (and, perhaps, certain surfaces)
and is characterized in a number of systems by a focal
proliferationofcellsofwhichasmallfractionwillpersist
after the promoter stimulus is removed. Few focal pro-
liferations in any experimental system willbecome neo-
plastic. Although the aspect oftumor promotion which
is critical for tumorigenesis is not entirely clear, an in-
teresting possibility is the induction ofchromosomal al-
terations. The relationship of this process to viral car-
cinogenesis and the mechanisms by which alterations
maylead to aneoplasm are explored. However, acausal
relationship of chromosomal changes to carcinogenesis
has not been proven. Tumor promoters are tissue and
species specific, perhaps providing some insights into
how various tissues and species are differentially af-
fected by carcinogens.
Neoplastic progression, the process in which a neo-
plasticcellbecomesamalignanttumor, seemstoinvolve
several steps, none ofwhich is yet well understood. In
that complex process, the role oftheimmunological sys-
tem as one ofthe important modulators of progression
is discussed. An interesting recent approach has been
to consider the progression of tumors from an evolu-
tionary, ecological point of view.
Evaluation ofthe effect ofa number ofagents acting
concurrently has barely begun. Models for summation,
potentiation, or inhibition of effects are poorly devel-
oped, especially when considering the range of effects
that agents have on a number of metabolic and phys-
iological endpoints. Variation with species, tissue, and
individual at every stage incarcinogenesis produces the
added uncertainty if two or more compounds interact
at many levels.
Short-Term Tests for Potential
Carcinogens*
Introduction
Cancer can be induced by a variety of radiations,
biological, "physical" and chemical agents and is mani-
fested in a variety ofphenotypes. Notwithstanding our
lack ofunderstanding ofthe mechanisms by which can-
cer is induced and expressed, there is an urgent need
to identify the agents that cause and promote these
diseases. The rapid identification of potential chemical
carcinogens is one ofthe majorgoals ofshort-term test-
ing.
The hypothesis thatconversion ofnormal cellstoneo-
plastic cells results from heritable genetic changes-
the somatic mutation theory of cancer-was proposed
early in this century (393) and forms a basis for the
development ofmanyshort-termtests. Therelationship
of mutation and carcinogenesis has been stressed for
*Although the full committee participated in the framing of this
section, primary responsibility was assumed by Dr. R. Tennant, as-
sisted by Drs. R. Langenbach, M. Shelby and E. Zeiger of NIEHS.
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some time (394). However, early studies relating mu-
tagenesis and carcinogenesis were generally unsuccess-
ful, due in part to the need for metabolic activation of
most carcinogens. Pioneering studies bythe Millers and
associates (395) onmetabolic activation ofchemicals and
the coupling of metabolic activation systems and mut-
able targets (396,397) allowed further elucidation ofthe
possible relationship between mutagenicity and carcin-
ogenicity. During the past 15 years, many short-term
systems that detect mutagenesis and other genetic ef-
fectshave beendevelopedandattemptshavebeenmade
to correlate the results ofthese tests with carcinogen-
esis. The tremendous number ofchemicals that remain
to be evaluated for potential hazard and the mounting
cost of currently acceptable rodent carcinogenesis as-
says amply justify the continued effort to develop and
utilize short-termtests, andtoestablishamodefortheir
applicationinassessingthepotentialchemicalstoinduce
cancer.
The search for tests with the capability to identify
potential chemical carcinogens has yielded a variety of
assay systems with a diversity of endpoints. The exis-
tence ofsuch a large number ofassay systems (approx-
imately 100 have been described) (398,399) reflects both
limitations and differences between assays, as well as
our uncertainty about the mechanisms ofinduction and
progression of carcinogenesis. As described in the sec-
tion on current views on the mechanisms of carcino-
genesis, the induction ofcancer may have many poten-
tial mechanisms (gene or chromosomal mutation,
heritable changes in DNA transcription reflected in in-
duction or cessation of gene expression, etc.), but no
causal relationship has yet been established between
any mechanism ofinduction and any specific neoplasia.
In addition, a variety offactors or conditions, including
tumor promoters, hormonal levels, rate of cell prolif-
eration, cell type specificity, and geneticpredisposition,
are known to influence the expression ofneoplasia, re-
gardless of the nature of the inducing agent. Because
ofthe relatively small number ofknown human carcin-
ogens, thepredictivecapabilityofthe short-termassays
is usually assessed by validation with the many more
chemicals which are carcinogenic in long-term animal
tests.
This section describes the major categories of short-
term assays for chemical carcinogens, attempts to eval-
uate the assay systems, and recommends further stud-
ies required to define their predictive ability. The term
"genetic toxicity" is used to indicate any effect that can
be attributed to an interaction between the test agent
and the genetic material of the test organism. There
have been attempts to classify carcinogens on the basis
ofwhethertheyshowevidence ofdirectinteractionwith
DNA or act by some indirect effect ("epigenetic") (400).
However, the assay systems conventionally used to
make this distinction may not detect all types of chem-
ical-DNA interactions, nor do they adequately accom-
modate the tissue or cell-specific metabolism or target
specificity which many carcinogens demonstrate. It is
thus notpossible conclusively tomake acleardistinction
between genetically toxic and "epigenetic" on the basis
of currently available in vitro tests. However, the fact
that certain factors or substances do appear to induce
tumors without appearing to react directly with the
DNA indicates a need for development of short-term
testscomplementarytothosewhichdetectdirecteffects
on the DNA, ifall types ofchemical carcinogens are to
be detected.
Many ofthe tests for genetic toxicity are also useful
in the identification of potential germ cell mutagens;
however, this represents a distinct application of the
tests, and the reader is referred to the recent report of
the National Academy of Sciences (401) for further in-
formation on this subject. In addition, screening of
chemicals for genetic activity can identify agents that
may be involved in the aging process or atherosclerosis
(33,402).
Short-Term Test Systems
Therehavebeennumerous descriptionsofassaysthat
have been developed and evaluated for their capability
to detect potential carcinogens, but the details ofthese
systems will not be discussed herein. The reader is di-
rectedtotheEPAGene-ToxEvaluations (403-431), the
International Collaborative Program (432), and the re-
view by Hollstein et al. (398) for details and further
references to the individual systems. The four principal
biological endpoints represented by the available tests
are gene mutation, chromosomal effects, general DNA
damage, and neoplastic transformation. Some fre-
quently used assays are listed in Table 4.
GENE MUTATION. Although it is possible to assay for
chemically induced mutation with a variety ofmethods
in anumberoforganisms and cells, thegreatestamount
of information on tests for potential carcinogens is de-
rived from a relatively few systems. The system in
which the largest number of chemicals has been eval-
uated is the Salmonella/microsome test (Ames test)
(433,434), where several strains of the bacterium Sal-
monella typhimurium have been genetically altered in
order to provide increased sensitivity to potential mu-
tagens. In the Ames assay, reverse mutations in the
histidine locus (i.e., from a histidine requirement to in-
dependence) are detected. By virtue ofthe sensitivity,
easeandrelativelylowcostofperformanceandduration
ofthe test (48-72 hr), this assay has been used world-
wide to test for chemical mutagens. Other microbial
systems can also be used (Table 4) but have not been
used nearly as extensively asthe Salmonellaassay. Cul-
tured mammalian somatic cells (which are genetically
more similar to cells as they exist in humans than are
bacteria) such as the mouse lymphoma (L5178Y) (430),
Chinese hamster ovary (CHO) (405), and Chinese ham-
sterlungcells (V79) (409), have also beenused to detect
gene mutations induced by a variety ofchemical agents
and radiations. The various systems that have been de-
veloped are capable ofdetectingforward and/orreverse
mutations. However, none ofthe specific gene loci con-
ventionally used in the bacterial or mammalian cell mu-
tagenesis systems (his, tk, oua, hgprt, etc., Table 4)
appear to be related in any way to the cellular changes
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Table 4. Conventially used short-term assays.
Type of assay Endpoint Reference
Mutation
Microbial systems Histidine reversion (433)
Salmonella typhimurium
Escherichia coli Tryptophan reversion (403)
Mammalian cell systems
Mouse lymphoma (L5178Y) Thymidine kinase (bromodeoxyuridine or triflurothymidine [TFT] (430)
resistance)
Chinese hamster ovary Hypoxanthine guanine phosphoribosyl transferase (6-thioguanine (405)
(CHO) [6TG] resistance)
Chinese hamster lung (V79) Hypoxanthine guanine phosphoribosyl transferase (6TG resistance) (409)
Na/K ATPase (ouabain resistance)
Human lymphoblasts Thymidine kinase (TFT resistance) hypoxanthine guanine (435)
phosphoribosyl transferase (6TG-resistance)
Chromosome effects
Many cell types in vitro and in Chromosomal aberrations (408-410)
vivo Sister chromatid exchanges
Micronuclei
Chromosome gain or loss
Translocation
DNA damage
Unscheduled DNA synthesis Radioactive nucleoside incorporation (431)
(UDS)
Repair deficient bacteria Differential growth inhibition (411)
Mammalian cell transformation
Cellular (426)
Syrian hamster embryo Altered cellular morphology and growth pattern, growth in soft
(SHE), Balb/c 3T3, C3H/ agar, tumorigenicity
1OT1/2
Viral enhanced/mediated Same as above in appropriate host (426)
Syrian hamster embryo
(SHE)/Simian adenovirus
type 7 (SA7), Fischer rat
embryo cells/Rausher
leukemia virus
that occur in the induction of neoplasia. These loci are
used to measure the capability ofa chemical to interact
with the DNA of an organism in such a way as to give
rise to mutagenic effects. Although it has been widely
assumed and theorized that neoplasia arises from mu-
tation, it is known that heritable phenotypic changes
also occur in mammalian cells in the process of differ-
entiation and growth and such changes arise without
the induction ofgene mutation. Consequently, it is nec-
essary to use additional biological endpoints that reflect
the capacityofchemicalstocausechangesthroughother
types ofinteractions with the genetic material.
CHROMOSOME EFFECTS. Changes in the structure or
number ofchromosomes occur frequently in tumor cells
(436), and cells from individuals exposed to radiation
show evidence of chromosome damage (437). Cytoge-
neticshort-termtestshavedemonstratedthatanumber
of carcinogens can cause structural alterations of chro-
mosomes (aberrations) in the bone marrow of exposed
animals orincultured cells derived from various tissues
(410). There is increasing evidence that associates spe-
cific chromosomalrearrangements (translocations) with
specific neoplastic phenotypes (438). Although no defin-
itive causal associations have been defined, the use of
molecular and recombinant DNA techniques promises
to aid in resolving the relationship between transloca-
tion oflarge segments ofchromosomes and the specific
DNA sequences involved. Another assay often used in
conjunction with the search for chromosomal aberra-
tions is the induction of sister chromatic exchanges
(SCEs) (439,440) that are believed to result from the
induction ofrecombination by DNA damage. However,
the association between an increase in the frequency of
SCEs in cells in vitro or in vivo and heritable changes
has not been clearly defined.
It is also possible to identify the production of chro-
mosome fragments (micronuclei) in reticulocytes or
erythrocytes (441). Induction of micronuclei has been
associated with chemical exposure and is also believed
to be indicative of the ability of chemicals to induce
chromosomal aberrations, but it is also not yet clear
that the induction ofmicronuclei is related to heritable
228CHEMICAL CARCINOGENS
changes in cellular phenotypes.
Along-range potential value oftests forchromosomal
effects is that they may be used to assess the compar-
ative (trans-species) toxicity of chemicals. Since the
sampling for cells is nondestructive to the exposed an-
imal or individual, and because the assays can be con-
ducted on cultured cells, comparisons are possible be-
tween various species and humans. Additionally, the
monitoring ofhumanblood cellsforchromosomaleffects
may be a valuable method to assess human exposure to
hazardous chemicals (442). However, such comparisons
must be conducted with the understanding that chem-
ical disposition (pharmacokinetics) may vary with spe-
cies thus giving rise to species-dependent target cell
populations.
DNA DAMAGE AND REPAIR. These tests do not mea-
sure mutation per se, but DNA damage, or the cellular
repair of such damage, induced by the chemical treat-
ment ofmicrobial or mammalian cells. The most exten-
sively used method is to detect non-S-phase DNA syn-
thesis (unscheduled DNA synthesis, UDS) in
hepatocytes (431,443), although other cell lines (431)
have also been used. Techniques that measure DNA
strand breaks (414) or binding of chemicals to cellular
DNA in vivo or in vitro (444) are also used as assays
for DNA damage. Other assays use strains of E. coli
or B. subtilis and are based on differential growth in-
hibition of DNA repair proficient and deficient strains
(411,445).
CELLULAR TRANSFORMATION. Exposure ofcultured
mammalian cells from a variety of tissues and species
to carcinogens (biological, chemical and radiations) has
been shown to result in certain heritable phenotypic
changes. A variety ofthese changes has been described
(426,446), but some specific morphological changes have
been shown to be highly associated with the capacity of
the cells to induce tumors when inoculated into appro-
priate recipient animals. Because ofthis abilityoftrans-
formed cells to produce tumors in recipient hosts, these
assays have been considered by some to be the short-
term systems most relevant to detection of chemical
carcinogens (397,426,442). Anumberofcellularsystems
derived fromrodentembryos havebeenusedtoidentify
chemical carcinogens (Table 4), some ofwhich use con-
comitant infection with transforming or nontransform-
ing viruses (426,446). There is no clear understanding
of the mechanism of in vitro transformation, and it is
likely that the various heritable alterations can occur
through one of several possible mechanisms. Recent
innovative advances at the cellular and molecular level
are having a major impact on our understanding ofthis
process (447,448). As the implications of studies on on-
cogenes and transfected transforming genes become
better understood and are incorporated into methods
for detecting carcinogens, there is the promise of sig-
nificant improvement in the accuracy with which these
systems can be used to detect carcinogenic chemicals.
IN VITRO PROMOTION SYSTEMS. The existence of
chemicals which appearto cause (orpromote) cancerby
mechanisms which may or may not directly involve the
genome has necessitated the development ofshort-term
systems that can detect these types ofchemicals. How-
ever, it should be emphasized that chemicals may have
bothinitiatingandpromotingactivity, andthetwoprop-
erties are not mutually exclusive. The V79-metabolic
cooperativity assay (449) has been the most thoroughly
studied in vitro system developed to detect chemicals
with promoting activity. A basis forthis assay has been
attributed to be the interruption of cell-to-cell com-
munication, although the exact mechanism is unknown.
Further studies with this and other promotion systems
are needed before they could be reliably used as test
systems to detect chemicals that act as promoters of
tumorigenesls.
IN VIVO SHORT-TERM BIOASSAYS. Several short-
terminvivo bioassays to detect carcinogens and/orpro-
motershavebeendeveloped. Oftheseassays, themouse
skin papilloma system and the strain A mouse lung ad-
enoma have been used for testing, while the liver foci
bioassay is still in developmental stage. These systems
are generally viewed as intermediate in biological rel-
evance between in vitro systems and the long-term an-
imal bioassay, because invivo metabolism and/or chem-
ical disposition are provided for by in vivo exposure.
However, as with the in vitro tests, the relevance of
the endpoints measured to the development of malig-
nant tumors remains an open question.
The mouse skin papilloma system, first reported by
Berenblum (450), is based on a multistage (initiation
and promotion) hypothesis of cancer induction and has
been developed further in other laboratories
(314,327,352,451,452). The system relies on the induc-
tion of benign papillomas, although carcinomas do de-
velop in the later course of the assay. Variations in
experimental test design reportedly allow chemicals to
be classified as: initiating carcinogens, promoters, com-
plete carcinogens (chemicals with both initiating and
promoting activity), co-carcinogens, and co-promoters
(452). Several strains of mice have been used in the
assay, butthe SENCAR stockappearsparticularlysen-
sitive (452). The mouse skin papilloma assay is the in
vivo system in which the greatest numbers ofchemicals
have been tested (453); however, many ofthe chemicals
investigated have been polycyclic aromatic hydrocar-
bons, and the usefulness of the system to test other
classes ofchemicals, or chemicals with organ specificity
other than skin, is not presently clearly known.
The strain A mouse lung adenoma system was de-
veloped by Shimkin and colleagues (454-457). Although
lung adenomas do occur spontaneously in mice, the
strain A mouse, unlike other strains, has nearly a 100%
lifetime incidence (457). Therefore, the assay appears
to rely on decreasing the time-to-tumor onset by the
testchemical, although StonerandShimkinconsiderthe
test chemical to be inducing rather than accelerating
the process (456,457). A wide spectrum of chemical
classes has been tested in the lung system (457), and
good correlations of results and the tumorigenicity of
the chemicals have been reported, although one study
using diverse coded chemicals did not find a high cor-
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relation (458). The system has been criticized because
the adenoma is abenigngrowth and an analogous tumor
does not appear in humans.
The induction ofaltered foci in rat liver systems have
also been studied for use as short-term in vivo assays
for carcinogens and promoters. However, these sys-
tems are relatively new and are still in a developmental
stage compared to the mouse skin papilloma and lung
adenoma assays. The rodent liver systems have been
used by Peraino et al. (459), Pitot et al. (460), and Solt
and Farber (461), to study the initiation/promotion phe-
nomena. The endpoints that have been measured in-
clude the appearance of foci in the liver which have
increased gamma-glutamyl transpeptidase, basophilia,
or diaphorase; or foci with decreased glucose-6-phos-
phatase, adenosine triphosphatase oriron storage (462).
Chemicals can be tested either for initiating or pro-
moting activity in the liver assays. Since defined pro-
tocols have not yet emerged, further development is
required before the possible value ofthe approach in a
routine testing program can be assessed. In addition
therelationship ofthe alteredliverfocitohepatocellular
neoplasms remains to be determined.
Factors in Test Evaluation
METABOLIC ACTIVATION. Most target cells used in
short-term tests have limited endogenous metabolic ca-
pability for xenobiotics and, therefore, must be supple-
mented with an exogenous metabolic activation system.
The metabolic activation systems employed in short-
term tests may be one ofthe major limitations in these
assay systems, because a chemical may show a different
metabolic profile invitro fromwhat would occur invivo.
From a testing point of view, a major concern is that
specific activating enzymes or pathways may be de-
creased or lost during preparation of the metabolic ac-
tivation system, thereby giving a false negative result
with the test chemical. Alternatively, enhanced acti-
vation ofcertain chemicals would also be possible (false
positive). Essentially, three types of metabolic activa-
tion systems have been used with target organism -
host-mediated (415,463), intact cells (464,465), and or-
gan homogenates, usually 9000g supernatants called S9
(33,434). Most short-term assays have used rat liver S9
preparations because of the ease of preparation and
storage, capability to activate many chemical classes,
and the relative compatibility (nontoxicity) with most
target organisms used in genetic toxicity testing. How-
ever, it is also known that liver S9 preparations may
cause different responses in vitro from what would oc-
cur in vivo due to factors such as: organotropic differ-
ences, chemical induction of S9 preparations, and de-
struction of certain activation enzymes during S9
preparation, decrease in conjugation capability, etc.
Therefore, the inability of S9 preparations to mimic in
vivo activation has provided the impetus to modify S9
utilization and/or investigate other metabolic activation
systems.
Intact cells are another exogenous metabolic activa-
tion system used in short-term tests (465). These cells
can be primary cultures prepared from various organs
(liver is most common), embryonic cells that have been
cultured only a short time, or in certain cases, estab-
lished cell lines. For such an activation system to func-
tion, the test chemical must be taken up by the acti-
vating cell, be metabolized, and the activated product
be transferred to the indicator cell. Thus, a negative
response with a cellular system may be a function of
the uptake of the test substance and the transfer and
stability ofactive metabolites. Since most cells lose sig-
nificant metabolic capability with time in culture, cer-
tain enzyme systems may be functional at reduced lev-
els. However, this loss of activation capability can be
at least partially overcome by the use of freshly pre-
pared primary cells.
In the host-mediated assay, the indicator organism is
introduced intothe peritoneal cavityorinjected intothe
circulatory system of an intact mammal (415,463). The
animal is then treated with the substance under test,
sacrificed, and thetestorganismremoved and examined
for mutation induction. A wide range of indicator or-
ganisms has been used (415). Because an organism for-
eign to the host is commonly used as the indicator or-
ganism, problems arise such as interaction between the
host and the indicator organism, including immunolog-
ical interactions, and the limited time the indicator or-
ganismcanbekeptintheanimal. Therefore, thissystem
is unable to detect many carcinogens and chemicals
which show in vitro mutagenesis.
Attempts to improve metabolic activation systems
are certainly worthwhile and have increased our ability
to detect carcinogens by in vitro methods. One must
accept, however, that it is not possible to mimic in vivo
metabolism in a petri plate and the negative in vitro
results may represent false negatives and positive in
vitro results may represent false positives. These pos-
sibly erroneous test results due to metabolic activation
can sometimes be resolved through the use of short-
term in vivo rodent assays. A testing scheme has been
proposed by Ashby (466) whereby short-term rodent
assays are employed to study further chemicals falsely
identified in the in vitro systems.
STATISTICAL EVALUATION OF SHORT-TERM TEST
DATA. The overwhelming majority of short-term test
data in the literature has not been statistically evalu-
ated. In general, decisions of"positive" and "negative"
are made on a subjective basis or on the basis ofsimple
statistical procedures. Recently, several statistical pro-
cedures have been proposed for the Salmonella assays
(467-469), the mammalian cell mutation (470) assays,
and discussions of statistical approaches appear in the
respective Gene-Tox reports, but there is no consensus
as to which particular procedures should be used for
data evaluation.
FACTORS IN THE CORRELATION OF ASSAYS WITH
CARCINOGENESIS. Because short-term tests for carcin-
ogens employ neither the organism (humans) or the bi-
ological endpoint (cancer) ofconcern, there is a need for
a great deal of extrapolation of test results; hence, the
demand for proving the validity of the tests is great.
However, after more than a decade of effort to dem-
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onstrate the utility of short-term tests in predicting
carcinogenicity, it is still difficult to find sufficient test
results to assess the performance ofan assay within or
among chemical classes, the activity of a chemical in a
variety of tests, or the performance of a group of the
tests on even a small group ofchemicals. This deficiency
in the existing data results largely from two factors.
First, there has not been enough ofan effort to evaluate
systematically a large number of chemicals in a group
of selected assays, and second, there is a marked defi-
ciency of genetic toxicity results on noncarcinogens.
This latter point presents an immediate obstacle to the
evaluation of short-term tests for carcinogens, since in
the absence ofanadequate database onnoncarcinogens,
it is not possible to determine the performance of a
single test or group of tests in discriminating between
carcinogens and noncarcinogens.
Definition ofSome Terms. The reliability of a short-
term test system may be defined as its ability to predict
accurately a chemical's in vivo carcinogenicity. The
standard against which short-term testresults are most
often compared is the rodent cancer bioassay. A short-
term test which correctly identifies, when used without
bias, a high percentage of known carcinogens and non-
carcinogens is assumed to be capable of predicting the
carcinogenicity of chemicals of unknown activity with
the same degree of accuracy. The short-term assay's
performance can be expressed by three criteria: sen-
sitivity, specificity, and accuracy. Sensitivity is the pro-
portion ofcarcinogens givingpositive results; specificity
is the proportion ofnoncarcinogens giving negative re-
sults; and accuracy is the overall proportion of correct
results. Unfortunately many, if not all, previous test
system evaluations, have been characterized by an in-
adequate number of noncarcinogens, and, hence, a de-
termination of specificity and accuracy is severely lim-
ited. Also, the accuracy of short-term tests could be
altered by the ratio of carcinogens and noncarcinogens
in the test sample (471). Additionally, the expected ac-
curacy ofa test battery (see below) is influenced by the
number of tests in the battery and the number of in-
dividualtestsrequiredtobepositivebeforethechemical
is considered to be positive in the battery (472).
Noncarcinogens and Test Analysis. The inadequate
identification of, as well as the use of, noncarcinogens,
as has been noted, is one of the key problems. Many
chemicals have been identified as noncarcinogenic
merely on the basis of their chemical structure or per-
functory carcinogenesis tests. To date, relatively few
chemicals used as noncarcinogens in short-term tests
have been tested in lifetime studies using adequate
chemical exposures. A major source of information on
noncarcinogens is that ofthe NCI/NTP rodent bioassay
where two sex/species are exposed at sufficient concen-
tration of the chemical and for sufficient duration to
insure that the chemical has been tested adequately.
However, few ofthesenoncarcinogens have beentested
inmostgenetictoxicityassays (473). Inaddition, factors
that determine a "positive" or "negative" short-term
test response for a test chemical can vary from labo-
ratory to laboratory or even experiment to experiment
within a laboratory. Often parameters such as control
background levels, acceptable range ofpositive control
responses, statistical significance of test chemical re-
sponse, etc., all of which are important in determining
whether a chemical is "positive" or "negative," can be
subjective. Such uncertainties could lead to an inaccur-
ate estimation ofthe sensitivity and specificity ofshort-
term tests.
Test Endpoints and Carcinogenicity. The develop-
ment ofthe Ames test and subsequent short-term tests
waspredicated onthe assumptionthatmostcarcinogens
were mutagens and, conversely, that mutagenic chem-
icals will be carcinogenic. Implicit in this reasoning is
the hypothesis that nonmutagens will not be carcino-
genic. However, this hypothesis put forth by Ames et
al. (397) and supported by others (474-478), that car-
cinogens are mutagens and the majority of noncarcin-
ogens are not mutagens, may be based on biased data.
The majority of the data used to justify this statement
comes from studies where the identity ofthe chemicals
and their carcinogenicity were known to the investi-
gators before they were tested. Because the investi-
gators knew the identity ofthe chemicals and their "ex-
pected" mutagenicity, the test protocols could be
modified until the desired results were obtained. While
these practices may lead to a true picture of the mu-
tagenicity ofa chemical, and are necessaryforthe assay
system development, they probably tend to overesti-
mate the carcinogenicity/mutagenicity correlations.
The correlation of data obtained for other endpoints
(i.e., UDS, cell transformation, SCE induction) with car-
cinogenesis data also is subject to the same limitations.
However, the correlations between results from these
other systems and carcinogenesis are further complicated
by the lack of an adequate data base on chemicals of
different classes, and, in some cases, a lack of demon-
strated interlaboratory reproducibility of test results.
A method which may establish more objectively the
correlations between short-term test results and rodent
(or human) carcinogenicity is one where chemicals,
coded so their identity is unknown to the persons con-
ducting the assay, are tested, and all the test results
are judged by the same criteria. Thus, the one con-
ducting the test does not know whether the short-term
test results and conclusions are "right" or "wrong" until
after a determination is made. This approach may min-
imize the proportion ofcarcinogens detected, but it also
eliminates preconceptions about the activity of the
chemical. In actualpractice, however, additionaltesting
usingmodifiedprotocols canbe done on chemicalswhose
structure would lead one to believe thatthe original test
conditions were not appropriate. For example, some
benzidine-based dyes require reducing conditions, fol-
lowed by an oxidative system, rather than a strictly
oxidative system for their activation. Therefore, choice
of test systems should vary with chemical class or na-
ture ofthetestchemical, butdeterminations ofresponse
should be independent of knowledge of the chemical's
identity.
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Attempts to Evaluate Short-Term Test Performance.
Though not definitive, there have been several system-
atic efforts to evaluate the short-term assays, singly or
in combination, for their ability to detect or predict
chemical carcinogens. The largest effort to date was
conducted by the Gene-Tox Program of the U.S. En-
vironmental Protection Agency and is a multiphased
effort to review and evaluate selected bioassays formu-
tagenicity and related endpoints using the published
literature. Initially, the literature published from 1969
to 1979 was reviewed to assess test system perfor-
mances, to determine the chemicalstested, and the abil-
ity ofthe various systems to discriminate between car-
cinogens and noncarcinogens. Reports on the individual
systems have been published (403-431). Duringthe sec-
ond phase, a computerized database ofover 2600 chem-
icals is being analyzed to determine which tests or com-
bination of tests may be used for routine screening or
need further development; determine if specific types
of genetic damage are related to chemical class; dis-
criminate between carcinogens and noncarcinogens; and
predict heritable mutagenic risk. To aid in evaluating
system performance, the Gene-Tox Program convened
a panel to review and evaluate the literature on chem-
icals designated as carcinogenic and to develop a list of
carcinogens and noncarcinogens which could be used in
determining system performance.
The International Program for the Evaluation of
Short-Term Tests for Carcinogenicity (432) was a co-
ordinated effort designed to determine and compare the
ability of a series ofshort-term tests to identify carcin-
ogens and noncarcinogens. Sixty laboratories partici-
pated, using their own laboratory protocols, to test
coded samples of chemicals supplied from a common
source. Test results from this collaborative study led to
the following general conclusions. First, while short-
term tests are useful in the assessment ofpotential car-
cinogenicity, no single test orgroup oftests was capable
of detecting correctly all carcinogens and noncarcino-
gens. Secondly, there areinvitroeukaryotic assaysthat
may complement the bacterial tests by identifying car-
cinogens not detected in bacteria.
Following the completion of the collaborative study
discussed above, a subsequent study was initiated to
focus specifically onthe evaluation ofinvitro eukaryotic
assays with potential for identifying carcinogens not
detected, orpoorly detected, in bacterial mutation tests
(479).
Othersystematic attempts to evaluate the short-term
assays include an analysis oftheir ability to detect pes-
ticides (480) and a series of reports prepared for the
International Commission for Protection Against En-
vironmental Mutagens and Carcinogens (ICPEMC)
(463,481). The NIH/NTP is currently conducting a sys-
tematic genetic toxicity assay of chemicals, both car-
cinogens and noncarcinogens, tested or under test in
the rodent, two-sex/species carcinogenesis assay. The
major categories of genetic toxicity are represented,
and the chemicals are tested under code.
Practical Assay Utilization
ASSAY SELECTION. The proposed use of short-term
tests to detect or predict chemical carcinogens is based
on two factors: first, that they require less time to con-
duct than a rodent carcinogenicity study; and, second,
that they are less costly. Currently used tests require
from a few days to several weeks to conduct, and the
costs may range from $1000 to $20,000 per chemical.
Since there has been little success in establishing a
cause-effect relationship between specific genetic
changes and cancer, all categories of induced genetic
change may be potential mechanisms by which cancers
arise, and this is reflected in the variety of endpoints
detected by short-term tests. Current short-term test-
ing practices generally involve groups oftests selected
on the basis of theoretical prudence rather than on an
empirical demonstration of their ability to predict car-
cinogenicity. By theoretical prudence, it is meant that
a range of organisms (bacteria, yeasts, cultured mam-
malian cells, intact rodents) and endpoints (gene mu-
tations, chromosomal damage, DNA damage, and in
vitro neoplastic transformation) are employed in an at-
tempt not to miss any effect that might be related to
the carcinogenicity of the test agent. However, until
the time that basic research on mechanisms of cancer
induction provides us with a better understanding of
the process, it will be necessary to base testing strat-
egies on a combination oftheoretical prudence and cor-
relative evidence obtained by comparing short-term
test results with carcinogenicity test results.
Inthe selection ofshort-termtests, factors otherthan
ability to discriminate between carcinogens and non-
carcinogens must be considered. Reproducibility oftest
results is a paramount consideration that applies not
only to reproducibility within a laboratory but also to
agreement of test results among laboratories. When
testing chemicals, the ability to reproduce test results
qualitatively is more important than quantitative re-
producibility. Quantitative differences in testresponses
represent the degree ofresponse and may be attributed
to protocol variables. However, qualitative differences
are more serious and affect the judgment of whether a
test chemical is "positive" or "negative." Therefore,
short-term test selection should be based on reprodu-
cibility as well as reliability, sensitivity, specificity, and
accuracy. In addition, the degree of development of a
particular assay system should also be taken into con-
sideration when selecting tests for use in a screening
program. This includes a consideration of the number
oflaboratories performing the assay, degree ofprotocol
standardization, and a consideration of the number of
chemicals and chemical classes which have been tested
in the assay.
ASSAY APPLICATION. The application of short-term
tests to chemical safety evaluation raises questions at
several levels ofthe process. As discussed above, assay
performance must be known to determine which tests
are useful. Next, it must be decided how many tests to
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use and in what scheme or order they will be utilized.
Tier and battery testing approaches have been pro-
posed. In the tier approach, the choice of assay system
varies depending on the activity of the chemical in the
previous system, beginning usually with the S. typhi-
murium assay. Therefore, decisions are made after
each test result is obtained. With the battery approach,
the test chemical is assayed in a group (battery) ofsys-
tems and a decision on the activity ofthe chemical made
when all results have been obtained.
Once test results from the short-term test scheme
have been obtained, it must then be decided how to
utilize the results. Within the framework of testing or
evaluating chemicals for potential carcinogenicity,
where possible regulatory action on the chemical may
be involved, short-term test results can be used to in-
fluence the process at numerous points, including: the
nomination and/or selection of the chemical for prech-
ronic and chronic studies; the selection of prechronic
studies to be conducted; the decision, used in combi-
nation with prechronic results, to proceed with chronic
studies; the evaluation of chronic toxicity results, as a
source of additional information; the design of postch-
ronic studies, again as an additional source of infor-
mation, to further elucidate mechanisms of activity.
In the industrial setting, short-term tests can be (and
are) used extensively in product development, process
improvements, product registration, evaluation of oc-
cupational environments, 'tc.
It is generally agreed that a scheme employing mul-
tiple tests is a better approach to carcinogen screening
than the use of a single test. The tests used should not
be limited to prokaryotic or lower eukaryotic test sys-
tems and should include assays for more than one ge-
netic endpoint. A problem that is immediately encoun-
tered when multiple test systems are used, however,
is a mixture of positive and negative results. The res-
olution ofthis problem is not easy, and several authors
(482-484) have attempted to deal with the issue. For
the present, there are at least three approaches to deal-
ing with such conflicting test results. One may (1) use
aweight-of-evidence approach to callachemicalpositive
by some predetermined criterion; (2) use one's best sci-
entificjudgment to reach a conclusion on a chemical-by-
chemical basis; or (3) simply postpone judgment until
the time that a sufficiently large data base is available
to permit an unequivocal conclusion from any pattern
ofpositiveandnegativeresults. Thislastchoiceisrarely
acceptable, and current practice generally utilizes some
combination of the first two. The systematic accumu-
lation of additional knowledge on cross-system testing
of various classes of chemicals should provide insight
into the proper choices of short-term systems in as-
sessing potential carcinogenic activity.
FUTURE DIRECTIONS. Short-term tests for genetic
toxicity and other effects continue to hold promise of
improving our ability to identify potential chemical car-
cinogens. However, there is at present insufficient data
available to justify the use of current tests to supplant
animal bioassays. To improve the interpretation of
short-term test results, there is a need for a systematic
effort to obtain across-test results using optimal test
protocols and coded chemicals, with particular emphasis
on noncarcinogens. Itis clearfromavailable results that
no one assay system is adequate, but it is not yet pos-
sible to determine which combination oftest systems is
most appropriate for most carcinogens. Studies are
needed to determine if human cells or tissues would be
betterpredictors ofhuman carcinogenicity thanthe cur-
rently used rodent systems. Some carcinogens, by vir-
tue of their intrinsic mechanism of action, will not be
identified by available tests, and we must continue to
search for assay systems that accommodate the various
molecular mechanisms. Concomitantly, we must con-
tinue to improve our understanding of the results of
rodent assays for carcinogens. Where there is a di-
chotomy of results between genetic toxicity or other
short-term test systems and the results of rodent car-
cinogenicity, appropriate follow-up studies in the ap-
propriate systems should be conducted to determine the
basis for such differences.
Summary
While many assay systems have been developed and
proposed to detect or assess the genetic toxicity of
chemicals, they can be generally grouped into four cat-
egories: genemutation, chromosome effects, DNA dam-
age, and transformation. The internal momentum ofthe
field has resulted in the emergence ofa few systems or
tests in each category that have been used extensively
to assess potential carcinogenicity, and the various as-
says within each grouping have characteristic strengths
and weaknesses. The test systems must be demon-
strated to have reliability, sensitivity, specificity, and
accuracy and to be reproducible both within and be-
tween laboratories. The various systems also measure
different biological endpoints, and there is no reason to
expect that all chemicals will cause an effect in all sys-
tems. Since no causal relationship has been established
between any specific mechanism of induction and any
specific type of neoplasia, we are presently limited in
ourabilitytopredictpotential carcinogenicity ofachem-
ical, particularly when there is apparent disagreement
between different in vitro test results.
The consensus ofavailable information suggests that
short-term tests, when properlyused and validated, can
provide strong indications of potential carcinogenicity.
However, based upon our limited knowledge of the
mechanisms of cancer induction, it appears that there
will be classes of carcinogens that are not detected by
currently available short-term tests. Chemicals which
act by a genetic mechanism but which have a high de-
gree of organ, species, or sex specificity may be pre-
dictably difficultto detect in any in vitro genetic toxicity
system, since the short-term system may not ade-
quately simulate the basis for these specificities. Ad-
ditionally, chemicals which appear to act by nongenetic
mechanisms would not be detected in currently avail-
able short-term tests.
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Long-Term Carcinogen Bioassay*
Long-Term Carcinogen Bioassay: Guidelines for
Protocols
BACKGROUND. The current carcinogen bioassay in
rodents has its origins in research efforts, begun in the
1920s, that sought to determine the carcinogenic po-
tential of chemicals as well as to delineate the mecha-
nism by which they produce cancer (485,486). Animal
strains were developed and tested fortheir specific sen-
sitivity orresistance to certain types ofcancer, the cen-
tral focus of these studies being the understanding of
the mechanism ofcarcinogenesis (485,486). While these
experiments led to the induction ofcancer in laboratory
animals and revealed many new carcinogens, most of
the investigators did not intend their highly specialized
test systems to be used as routine methods for testing
large numbers ofchemicals. Onlyinthe mid-1960s, with
the advent ofthe bioassayprogram atthe National Can-
cer Institute (NCI), did large-scale systematic testing
using a relatively standard protocol really begin (487).
As a consequence, only recently has there been a rea-
sonablyadequate database on alarge numberofdiverse
chemicals tested in a relatively uniform way (488,489).
The lack of such a data base, during the earlier devel-
opmental period, contributed to some degree of confu-
sion and speculation as to how carcinogens should be
tested and how the results from such tests should be
interpreted. One finding was clear; known human car-
cinogens, with the single exception of arsenic, are car-
cinogenic in appropriately conducted studies in some
animal system. [Arsenic has recently been reported to
produce carcinomas ofthe respiratory tract in hamsters
(490)]. This does not mean that all chemicals found car-
cinogenic in animals will turn out to be carcinogenic in
humans. Because ofdifferences intheproduction ofcrit-
ical metabolites and because of other differences be-
tween species, agiven carcinogen may notproduce can-
cer in all species or in all strains of rodents. Many
substances are known that seem to be carcinogenic in
one animal species but not in another. But a finding of
carcinogenicity in rodents is proof that the chemical is
carcinogenic in a mammalian species. And "in the ab-
sence ofadequate data on humans, it is reasonable, for
practical purposes, to regard chemicals for which there
is sufficient evidence of carcinogenicity in animals as if
they presented a carcinogenic risk to humans" (491).
The knowledge and experience accumulated over the
last decade, while by no means answering all questions,
have helped to focus the issues and have provided a
basis for developing some common procedures for con-
ducting and interpreting long-term bioassays.
CRITICAL DESIGN CRITERIA. Several national and
international groups have published guidelines on the
design and conduct of long-term bioassays (491-502),
andthe issue continues tobepursued. Forexample new
guidelines are currently being developed by the NTP
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Ad Hoc Panel on Chemical Carcinogenesis Testing and
Evaluation (503). Essentially, the long-term test in-
volves testing compounds in animals to obtain infor-
mation relevant to humans. When assessing the results
of toxicological testing of any chemical, the limitations
ofthe tests must be borne in mind. Ofnecessity, animal
systems are used, and the results then extrapolated to
humans. Such extrapolations may not always be accu-
rate either qualitatively or quantitatively. In some
areas ofcancer testing, uncertainty still exists concern-
ing the most appropriate experimental design. For ex-
ample, there are varying opinions on the optimum du-
ration of a study and the number and types of species
of test animals that are considered appropriate. It is
probably unwise to adopt rigid "standard" test methods
for all chemicals; judgment must be exercised to select
an appropriate model for a particular chemical (499).
Obviously, due to limitations ofsample size (the number
of animals on test), low incidence effects can go unrec-
ognized. Consequently, although the results of carcin-
ogenicity testing will, in many cases, give good indi-
cations of possible hazard, they do not eliminate the
need for continuing careful observations of humans
(492). In fact, most known human carcinogens, such as
2-naphthylamine and chlornaphazine, were first discov-
ered by observing humans, and only later were they
found carcinogenic in animals. The reverse was true for
othercompounds such as diethylstilbestrol (DES), vinyl
chloride, or bis(chloromethyl) ether.
The following constitutes a series of major issues
which should be carefully considered in the design of a
carcinogen bioassay.
Species and Strain ofAnimal. Ideally, the appro-
priate animal species and strain is one, which, for the
chemical tested, is able to predict human response ac-
curately. However, the fact is that only three species
have been routinely used in carcinogen bioassay (504).
All three are rodents: the mouse, the rat and the ham-
ster. Only these species generally meet the require-
ments that the animals be readily available, that the
bioassays are likely to be relevant to humans, and that
the bioassays be cost effective and relatively quickly
performed. Included in these requirements are: the life
span of the species must be of reasonable length, long
enough to allow time for tumors to develop and short
enough to be economically feasible (2-3 years); the an-
imal should be small and should live and breed well in
captivity; thereshouldbesimilaritytohumansinregard
to metabolism and pathology responses; strains should
be those most likely to be susceptible to cancer from
the particular chemical yet not hypersensitive. Only
these three species and a few strains currently meet
these specifications, however, there are potentially
many more inbred or hybrid strains which can provide
a wide range of diversity in their metabolism of and
response to carcinogens or carcinogenic precursors.
Thereisstillnoscientificconsensusoverwhetherinbred
or outbred strains of rodents are better for long-term
studies (504-509). While the use ofinbred strains may
produce more precise and more stable biological re-
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sponses, more prosaic strains may more accurately re-
flect human response, are less expensive, often hardier
and are less prone to deterioration due to genetic drift.
The NTP Ad Hoc Panel on Chemical Carcinogenesis
Testing and Evaluation strongly recommended but did
not insist that NTP bioassays be restricted to inbred or
hybrid strains (503). When the test substance is chem-
ically related to other human carcinogens, the strain
chosen can be that used for the carcinogenic chemical
analog. Extensive experience in using a particular
strain is often a strong reason for continuing its use
despite itsacknowledged limitations (501-510). Onema-
jor advantage is the availability of abundant data on
spontaneous tumor rates at specific organ sites.
Because ofgeneticdifferences intumorsusceptibility,
the use of only a single strain of animal rather than an
array of strains represents an experimental compro-
mise, but anessential onegiven the large cost ofa single
long-term study. The possibility of a false negative re-
sult is reduced by the current recommendation to use
two species instead of one in a carcinogen bioassay.
More than 90% ofthe time these species are the rat and
mouse. The Fischer inbred (F344) rat and the B6C3F1
hybrid mouse are commonly chosen for carcinogen
bioassay, in large part because ofthe experience gained
by the NCI from their use (488,503,511). Despite its
long history, the continued use of the B6C3F1 hybrid
mouse by the NTP is currently under review because
of the difficulty in interpreting the significance of pro-
liferative liver lesions (488,492,493,503,512,514). The
merits of using only a rat strain instead of both a rat
and a mouse strain have also been recently discussed
(514). This issue and others relating to species selection
are considered inthe NTPAd Hoc Panel's Report (503).
Animal Care and Diet. Stringent control of envi-
ronmental conditions and properanimal caretechniques
are mandatory for meaningful results (496). Access to
animal facilities should be limited to essential personnel
to prevent excessive traffic and the transmission ofdis-
ease. Factors such as housing conditions, intercurrent
disease, drug therapy, impurities in diet, air, water,
and bedding, and animal care facilities can significantly
influence the outcome of animal experiments.
The control ofintercurrent infectious diseases or par-
asites is facilitated if rodents are bred and maintained
in conditions free from specific pathogenic organisms.
Animals from outside sources should not be placed on
test without an adequate period ofquarantine. Bedding
to be used in long-term studies should be absorbent,
sterilizable and free of pesticides, other toxic contami-
nants, or enzyme-inducing substances. Animals should
be housed in quiet, well-ventilated rooms, having con-
trolled lighting, temperature, and humidity. It is ad-
visable to balance dose groups over rows, columns, and
racks toallowforpotentiallocationeffects acrossdosage
levels. Alternatively it may be advisable to rotate cages
or racks periodically to balance potential sources ofvar-
iability. Eye lesions (retinal and lenticular degenera-
tion) have been observed with animals kept in cages in
closest proximity to light. Experiments should not be
initiated until animals have been allowed a one- to two-
week period of acclimatization to environmental con-
ditions.
The absence of biases in selection and allocation of
animals between control and treatment groups, as re-
gards diet, husbandry, necropsy, and pathology is cru-
cial (515). Since mice are reservoirs of asymptomatic
viral disease, it is bestto house mice and rats separately
where possible. However, it is acceptable practice to
house rats and mice in the same room if they are free
of disease, if they come from the same supplier, and if
they are being treated with the same chemical. It is
preferable not to mix animals from different suppliers
or from two locations of the same supplier. Housing
disease-free animals in the same room reduces the
chance for differences due to environmental variables.
Ifapopulation ofanimalsis diseased, then consideration
must be given to aborting the study and starting over.
Drug therapy should be avoided in bioassays since it is
a confounding factor.
Control animals and test animals should be housed in
the same room unless there is a possibility of cross-
exposure. The availability of hoods, laminar air flow
rooms, cagingdevices, and personnelpractices all affect
the extent to which experiments should be separated
or combined. To minimize the chance for inadvertent
cross-exposure of animals to the test substance, it is
advisable totestonlyone chemicalineachroom. Ifmore
than one chemical is tested in a room, the actual cross-
contamination of chemicals within the room must be
measured. Good laboratory practice need not rule out
all flexibility nor restrict the use ofjudgment or impose
unnecessary expenses (516,517).
Cages, racks, and other equipment must be regularly
and thoroughly cleaned. Periodic analysis of the basal
diet should be conducted for both nutrients and unin-
tentional contaminants, including carcinogens. The re-
sultsfromsuchanalyses shouldberetained andincluded
in the final report on each test substance. The essential
dietary requirements of rodents are relatively high in
protein and low in calories derived from fat (about 2-
4% of calories). In the administration of substances by
gavage using vegetable oils, the amount offat ingested
in rats can reach 30% (509). These facts, coupled with
emerging data on the influence of dietary protein and
fat on cancer incidence, and the presence oftrace levels
of carcinogens in animal diets may be important to fu-
turere-evaluation ofbioassayresults. Furthermore, the
quality ofthe agricultural crops that go into animal feed
can vary seasonally. Varying amounts of naturally oc-
curring enzyme inducers from plant material in animal
feeds may affect the course of a long-term test for car-
cinogenicity. It is therefore important to document and
retain pertinent information on diet source and quality.
When the test substance is administered in long-term
studies, stabilitytests areessential. Properlyconducted
stability and homogeneity tests, prior to the chronic
study, should be used to establish the frequency ofdiet
preparation and monitoring required. Similar monitor-
ing is required of the atmosphere within a chamber in
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inhalation tests to determine the necessity of rotating
animals within the exposure chamber and the frequency
of monitoring required. The stability ofthe neat chem-
ical, if it is to be used for a long time, as in long-term
skin-painting studies, should also be determined.
If diets are sterilized, the effects of such procedures
on the test substance and dietary constituents should
be known. Appropriate adjustments to nutrient levels
should be made.
During carcinogenicity tests, investigators should be
aware of potential chemical contaminants in the water
used. Although water approved forhuman consumption
is generally satisfactory, the investigator should deter-
mine the levels ofpotential contaminants that are likely
to influence the outcome of the study. The analyses of
the water supply should be included in the reports of
these studies.
Test and Control Groups. The number of animals
to use has been the subject ofgreat concern because of
the fact that the test animals may be serving as sur-
rogates for more than 200 million people in the U.S.,
and potentially for far more worldwide. While it is de-
sirable to enhance the sensitivity of the test, it is not
feasible to use verymany animals. Furthermore, amod-
erate increase in the group size provides relatively little
increase in the statistical power ofthe test. Therefore,
careful attention must be paid to experimental design
to assure the maximum reliability ofthe study and that
the results are amenable to statistical evaluation. The
use of adequate randomization procedures for the
proper allocation of animals to test and control groups
is of particular importance. A sufficient number of an-
imals should be used so that at the end of the study
enough animals from each group are available for thor-
ough pathological evaluation. For such reasons, it has
beenrecommended thateachdosegroupand concurrent
control group should contain at least 50 animals ofeach
sex (488,498,499,503). Ifinterim sacrifice(s) is included
inthe study plan, the initial numbershould be increased
by the number of animals scheduled for the interim
sacrifice(s).
At least one concurrent untreated control group,
identical in every respect to the exposed groups, except
for exposure to the test substance, should be used. In
certain studies, such as with inhalation exposures that
require unique housing conditions, it may also be ap-
propriate to include an additional concurrent control
group housed under conventional conditions.
Occasionally, a positive concurrent control group is
useful, particularly when there is reason to believe that
the strain of animals may be resistant to the particular
class ofcarcinogens orthat a previously sensitive strain
has become insensitive because ofgenetic drift. A pos-
itive control can also provide some information on the
relative carcinogenic potency ofthe tested chemical. In
routine carcinogenicity testing, no positive controls
need be used (488,498).
Dose Levels, Frequency, andRoute ofExposure. If
a single bioassy is to be used both for detection and for
risk assessment, at least three dose levels in addition
to the concurrent control group are recommended. The
question ofwhat maximum dose should be administered
may be the most controversial issue concerning bioas-
says (497,503,517).
The highest dose currently recommended is that
which, when given forthe duration ofthe chronic study,
is just high enough to elicit signs of minimal toxicity
without significantly altering the animal's normal lifes-
pan due to effects otherthan carcinogenicity (503). This
dose, sometimes called the maximum tolerated dose
(MTD), is determined in a subchronic study (usually of
90 days duration) primarily on the basis of mortality,
toxicity, and pathology criteria. The MTD should not
produce morphologic evidence of toxicity of a severity
that would interfere with the interpretation of the
study. Nor should it comprise so large a fraction ofthe
animal's diet that the nutritional composition ofthe diet
is altered, leading to nutritional imbalance.
The MTD was initially based on a weight gain dec-
rement observed in the subehronic study; i.e., the high-
est dose that caused no more than a 10% weight gain
decrement (494). Morerecent studies andtheevaluation
of many more bioassays indicate refinement of MTD
selection on the basis of a broader range of biological
information (503). Alterations in body and organ weight
and clinically significant changes in hematologic, uri-
nary, and clinicalchemistrymeasurements canbeuseful
in conjunction with the usually more definitive toxic,
pathologic orhistopathologicendpoints. The 1984report
of the NTP Ad Hoc Panel (503) contains a helpful dis-
cussion of the use of such corroborative information to
more reliably determine the MTD (see pages 126-145
ofthe NTP Report). Therationaleforthedoseselection,
including the data elements rationale for the selection
of the dose based on these data.
The Report of the NTP Ad Hoc Panel also discusses
the kind of data which may be helpful in selecting the
spacing of doses below the MTD. Such doses are ordi-
narily simple fractions of the MTD; e.g., 1/2, 1/3, etc.
Dose selection is influenced primarily by one or more
of these types of information: observations in the sub-
chronic studies, particularly the dose-response curve;
nonlinear behavior and the doses at which this occurs;
and anticipated human exposure levels or relevant ex-
posure guidelines (such as the threshold limit values
[TLVS]).
The important contribution ofpharmacokinetic stud-
ies to the selection of doses below the MTD is the in-
formation such studies may provide on the presence of
dose-dependent and the time-dependent processes af-
fecting the disposition of substances in the body
(503,519-525). Such information may also identify
changes in the internal concentrations of the chemical
or its metabolites that are not directly proportional to
administered dose and may also indicate ifaccumulation
of the chemical or its metabolites occurs with repeated
exposures. To be ofmaximum use in the dose selection
process, this information should be obtained early, be-
fore or during the prechronic phases of the bioassay.
However, because pharmacokinetic data may also re-
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veal distinct changes in the animals' treatment of the
chemical at low as compared to high doses, such data
may also aid in the interpretation of the bioassay.
Because ofcost, a single long-term study may be uti-
lized to obtain data on chronic toxicity, on carcinogenic
potential and for carcinogenic risk assessment. The
present discussion envisions the combination ofboththe
qualitative objective of a carcinogen bioassay, the de-
tection of carcinogenic potential, and the quantitative
objective, obtaining dose-response data for risk as-
sessment, into a single bioassay. If only one of these
objectives is sought, it may be advisable to select the
doses differently. The purpose of using the MTD is to
provide maximum opportunity for the detection of a
neoplastic response. The purpose ofseveral lowerdoses
is to provide adequate information on the shape of the
dose-response curve for risk assessment and to ensure
a meaningful comparison with the controls even if the
MTD was unfortunately selected attoo high alevel. The
pathological responses observed inthe subchronic study
and the slope of the subchronic dose-response curve
should aid in the selection of the range and number of
doses for the long-term study. For example, a steep
dose-response curve would suggest closer spacing of
intermediate dosesthanashallowdose-response curve.
The existence of metabolic saturation (as indicated by
pharmacokinetic data) at doses well below those iden-
tified by pathological criteria suggest a spacing ofdoses
designed to determine both whether the highest dose
has any carcinogenic effect and to adequately define the
dose-response curve forthe saturable process. This may
require additional doses. Generally four doses including
the control, (occasionally three) will be necessary to
adequately define the dose-response curve, assuming
an appropriately chosen MTD. Since the MTD is an
estimate at best, the value of additional doses is gen-
erally difficult to judge. If the estimated MTD even-
tually produces moderately high or excessively high tu-
mor incidence, additional lower doses may aid in
defining the shape ofthe dose-response curve and may
even salvage a study when the MTD is overestimated.
If the estimated MTD produces no tumors, or a low
incidence oftumors, the additional doses will have been
unnecessary as regards carcinogenicity but can help es-
tablish safe nontoxic doses. As indicated above, the best
guide to the number ofdoses is the acquisition ofknowl-
edge on the pathological and pharmacokinetic criteria
upon which a sound, scientific judgment can be based.
The National Toxicology Program (NTP) has published
more detailed recommendations for prechronic testing
and dose selection from its Ad Hoc Panel on Chemical
Carcinogenesis Testing and Evaluation (503). Interrup-
tions in the administered dose may permit some cellular
repair and reduce the sensitivity ofthe test. Therefore,
ifthe chemical is administered in the drinking water or
mixed in the diet, it should be continuously available.
The frequency of exposure may vary according to the
route chosen or may be adjusted according to the tox-
icokinetic profile or stability ofthe test substance. Pro-
tocols for inhalation or for dermal exposure are usually
subject to special constraints (498).
The route of administration used for the bioassay is
critical for both its qualitative and quantitative objec-
tives-but in different ways. If the route of adminis-
tration results in the absorption, distribution and met-
abolic activation (if required) of the substance, it is
reasonable to regard the test as relevant for a quali-
tative demonstration of human carcinogenic hazard.
This comparison is obviously most directly made when
the route used in the test and the route of human ex-
posure are the same, but as long as the criteria above
are satisfied, the results ofanimal studies are generally
considered qualitatively meaningful.
If, because of its palatability, solubility, stability, or
volatility, a substance can not be given in feed orwater,
oral gavage may have to be considered. This is clearly
less desirable, however, since single large boluses can
result in absorption and pharmacokinetic patterns dif-
ferent from those anticipated from human exposures.
Sometimes, the use of gavage can be avoided by grad-
ually increasing dietary concentration of the test sub-
stancetogainacceptance, byalteringotherdietarycom-
ponents to increase the palatability or by
microencapsulation.
Certain site specific tumors, e.g., bladder carcinoma
following bladder implantation and subcutaneous sar-
comas following injection, may not be relevant for hu-
man oral exposure. The presence oftumorsremotefrom
the site of administration and a knowledge of site-spe-
cific metabolism play a significant role in the final eval-
uation. Some routes of administration may fail to pro-
vide adequatemetabolic activation orexposureoftarget
tissues andtherefore lead tofalsenegativeresults (498).
Such data require careful evaluation.
When an assessment of human risk is desired, it is
desirable to obtain sufficient datatopermit areasonably
accurate estimate ofthe dose ofthe carcinogenreaching
thetargettissue. In someinstances, e.g., forsubstances
used on the skin, this may require a bioassay to detect
tumorigenic potential and a separate study of the sub-
stance's permeability across the skin to measure the
amount absorbed. In inhalation studies, this may re-
quire a separate study for determining the amount of
inhaled material deposited on, or absorbed by the res-
piratory tract.
Duration ofStudy. Test animals should be exposed
for the majority oftheir normal life spans. While there
are certain animal test systems which offer the possi-
bility of inducing cancer within only a few weeks or
months, such systems at the present time are useful
mainly as research tools to explore specific, well-defined
questions. They cannot be relied upon to test unknown
substances for carcinogenicity and are insufficient as a
primary basis for regulation.
Treatment is preferably begun as soon after weaning
as possible 'qnd continued for the major portion of the
animals' lifespans. This is at least 18 months for mice
and hamsters and 24 months for rats. In some instances
where the cumulative mortality at the planned time of
sacrifice is still very low, e.g., less than 10%, a longer
237CHEMICAL CARCINOGENS
duration may be appropriate. Some protocols call for
treatment soon after birth (neonatal) or during fetal
development (in utero). The rationale is based on the
greater susceptibility of certain organ systems to car-
cinogens during their early development. However,
there are logistical problems which preclude using neo-
natal or in utero systems for routine bioassays.
Termination of the study is ordinarily acceptable
when the number ofsurvivors in the low dose or control
group is reduced to 20-25%. Generally, because of dif-
ficulties produced by naturally occurring tumors, long-
term studies are conventionallyterminated by week 100
for hamsters, 120 for mice, and by week 130 for rats,
regardless ofmortality. When there is an apparent sex
difference in response, each sex should be considered a
separate study (496). If the high-dose group dies pre-
maturely from obvious toxicity, this should not trigger
termination ofthe lower-dose groups orcontrols. Aneg-
ative test is ordinarily accepted by regulatory agencies
ifno more than 10% ofanygroup is lost dueto autolysis,
cannibalism or management problems and ifsurvival of
all groups (per sex per dose) is no less than 50% at 80
weeks for hamsters, 96 for mice, and at 104 weeks for
rats (499).
Rigid rules for termination are not helpful, the best
guide is professional judgment, experience and careful
observation ofthe condition ofthe animals. The longer
the test continues, the greater the opportunity for the
development of tumors (526,527). On the other hand,
the sensitivity of bioassays decreases with time, be-
cause of the natural appearance of age-related tumors
in the controls. In theory, it is necessary to know both
the incidence and growth rate of naturally occurring
tumors and experimentally induced tumors at various
organ sites in the sex and strain ofanimal used in order
to determine the optimal time for termination. This in-
formation is ordinarily not available until the end ofthe
test and while serial sacrifices are useful, they are con-
sidered too expensive for routine testing of chemicals.
Data Collection and Reporting. Animals should be
checked carefully at least twice each day. Observations
should be sufficient to detect onset and progression of
all toxic effects, as well as to minimize loss due to dis-
eases, autolysis, or cannibalism. Body weights should
be recorded individually for all animals once a week
during the first 13 weeks ofthe test period and at least
once every 4 weeks thereafter. Loss of body weight
should trigger careful clinical examination ofthe animal
and its sacrifice, if necessary. Food intake should be
determined weekly during the first 13 weeks of the
study and then at approximately monthly intervals, un-
less health status or body weight changes dictate oth-
erwise (499).
Clinical signs and mortality should be recorded for all
animals. Special attention mustbepaid toclearly visible
tumor development; the time ofonset, location, dimen-
sions, appearance, and progression of each grossly vis-
ible or palpable tumor should be recorded.
The pathological examination, macroscopic as well as
microscopic, is the cornerstone of the carcinogenicity
study. A thorough gross necropsy with subsequent se-
lection ofappropriate lesions for histopathology is man-
datory. It is vital that the sampling among the test and
control tissues be uniform so that no bias is introduced
into the comparisons. Microscopic examination of both
test and control tissues is required. While an all-inclu-
sive microscopic examination of all tissues is theoreti-
cally desirable, the resource limitations may dictate a
more selective approach such as the one recently pro-
posed by the National Toxicology Program or earlier
by the National Cancer Institute (528,529). The quality,
extent and completeness of the documentary record of
the bioassay are of critical importance in establishing
its validity for scientific and regulatory purposes. It is
crucial that the physical evidence, e.g., the original tis-
sue sections and slides, is accurately prepared andmain-
tained. Sponsors of bioassays that are to be submitted
toregulatoryagencies should be familiarwith additional
requirements of GLPs (Good Laboratory Practice)
(516).
Interpretation and Evaluation ofLong-Term Car-
cinogen Bioassays
BACKGROUND. Several attempts have been made
overthe last 10 years to construct a suitable operational
definition for a chemical carcinogen (493,494,497,498,
530,531). Though none of these have succeeded fully,
there is common agreement that a chemical carcinogen
is a substance which induces cancer by some chemical/
biological mechanism. A chemical carcinogen may be a
substance which either significantly increases the inci-
dence of cancer in animals or humans or significantly
decreases the time it takes a naturally-occurring (spon-
taneous) tumor to develop relative to an appropriate
background orcontrolgroup. Eitherphenomenonissaid
to represent the effects of a carcinogen (467).
Theinterpretation ofcarcinogenicity datahasevolved
considerably in the last decade. In past years, there
were no standardized protocols for testing carcinogens.
Typically an identified carcinogen was used as a re-
search tool to study the mechanisms of carcinogenesis,
so that many experiments were performed with the
compound. This intense study usually dispelled any
doubt as to whether the substance was actually a car-
cinogen. This degree of confirmation gradually de-
creased as more of the experimentation turned from
research on the process of carcinogenesis to detecting
as many chemicals as possible that might pose a cancer
risk to humans. For this latter purpose, which began
in earnest in the mid 1960s with the "screening" bioas-
says conducted by NCI, it was necessary to devise "de-
cisionrules" bywhich to declare achemical acarcinogen
(487). Since then, considerable progress has been made
in refining basic principles and criteria to guide the
interpretation ofcarcinogenicity (488,489,498,499). Ex-
perience has taught that these criteria should be re-
garded as general guidelines in evaluating rather than
rigid rules and that final decisions are best made after
careful communication between pathologists, toxicolo-
gists and statisticians. Most useful to the process is the
experience and the data derived from large numbers of
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recent tests using a uniform protocol.
With some oversimplification, the task ofthe pathol-
ogist and toxicologist is to decide whether a lesion is
cancerous or precancerous and whether it is related to
exposure to the test chemical. The statistician, on the
other hand, has the task of determining whether any
observed tumors are more likely to have occurred by
chance oras aresult oftreatment. Neitherofthesetasks
is simple or completely independent of the other and,
more importantly, each requires experience and judg-
ment if sensible decisions are to be made.
ToXICOLOGICAL ISSUES IN BIOASSAY EVALUA-
TION. Largest doses (i.e., doses far exceeding human
exposure levels) have been strongly recommended by
several national and international bodies in order to
overcome the inherent low sensitivity of bioassays
(498,499,503). These recommendations have been con-
troversial because high doses may themselves produce
altered physiologic conditions which can qualitatively
affect the induction ofmalignant tumors. Normal phys-
iology, homeostasis, and detoxification or repair mech-
anisms may be overwhelmed, and cancer, which oth-
erwise might nothave occurred, isinduced orpromoted.
Normal metabolic activation of carcinogens may possi-
bly also be altered and carcinogenic potential reduced
as a consequence. Ifqualitatively different distribution,
detoxification, or elimination ofthe test chemical is pro-
duced at the highest dose, a toxic response at this dose
may not be indicative of effects at low exposure levels.
The cancers which arise from high doses of corticoste-
roids, estrogens, certain sulfonamide compounds and
from some instances ofbladder implantation may result
from such "secondary" effects (532). This concern is not
easily resolved, for if the dose is not high enough, car-
cinogens may remain undetected by traditional bioas-
says.
Use ofthe Maximum Tolerated Dose. The concept
and operational definition of the MTD have undergone
modification during the last several years in response
to some of these concerns. The 1971 FDA Advisory
Committee on Protocols recommended that: "Testing
should be done at doses and under experimental con-
ditions likely to yield maximum tumor incidence" (493).
However, as the use of these tests for human risk as-
sessment increased, it became vital not only to detect
carcinogens qualitatively (i.e., avoid false negatives),
but also to estimate effects at low dose levels. Both the
National Cancer Advisory Board Subcommittee
(NCAB) (531) and the Interagency Regulatory Liaison
Group (IRLG) (498) cautioned against the use of a dose
so high that it produced "unwanted toxic side effects"
(IRLG) or "unphysiologic conditions [which] may in
themselves enhance tumor formation" (NCAB). Recent
publications have emphasized the need to select the
doses not only on the basis ofthe results of subchronic
toxicity studies, but also on the basis of what is known
about the pharmacokinetics and metabolism ofthe test
substance (497,503,517). Better techniques to observe
and detect significant differences in metabolism and
pharmacokinetics throughout the dose range used are
being developed; these should help in a better deter-
mination of the MTD (519-525). The desirable goal is
that the dose used meets the objectives of maximally
enhancingthe sensitivity ofthetest withoutintroducing
qualitative distortions in the results.
Promoters vs. Initiators, Current Experimental Sta-
tus. Inthe portion ofthis report titled "Current Views
on the Mechanism of Carcinogenesis," the evidence for
the beliefthat cancer occursthrough at least atwo stage
process consisting of initiation and promotion was dis-
cussed. The basic question ofwhether tumor promotion
is a general feature of carcinogenesis or is only char-
acteristic of some organ systems is still debatable, al-
though more and more evidence for the initiation-pro-
motion process in a variety of organs is becoming
available (533). The question naturally arises as to
whether such promoting agents can reliably be distin-
guished from initiators by traditional bioassays.
A number of examples of promoting agents are well
documented; most of the work on their mechanism has
been done on skin, e.g., the phorbol esters in epidermal
carcinogenesis. Other examples are butylated hydrox-
yanisole in pulmonary carcinogenesis, phenobarbital in
hepatocarcinogenesis and estrogenic hormonesinbreast
cancer. Some known promoting agents also have weak
tumorigenic activity and some are also initiators, i.e.
complete carcinogens. Carcinogens may act as pro-
moters at some tissue sites and initiators at others. It
is very difficult both in principle and in practice to con-
firm the claim that a given chemical acts by promotion
alone. If such a mechanism is postulated for a specific
chemical, data on the purported mechanism at the af-
fected tissue sites and dose response data would be
needed to support the proposition.
Need.forBiological Significance, OtherData. There
is no simple or generic solution to the problems which
arisewhenattemptingtointerpret carcinogenicity data.
Over recent years, review groups charged with the re-
sponsibility to evaluate carcinogenicity data and come
to some decision regarding the carcinogenicity of a
chemical have recognized the need to consider all ofthe
available scientific information which may bear on such
a decision (492,493,497,531). In addition to statistical
significance (see Evaluation of Statistical Significance),
there should be biological significance as well. The use
of a variety of biological information on dose response,
tumor progression, tumor latency, tumor multiplicity,
findings in other studies, etc. can add confidence to the
final assessment. Other often useful information in-
cludes historical data on control animals, information
from in vitro mutagenicity or neoplastic transformation
systems, toxicological information which might indicate
that the organ or tissue which is at risk for carcinogen-
icity appears to be a target for the toxicity of the com-
pound. Mutagenicity, DNArepair, andneoplastictrans-
formation studies can sometimes be used in aiding
judgments on carcinogens (484). For example, if the
data indicating carcinogenicity are ofonly marginal sig-
nificance, negative findings in properly designed and
well-conducted in vitro tests, depending upon their rel-
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evance to the specific situation, may lead to aconclusion
that the chemical is probably not carcinogenic. On the
other hand, if the results from in vitro testing were
clearly positive, and if evidence existed to show that
the organ in which the cancer question arose was also
the toxicological target of the chemical, the conclusion
would be likely to be that the chemical is carcinogenic.
To make thesejudgments, it is important that there be
a good interaction and deliberation among scientists
from different disciplines.
Human Relevance of Rodent Tumors. The infer-
ence stated earlier, "that in the absence of adequate
data on humans it isreasonable toregard chemicals that
are carcinogenic in laboratory animals as if they were
also carcinogenic to humans," should be given great
deference as a general principle. But this need not fo-
reclose further scientific inquiry in individual cases if
experimental evidence on the mechanism of tumor for-
mation in the animal is available. As science advances
and more sophisticated studies are done, it may become
possible to demonstrate the existence ofunique suscep-
tibilities to chemical carcinogenesis inrodents that have
no relevance for humans. All the available scientific in-
formation should be used in attempting to reach the
most likely correct scientific conclusion. The inferential
relevance ofobservedanimal carcinogenesis topotential
carcinogenic risk in humans is obviously justifiable in
the absence of such mechanistic information.
ISSUES OF PATHOLOGY IN THE INTERPRETATION OF
TUMOR DATA. Asmentioned earlier, acarcinogenmay
be defined as a substance which increases the incidence
of cancer above the background rate. However, from a
practical point ofview, the most important question is:
how does one estimate or deduce cancer incidence from
tumor data? For instance, should all cancers in the an-
imal be combined and the total number of tumors in
treatment groups compared to total cancers in the un-
treated controls? Alternatively, should carcinomas be
separated from sarcomas since they are derived from
different tissue? Should the comparisons between
treated and controls be restricted to specific organ sites
and, ifso, should alltumors be combined, oronlycertain
types? Other questions are: should benign and malig-
nant tumors be separated or combined; iftumors occur
at multiple organ sites, can they be combined and how
should it be done; should cancers which shorten the life
of the animal be separated from those which do not?
These questions and many more must be answered be-
fore cancer incidence(s) can be estimated. Unfortu-
nately, there is no universal agreement among experts
in the field relevant to the rules for calculating cancer
incidence that is applicable to "all" carcinogens "all" of
the time.
Tumor Number, Type, and Site in the Assessment
ofIncidence. Generally, most experts agree that the
incidence oftotal tumors at all organ sites is not a very
useful expression of cancer incidence, nor is the calcu-
lation ofthe incidence oftotal benign or total malignant
tumors. Most useful appears to be the number of his-
tologically unique tumors at specific organ sites (534).
Thegroupingoflesions forevaluation shouldbebased
on commonality of histogenetic origin. Therefore, sar-
comas should not be combined with carcinomas for the
purpose ofestablishing a value for the incidence ofcan-
cer at a specific organ site. It is often necessary, at least
in the judgment of many pathologists, to combine cer-
tain benign tumors withmalignant ones occurringin the
same tissue and at the same organ site. This practice
can make the total neoplastic response (benign and ma-
lignant) clearly significant, despite the lack ofstatistical
significance in the tumors diagnosed as malignant.
These pathologists believe that truly benign tumors in
rodents are rare and that most tumors diagnosed as
benign really represent a stage in the progression to
malignancy. For some tissue sites, this view is widely
accepted. Examples of this are adenomas versus ad-
enocarcinomas in the pituitary, thyroid, lung, kidney
tubules, and according to some experts, in mouse liver.
In each of these cases, it is argued that the judgment
ofthepathologist astowhetherthe lesionis an adenoma
or an adenocarcinoma is so subjective that it is essential
they be combined for statistical purposes. It is also ar-
gued, in these specific cases, that the adenoma is a pre-
cursor ofthe adenocarcinoma. Indeed, the Subcommit-
tee on Environmental Carcinogenesis of the National
CancerAdvisoryBoardrecommendedin 1976thatthese
lesions be combined for statistical purposes (531). Most
U.S. regulatory agencies have followed this recommen-
dation. Ordinarily the tumor or cancer incidence is cal-
culated as the number oftumor-bearing animals having
tumors at a specific organ site divided by the total num-
berofanimals that survived longenough on experiment
to have been at risk for that specific type oftumor. For
reasons discussed in the statistical part ofthis section,
life-shortening tumorsshouldnotbe combinedwith non-
life-shortening tumors.
Time to Tumor. Apositiveresultinacarcinogenesis
bioassay can be based on evidence of a substantially
decreased latency period, as well as on the induction of
an increased incidence ofmalignant tumors. A good dis-
cussion of the precautions that should be observed in
order to establish decreased latency is given in the 1979
IRLG report (498). Such data, in conjunction with in-
cidence data, can be useful to distinguish between the
relative potencies of carcinogens.
Problems in Tumor Diagnosis. A major problem
facing those who must make either scientific or public
health policy decisions based on carcinogenicity data is
that the diagnosis of pathological lesions is subjective
and pathologists may disagree on diagnosis. Fre-
quently, the disagreement is not as serious or far-rang-
ing as it may appear to nonpathologists. The disagree-
ment may be focused on an issue where neither
pathologist is absolutely certain and each is forced to
offer his "best opinion." In practice, for most com-
pounds, NCI and NTP have used panels composed of
two to four pathologists to review and analyze the le-
sionsthathave been observed (528,534). This procedure
helps to provide consistency in diagnosis, but it may
not solve all the problems. For instance, most pathol-
240CHEMICAL CARCINOGENS
ogists do not review the microslides "blind." They know
which slides come from control animals and which from
treated animals. The extent to which this information
leads to bias in diagnosis is not known (528).
A common problem with the interpretation of path-
ological data concerns the selection of the tissues at
necropsy, how the tissues were prepared, the slides
mounted and so on. For instance, a few years ago most
investigators did not open the skulls and carefully ex-
amine the brain. In other cases, only brains appearing
abnormal were examined in detail. Currently, the brain
as well as other tissues such as nasal turbinates are
routinely examined histologically (526,534), though the
techniques vary somewhat. As a consequence, sponta-
neous tumors of these tissues are now being reported.
Dependinguponhowextensivelythesetissuesarebeing
sectioned for histological analysis the observed inci-
dence mayvaryfromlowtomoderatelyhigh. Suchmod-
ifications in the pathology protocol, if not recognized
andunderstood, couldleadtoserious errorsinjudgment
concerning the carcinogenicity of a chemical.
Criticaltodecisionsaboutcarcinogensisthebiological
significance and human relevance of certain types of
tumors, particularly the liver tumors in the mouse. This
matter has been the subject of heated debate for the
past 15 years. Some scientists are certain that the
mouse liver is overly sensitive and will respond to al-
most any toxic insult by developing cancer. Other sci-
entists are just as certain that the mouse liver is a
reliable indicator of carcinogenicity and as good a pre-
dictorofpotentialhumanrisk as anyindicatoravailable.
In one review, 61 of 85 chemicals (73%) that increased
the incidence oflivertumorsinmicealsoinduced tumors
in other tissues of mice and/or in rats (511). Some tox-
icologists believe that part of the problem stems from
workonC3H strains ofmice wherethebackgroundliver
tumor incidence is high and false positive errors are
possible. Generally, there is consensus that the mouse
liver model in principle does have significance in terms
ofhumanrisk, butunambiguous diagnosis between "be-
nign" or"hyperplastic" livernodules andmalignant neo-
plasiaremains elusive andthereis no apparent scientific
consensus. Arecentreview ofthis issue has emphasized
the need for judgment on a case-by-case basis and the
possible relevance of other toxicological information
(535).
In addition to liver tumors, other tumors, including
lymphomas in the mouse, which appear to be of viral
origin, have been questioned as to their relevance to
human cancer. As a general matter, toxicologists must
question the relevance to humans of any experimental
tumor which has a known viral background where the
virus may be unique to the animal. This includes a va-
riety of lymphomas and sarcomas in rats and mice, as
well as mammary tumors in the mouse. Likewise, the
relevance to human exposures ofthe induction ofblad-
der cancer in rodents which are shown to have bladder
stones and crystaluria only at high doses of the test
substance is questionable.
EVALUATION OF STATISTICAL SIGNIFICANCE. For
the analysis of tumor incidence data, a widely-used
method for comparing experimental and control groups
is Fisher's exact test (536). This analysis is generally
carried out in conjunction with a Cochran-Armitage
trend test (537,538) which examines the relationship
between tumor incidence and dose. The trend test has
the advantage of utilizing cancer incidence data for all
doses and as a result is somewhat more sensitive than
pairwise comparisons to the detection of carcinogenic
effects.
The statistical procedures mentioned above for the
analysis of tumor incidence data do not take survival
differences into account (515). This can be a problem
with chemicals that produce alife-shortening effect. Al-
though "survival-adjusted" tumor incidence analyses
(515,539,540) are more complex, they have the advan-
tage ofadjustingforintercurrent mortality and ofbeing
sensitive to shortened latency period as well as to in-
creased tumor incidence. These procedures require the
determination of whether tumors in individual animals
are "lethal" or "incidental" with respect to the under-
lyingcause ofdeath. This determination maybe difficult
if not impossible to make for many animals, but exper-
imentalists should try to distinguish in their records
between lethal and incidental tumors.
While it is customary practice in the conduct ofbioas-
says to regard an increased tumor incidence that is sta-
tistically significant (e.g., p < 0.05) as reasonable as-
surance that the effect is real and not due to chance
alone, the final judgment regarding a compound's car-
cinogenicity is rarely based on a single finding of sta-
tistical significance (540). One must be assured that the
effects observed are biologically significant as well.
Other factors that must be taken into account include:
the reproducibility ofthe effect in other doses and/or in
other sexes or species; the historical incidence of the
tumor in question; the survival histories of dosed and
controlanimals; andevidence ofhyperplasia, metaplasia
or other signs of an ongoing carcinogenic process.
The0.05p-valueisareasonable statisticalbenchmark
with a history of use in the bioassay field. It would be
imprudent to disregard it as an index of significance
without good reason. It would be equally unwise to
regard it as an absolute requirement or a sine qua non
without considering the weight of biological evidence.
For example, doubling or tripling the incidence of a
tumor that occurs at low incidence in the controls may
not be statistically significant, but may indicate a bio-
logical effect that should not be dismissed. Similarly,
the finding ofnominal statistical significance (p = 0.05)
at a single tumor site may be less important to the final
evaluation than knowledge of the target site and the
lack of consistency with related biological findings. As
stated by IARC (499): "The p-value from a good ex-
periment is an objective fact, subject to public agree-
ment. The weight to be given it and to the available
pieces of information is not."
Problem of False Positives and False Nega-
tives. Because ofthe time and expense involved, most
chemicals, if tested at all, are tested in only one bioas-
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say. It is vital that this test have good sensitivity, since
otherwise many true carcinogens would remain unde-
tected (a false negative). The test must also possess a
high degree of specificity, since there are economic
losses as well as disincentives for testing ifsafe, useful
substances are mistakenly declared carcinogens (a false
positive).
The typical bioassay, due to inherent limitations (low
number of animals and biological variation) cannot re-
liably detect an increased tumor incidence ofmuch less
than 10-15% over background. High test doses are one
way around this limitation, but as discussed above this
can introduce confoundingfactors ifthe dose is too high.
In addition, the possibility always exists that for a spe-
cific substance, the most sensitive species may be in-
appropriate for qualitative extrapolation to humans.
Until more is known concerning the mechanism of can-
cer and the similarity in response between man and
animal, this uncertainty will persist.
Confidence in an apparently negative bioassay in-
creases with the number ofanimals used, the adequacy
ofthe doses, the extenttowhichitsduration approaches
the animals' expected lifetime, and the adequacy ofthe
gross and histological examination of both control and
treated groups. Corroborative evidence such as exper-
imentally consistent biological results in different spe-
cies or sexes, or at different doses, strengthens the
likelihood that the bioassay is correctly interpreted.
Rigid rules or definitions are not very useful. The ul-
timate decision must be based on the knowledge of ex-
perienced pathologists and toxicologists, the weight of
corroborative evidence and a careful statistical evalu-
ation.
The spontaneous tumor incidence can be of consid-
erable importance in the interpretation of results from
carcinogenicity studies. If, for example, the effect of a
chemical is to double or triple the background tumor
incidence, tissue siteswith lowspontaneous tumorrates
are more likely to yield false-negative results than are
sites with high spontaneous tumor rates. For example,
if a tumor is a rare tumor, even a slight increase in
incidence may be biologically significant and may be
considered adequate evidence of carcinogenicity (536).
This factor must be taken into account in the overall
evaluation ofthe data. Forsuch tumors (e.g., with spon-
taneous tumor rates of 1% or less), the utilization of
historical control data may be particularly useful in in-
creasing the sensitivity of the study for detecting car-
cinogenic effects. All recent work emphasizes the fact
that the evaluation of the bioassay is not a simple nor
routine statistical exercise, but a multidisciplinary pro-
cess requiring the interaction of toxicologist, patholo-
gist and statistician.
Appropriate precautions in the design and evaluation
of bioassays can minimize the chance of false positive
results. The test substance must be free ofcarcinogenic
contaminants and appropriate doses and routes of ex-
posure must be used. However, careful attention to
these and to other factors cannot eliminate entirely the
possibility of either false positive or false negative re-
sults. These problems are fundamental to the process
of drawing inferences from observed sample data.
Many investigators familiar with data from bioassays
believe that in practice the overall false-positive rate
does not greatly exceed 0.05 (540,541). Others are not
as certain, and all admit that this is an important prob-
lem area that must be considered in the interpretation
of carcinogenesis bioassay data. The very effort to be
as thorough and as complete as possible in the selection
oftissue at necropsy, and in the detection ofresponses
from various doses, increases the chance for a false pos-
itive error. Typical bioassay protocols require section-
ing and analysis oftissues from 20-30 sites in two spe-
cies, in two sexes, and, at the least, two dosage levels.
It has been suggested that the multiple tests for sig-
nificance applied to these many sites produce an unac-
ceptably high overall false positive rate. The argument
is that, if n independent tests are conducted at the a
significance level, the probability of finding a signifi-
cance somewhere (the false positive rate) is [1 - (1 -
a01]. For n = 20 and p = 0.05 for a single dose-sex
comparison, this probability is about 0.64.
However, recent investigators have shown that this
argument overestimates the likely false-positive rate of
the bioassay. Gart et al. (536), usinghistorical incidence
rates for B6C3F1 mice, found the probability ofat least
one significant result at the 0.05 level at some site in at
least one sex was only about 8%. In a commonly used
strain of rat (F344) the same probability was approxi-
mately 21%. These findings are well below the 64%
value cited above. One reason for this difference is that
tumor incidences are discrete count data, and in this
situation, the actual significance level oftest procedures
comparing tumor rates is always less than the nominal
level, often considerably less.
This is particularly true fortumors havingalow spon-
taneous incidence. Even the estimated false-positive
rates reported by Gart et al. (536) may be too high,
since (as noted earlier) the final judgment that a com-
pound is carcinogenic is rarely based on asingle isolated
"significant" increase in tumor incidence. Generally
more stringent evidence is required, such as the re-
producibility of the effect in other doses and/or other
sexes or species. For example, if a chemical is judged
carcinogenic only if it is positive (p < 0.05) at some
tissue site for both the low and high doses, the overall
falsepositiverateforatwo-sex, two-species experiment
has been estimated to be 5.1% (542).
In a recent examination of 25 NTP feeding studies,
a simple statistical rule was derived by Haseman (541)
which appears to mimic closely the scientific judgment
process used in these experiments. This "rule" was as
follows: regard as carcinogenic any chemical that pro-
duces a high-dose increase in a common tumor that is
statistically significant at the 0.01 level or a high-dose
increase in an uncommon tumor that is statistically sig-
nificant at the 0.05 level. The overall false positive rate
associated with this particular decision rule (which ap-
pears to approximate closely the overall evaluation pro-
cess) was estimated by Haseman and found to be no
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more than 7-8% for the current NTP two-sex, two-
species protocol (543).
In summary, in the interpretation oftumor incidence
dataaninvestigatorshouldbe awareofthefalsepositive
issue. In the overall evaluation process, one should be
guided by (but not rely exclusively upon) the statistical
significance ofan observed tumor increase. This aware-
ness will help minimize the likelihood ofa false positive
result.
Use ofHistorical Controls. It is extremely impor-
tant for the interpretation of a bioassay that the vari-
ability of the incidence of spontaneous tumors in the
strain of animals used be established with the highest
precision possible. These variations present problems
in interpreting the results of bioassays. NTP has rec-
ognized this problem and has continued to accumulate
data from untreated and corn-oil gavage control groups
forthe strains ofanimalsused(509,510). Withsuchdata,
the toxicologist may conclude that a study yielding sta-
tistical significance is not biologically significant or con-
versely that an effect is real, even though there is no
"significant" difference between test and concurrent
controls. Of27bioassay studyreportsissued bythe NCI
from 1978 to 1980, historical controls were used in 14
studies to show that an apparent increase of a specific
tumor was not related to treatment (543). In 13 studies,
the use ofhistorical controls showed that an increase in
tumorswasrelated totreatment. Historicalcontroldata
can be valuable when used appropriately, especially
when the differences in incidence rates betweentreated
and concurrent negative controls are small and can be
shown to be within the anticipated historical incidence.
However, the use ofhistorical control data is not with-
out its own problems. Over the course oftime, the thor-
oughness of pathologic evaluations has improved and
pathologic diagnosis has evolved and nomenclature has
changed. There is also the possibility that the genetic
susceptibility of the strain has shifted. The sources of
variability in historical control data should be identified
and, ifpossible, controlled. Obviously one has more con-
fidence in the most recent historical control data from
the same laboratory conducting the current study than
in a compilation of pooled older data from other labo-
ratories. Several procedures have recently been pro-
posed for utilizing historical control data in a formal
testing framework (543-546). The relative merits of
these methodologies are currently being investigated
by the NTP.
Summary
Althoughthe identification ofcarcinogenic substances
has long been of interest to the scientific community,
until the 1960's the focus of most studies was research,
not testing for substances which may pose a public haz-
ard. The National Cancer Institute, and later the Na-
tional Toxicology Program, have conducted a number
oftest-oriented studies, the chronic bioassays, and have
also attempted to standardized many important param-
eters in conducting these studies. Type and number of
animals, dose level and route, and study duration are
fairly uniform in an effort to make the data base as
comparable as possible from test to test.
Certain issues remain as problems. One of these is
the use ofthe maximum tolerated dose (MTD) in long-
term studies and the appropriateness of dose route,
schedule, and length of exposure. Use of the MTD, if
not an ideal solution to the problem of bioassay sensi-
tivity, is appropriate if it is properly determined. An-
other problem is the interpretation oftumor data. This
includes tumor number, type, time to tumor, tumor
diagnosis, etc. and the significance of certain tumors.
General guidelines have been recommended, with the
proviso that they are to be used in conjunction with
sound judgment.
Furthermore, although several methods ofstatistical
analyses oflong-term test results have been developed,
the questions of false negatives and false positives and
theuseofhistorical controls, suggestthattheevaluation
of a long-term test is not a routine statistical exercise,
but is instead a multidisciplinary process requiring the
interaction oftoxicologist, pathologist, and statistician.
The utilization of long-term animal studies for quanti-
tative human risk assessment has accentuated and fo-
cussed attention on the real scientific uncertainties in-
volves in high-to-low dose and animal-to-human cancer
risk extrapolations. Nonetheless such animal studies,
with all their limitations, remain the best way of pre-
dicting effects in humans when epidemiological data are
unavailable.
Current Views on Epidemiological
Methods*
Introduction
Epidemiology is generally defined as the study ofthe
distribution and determinants ofdisease in human pop-
ulations, and thus it involves two major approaches
(547). Descriptive studies examine the "distribution" of
disease and are usually employed to generate etiologic
hypotheses, while analytical studies are used mainly to
test hypotheses and identify the "determinants" of dis-
ease. A primary objective ofepidemiology is to identify
and quantify relationships between exposure to envi-
ronmental agents and deleterious health effects. These
associations may lead to causal inferences (548), which
in turn provide the basis for instituting preventive
measures for various diseases.
Strengths andLimitations ofEpidemiology
STRENGTHS. In contrast to studies in other biolog-
ical systems, epidemiology directly evaluates the ex-
perience ofhuman populations and their response (risk
ofdisease) to various environmental exposures and host
factors. Thus, it is often possible to evaluate the con-
sequences of an environmental exposure in the precise
manner in which it occurs and will continue to occur in
human populations. This includes such important con-
siderations as dose, route ofexposure, and concomitant
*Although the full committee participated in the framing of this
section, primaryresponsibility was assumedby Dr. R. Adamson, with
Drs. J. P. Fraumeni and R. Hoover ofthe National Cancer Institute.
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exposures to other exogenous and endogenous factors.
Through epidemiological studies human cancerhas been
linked to a number oflifestyle and other environmental
hazards, including tobacco products and alcohol, ultra-
violet and ionizing radiation, certain occupational and
medicinal chemicals, dietary factors, and some infec-
tious agents (549-551).
Epidemiology has played a central role in detecting
carcinogenic exposures, and it has complemented stud-
ies in laboratory animals in clarifying the carcinogenic
potential of specific agents (552). Another strength of
the epidemiologic approach is its ability to provide in-
sights into the mechanisms of human carcinogenesis.
Thus, epidemiological observations have complemented
experimental evidence that carcinogenesis is a multis-
tage process, and that many cancers may result from
the cumulative effect ofenvironmental and host factors
that accelerate or retard the transition rates at various
stages of carcinogenesis (553).
LIMITATIONS. Although epidemiology is the only
means of assessing directly the carcinogenic risks of
environmental agents in humans, the method has sev-
eral limitations that are difficult to overcome (547,554).
One problem is that evidence of an environmental haz-
ard is usually obtained from persons with high or in-
termediate levels of exposure. Just as for studies in
laboratoryanimals, detectingcausalrelationships atlow
exposure levels is difficult, since the observed associa-
tions with disease are usually less pronounced and may
have alternative explanations, including those related
to chance, errors, biases or confounding variables. To
provide a valid basis for risk estimates, large numbers
of human subjects are often needed, especially if the
exposure is low or rare, or if the excess risk is small
compared tothatofthebaseline incidencerate. Another
obstacle to epidemiology is the long latency period be-
tween exposure and the development of cancer. This
complicates thedetection ofrelationships and, ofcourse,
makes it impossible to identify the carcinogenic risks to
humans of agents newly introduced into the environ-
ment. Another common problem in epidemiology is that
of exposure assessment. Often the specific exposure of
interest cannot be measured directly so that surrogate
measures must be used (e.g., occupation, place of res-
idence). Since exposure data are usually derived from
historical records generated for other purposes or from
the recollections of subjects, opportunities for either
random or biased misclassification of exposure are fre-
quently encountered. In addition, appropriate study
groups are often simply unavailable or inaccessible.
Furthermore, it may be difficult to implicate specific
carcinogens when the environmental hazards involve
complex exposures to a variety ofagents, the effects of
which are difficult to disentangle. Still anotherdifficulty
is the inability of epidemiological studies to adjust for
unknown risk factors, since control can be introduced
onlywhentheriskfactors arealreadyrecognized. Thus,
when a particular factor is related to exposure and dis-
ease outcome, it may be confounding and give the ap-
pearance of an association when in fact none exists, or
it may inflate or decrease the magnitude of an associ-
ation. In view of these difficulties, it is not surprising
that epidemiological data exist for only a small propor-
tion ofthe many chemicals that have been shown to be
carcinogenic in laboratory animals.
Determining Causality
Ininterpretingepidemiologicalfindings, one isguided
by the magnitude ofthe risk estimates, their statistical
significance (likelihood ofbeing due to chance), and the
rigor ofthe study design to avoid various kinds ofbias,
including those related to selection, confounding, clas-
sification, and measurement (548,555). A determination
of causality in epidemiology is bolstered by dose-re-
sponse relationships, the consistency and reproducibil-
ity of results, the strength and specificity of the asso-
ciation, its biological plausibility, and other
considerations. Thus inferences from epidemiology, as
from othermethods ofinquiry, arenotmadeinisolation,
but should take into account all relevant biological in-
formation. Although epidemiological and other obser-
vations can accumulate to the point that a causal hy-
pothesis is likely, it is not possible to ever prove
causality (in the strict sense, a hypothesis can only be
disproven). Nevertheless, a causal hypothesis can be
sufficiently probable, as in the case ofcigarette smoking
and lung cancer, to provide a reasonable and even com-
pelling basis for preventive and public health action.
Epidemiological Investigations
DESCRIPTIVE AND CORRELATIONAL STUD-
lES. Descriptive (or demographic) studies are con-
cerned with identifying the distribution or patterns of
disease in populations (547). It is basic tenet of epide-
miology that diseases, including cancer, do not occur
randomly, butfluctuate accordingtofactors such as age,
sex, race, time, and geographical location. The use of
rates as measures of disease frequency is fundamental
in describingpatterns ofcancer amongthese population
groups. Prevalence, incidence, and mortality rates of
cancer define the levels of risk prevailing in different
populations and permit comparisons between groups.
Descriptive surveys ofcanceroccurrence have been val-
uable in stimulating etiologic hypotheses and providing
direction for analytical studies, which are then neces-
sary to establish whether risks are associated with par-
ticular exposures (556).
Thus, important leads to etiology have come from
population-based cancer surveys, which have revealed
substantial international variations in cancer incidence,
shifts in risk among migrant populations, changes in
risk over time, and geographic peculiarities from map-
ping cancer mortality at the county level (550).
Descriptive studies may utilize the correlational (or
ecological) approach, in which the rate of disease in a
population is compared with the spatial ortemporal dis-
tribution of suspected risk factors (556). This type of
study may be particularly helpful in developing or re-
fining hypotheses about carcinogenic risks, but falls
short ofestablishing causal relationships. Correlational
studieshavetheadvantageofbeingmuchlessexpensive
and time-consuming than analytical studies, because
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they often utilize mass statistics previously collected for
another purpose (554). The primary weakness of such
studies, as with descriptive studies generally, is that
data are collected on populations, rather than individ-
uals. In other words, the rate of disease and the prev-
alence of exposures to variables of interest are known
for various population groups, but information on the
exposure status of persons who have the disease and
those who do not within each population is not known.
Thus, one cannot infer from the correlations ofthe pop-
ulation levels that the exposure ofconcern is associated
with the risk of developing disease within each popu-
lation (555). For example, in early surveys oflung can-
cer, the international variation in mortality rates and
temporal increases among males appeared consistent
with the reported patterns of cigarette smoking, but
these correlations by themselves may have been cir-
cumstantial rather than causal, since a variety ofother
exposures (e.g., occupationalhazards, airpollution) also
varied concomitantly with the patterns of lung cancer.
It took the analytical studies that pursued these leads
to establish the cause-and-effect relationships between
smokingandlungcancer. Correlational studies alsomay
provide supporting evidence in evaluating relationships
detected by analytical studies or laboratory data. This
is illustrated by the more recent temporal increases in
lung cancer among females, who have lagged about 20
years behind males in their adoption ofsmoking habits.
Another example is the temporal variation in endome-
trial cancer incidence, showing a rise and fall in rates
associated with the usage ofestrogenic drugs for men-
opausal symptoms (557). Because correlational studies
deal with aggregate exposures and disease occurrence
at the population level, they are also often seriously
limited bythe imprecise measurements ofexposure and
the many potentially confounding variables. However,
occasionally the correlational approach mayprovide evi-
dence that strongly suggests a causal relationship, as
with flatoxin, which has been linked to primary liver
cancer based on concomitant geographic variation with
the intake of contaminated foodstuffs.
ANALYTICAL STUDIES. Inordertotestetiologichy-
potheses and to identify and quantify carcinogenic risks
to man, it is necessary to conduct analytical epidemiol-
ogical studies (555,556). These studies are the principal
means fordeterminingthe humanhealth hazards ofspe-
cific environmental exposures and agents. In contrast
to descriptive surveys, data are obtained on disease
occurrence and putative risk factors for specific indi-
viduals, usingmainlythe case-control orcohortmethod.
Thus, by grouping exposed individuals and comparing
them to those unexposed, after controlling for all other
relevant variables, the risk of disease associated with
exposure can be estimated. While it is important not to
impose unnecessary constraints on epidemiological in-
vestigation, there are some methodological guidelines
toconsiderindesigning astudy. Inparticular, the study
groups should be sufficiently large and the time inter-
vals between initial exposure and tumor onset suffi-
cientlylongtoidentify the lowest excessriskconsidered
important to detect. Reliable and valid estimates ofex-
posure should be sought, with quantitative measure-
ments to permit dose-response evaluations.
Studies should be designed in a manner that mini-
mizes potential sources of bias and permits detection
and control of confounding variables. Because the pu-
tative exposure may act either at an early stage or at
a late stage of carcinogenesis (or both), it is possible to
provide insight into the mechanisms of action by ex-
amining risk in relation to several temporal aspects of
exposure. The studies should also strive to identify in-
teractions of a particular exposure with other risk fac-
tors that may contribute to the carcinogenic process.
Analytical epidemiological investigations are essen-
tial to achieve a better understanding ofthe causes and
meansofpreventingcancer. Thesestudiescoverabroad
range ofexposures with special relevance to public pol-
icy. Occupational studies havebeenatime-tested means
ofidentifying carcinogens, but they require further em-
phasis to assess industrial hazards suspected on the ba-
sis ofexperimental, clinical, and field observations. Ra-
diation studies also need increased emphasis to clarify
the effects of low-level exposure and the shape of the
dose-response curve. Drug studies have been useful
both for direct evidence of risk associated with taking
certain medications and also for insights into mecha-
nisms of human carcinogenesis. They require an ex-
panded effort to evaluate the late effects of estrogenic
compounds, immunosuppressive and cytotoxic agents,
and other medications suspected ofhaving carcinogenic
activity. Because ofincreasing clues to nutritional risk
factors, emphasis is needed to clarify the role ofdietary
components including fat, fiber, micronutrients, trace
elements, and food additives as well as cooking prac-
tices. The influence ofgeneral environmental pollutants
remains anepidemiological challenge and requires more
intensive evaluation through analytical studies, some of
which may integrate appropriate environmental and
body-burden measurements. Finally, multidisciplinary
projects combining epidemiological and experimental
approaches to chronic disease have recently gained im-
petus, and should be encouraged to evaluate the influ-
ence ofoncogenic viruses, dietaryandmetabolicfactors,
host susceptibility, general environmental pollution,
and other causative factors that may continue to elude
detection by traditional observational methods.
Case-Control Studies. Case-control studies identify
persons with a particular disease (cases) and a group of
similar persons without the disease (controls). Infor-
mation on past exposure to known or suspected risk
factors is then collected from interviews, question-
naires, medical records, occupational logs, or other
sources. The frequency ofa particular exposure among
the cases is compared with that in the control group,
after making appropriate adjustments for other relev-
ant differences between the two groups. Ifthe propor-
tion of cases with a certain exposure is significantly
greaterthanthatofthe controls, anassociation between
exposureanddiseasemaybeindicated. Thecase-control
approach is especially well suited to studyingrelatively
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rare conditions, such as most cancers, where the pu-
tative exposure is common in the general population
(e.g., menopausal estrogens and endometrial cancer),
or when the exposure is rare but accounts for a large
portion of a particular cancer (e.g., vinyl chloride and
liver angiosarcoma) (558).
Cohort Studies. These studies identify a group of
individuals with a particular exposure and a similar
group of unexposed persons and following both groups
over time to determine subsequent health outcomes.
The rates of disease in the exposed and unexposed
groups are then compared. Information on disease fre-
quency and otherfactors maybe identified from medical
records, occupational records, physical examinations,
questionnaires, tumor registries, or death certificates.
An association between exposure and disease may be
indicated if the rates of disease are greater in the ex-
posed group than in the unexposed group. These in-
vestigations may be based on current exposure and fu-
ture health outcomes (prospective cohort study), but
more commonly they utilize past exposure information
and disease occurrence (retrospective cohort study). In-
stead of an unexposed comparison group, general pop-
ulationmortalityorincidence rates(specificforage, sex,
race, and calendar time) are often used to determine
the expected number of cases of disease. This method
assumes that in the absence of specific exposure the
study group would have had the same probability of
developing the disease as the general population, but
differences in ethnic, socioeconomic and other variables
must be considered in evaluating the validity of this
assumption. The cohort approach is used mainly when
it is possible to evaluate heavy exposures in clearly
defined subgroups of the population. Thus it has been
especially helpfulinassessingthe carcinogenicriskfrom
occupational hazards or medical exposures such as ra-
diation and certain drugs.
The statistical measures of association most often
used in analytical studies are the odds ratio and the
relative risk. The odds ratio is usually associated with
the case-control study and represents the odds or prob-
ability of disease occurrence in the exposed compared
with unexposed individuals. An odds ratio of 1 indicates
no association between exposure and disease, assuming
that proper adjustments for confounding factors have
been made. The relative risk is a measure ofassociation
incohort studies andisdefined astheratio ofthe disease
rate in the exposed group to that in the unexposed
group. Forthis reason it is also known as the rate ratio,
and it permits a direct estimate of the risk of disease
associated with aparticularexposure. Whenthe disease
is rare, when incident cases are collected, and when
cases and controls are representative of the same pop-
ulations, the odds ratio is agood estimate ofthe relative
risk (558). The magnitude of the odds ratio or relative
risk is a measure of the strength of an association, al-
thoughtheyarebothsubjecttounknownorunmeasured
biases which may distort theirtrue value. Another term
oftenusedinepidemiology isthepopulation attributable
risk or etiologic fraction, which is the absolute amount
ofdisease contributed or caused by a specific exposure.
Both the case-control and cohort methods are char-
acterized as having certain strengths and weaknesses,
although they complement each other in the testing of
specific etiologic hypotheses. Case-control studies pro-
vide a more efficient means of studying rare disease,
with fewer individuals needed for study as compared
with the cohort approach; a shorter time period for
study completion and generally lower costs are com-
pared with the cohort method; an opportunity to eval-
uate simultaneously several causal hypotheses as well
as interactions (the extent and manner in which two or
more risk factors modify the strength of one another);
and a capacity to evaluate the effects of common ex-
posures as well as those rare exposures which may ac-
count for a large proportion of the cases. On the other
hand, the case-control approach has some problems in
directly estimating the risk associated with a particular
exposure, except in special circumstances noted above;
in reducing certain biases (e.g., selection, historical re-
call) that affect the comparability ofcases and controls;
and in providing detailed and precise information on
exposures occurring in the past (557). Such investiga-
tions also, by definition, can only evaluate one disease
or outcome at a time. The advantages ofcohort studies
are their capacity to estimate directly the risks attrib-
uted to a particular exposure, since incidence or mor-
tality from disease is actually beingmeasured; to reduce
subjective biases by obtaining information before the
disease develops; to determine associations between a
particular exposure and multiple health outcomes; and
to evaluate temporal relationships such as latency pe-
riod and duration ofeffect. However, cohort studies are
usually expensive and complex undertakings. They re-
quire large numbers ofexposedindividuals, particularly
when relatively rare events, such as most cancers, are
being investigated; long periods of follow-up to accom-
modate the latency period for chronic diseases, such as
cancer; and specialhandlingofproblems associated with
persons lost to follow-up and with biased estimates of
risk as from the "healthy worker effect" ofoccupational
studies (547).
Intervention Studies. Also referred to as experi-
mental studies (557), these represent a third strategy
ofanalytical epidemiology, which is especially useful in
confirming causal relationships suggested by case-con-
trol or cohort studies. This approach may be applied in
programs designed, for example, to reduce cigarette
smoking and alcohol intake, modify diet, control occu-
pational pollutants, orevaluate candidate preventatives
(e.g., vitaminAsupplements, hepatitis-B vaccine). Eth-
ical considerations are obviously critical when devel-
oping this approach, and after intervention the statis-
tical procedures resemble those employed for cohort
studies.
Biochemical Epidemiology
It seems likely that some limitations of cancer epi-
demiology may be overcome by incorporating labora-
tory methods in analytical investigations. This has been
a valuable routine practice in infectious disease epide-
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miology for the past century. This approach, sometimes
called biochemical or molecular epidemiology (559), has
only recently been developed in cancer epidemiology.
There is current enthusiasm for these kinds of inves-
tigations, since they merge the strengths of observa-
tional human studies with newly developed experimen-
tal probes to derive information that could not be
developed by epidemiology or laboratory study alone.
The laboratory aspect may make it possible to define
past exposures and subclinical or preclinical response
to initiators, promoters, and inhibitors of carcinogen-
esis, or to evaluate hose-environmental interactions.
There is special interest at present in using this tech-
nique to clarify carcinogenic risks associated with nu-
tritional influences or specific enviromental agents that
can be detected in tissues or body fluids. Opportunities
are also available to assess specific host factors that
influence susceptibility to carcinogenesis, including en-
docrine parameters, immunocompetence, and genetic
markers. Techniques are being refined to detect and
quantify particular carcinogens or their metabolites in
tissues or body fluids through chemical analyses, mu-
tagenesis assays orimmunological detectiontechniques.
It is already possible to measure the interaction ofspe-
cific agents with cellular target molecules, for example,
through adduct formation with proteins and nucleic
acids, excretion levels of excised adducts, or markers
ofaltered gene expression (559). The task ofidentifying
the effects oflifestyle and other environmental and host
factors is obviously formidable. Biochemical epidemiol-
ogy represents an innovative approach that may help
to elucidate further the causes ofcancer and the actual
mechanisms of carcinogenesis.
Implications ofNegative Studies
Epidemiological observations often provide regula-
tory agencies with health information which is helpful
in establishing sound, defensible rules governing work-
place exposures as well as exposure to general envi-
ronmental contaminants. The clinical and laboratory ob-
servations and subsequent epidemiological confirmation
linkinghepatic angiosarcoma and exposure tovinylchlo-
ride led directly to safeguarding of workers by regu-
latory limitation of permissible exposure levels. Al-
though, as in other areas of science, epidemiological
studies can never "prove" the absence ofan association,
sufficiently large and well controlled studies that fail to
detect a hazard can also be useful. Specifically, for the
types ofpopulations studied, forthe doses and duration
ofexposure to the putative agent, and for the assessed
time following exposure, likely upper and lower bounds
on the estimates of risk can be made, as well as the
statistical likelihood of the study to identify an effect.
As an example, the results ofalarge collaborative study
of bladder cancer and artificial sweetners were inter-
preted as indicating that saccharin use was not a sig-
nificant public health problem (560).
The likelihood of a study to identify an effect, if one
isreally present, isreferred to asthe statistical "power"
of the study. Its estimation involves consideration of
the size of the study group, the number of subjects
exposed, and the level ofexcess riskwhichis considered
important not to miss. With this information, the power
ofcase-control and cohort studies can be calculated and
thus some index of confidence can be attached to the
observation of no association. The statistical power of
"negative" investigations should be routinely consid-
ered when such studies are reviewed.
Regulatory agencies are often in the position ofmak-
ing decisions, not simply on the effect of an exposure
on the "average" exposed population, but on the effects
among particularly susceptible subgroups of this pop-
ulation (e.g., the concern over the acute effects of air
pollution on infants, the very old, and the infirm). The
risk of malignancy following exposure to a carcinogen
is rarely uniform across all subpopulations but is rou-
tinely modified by genetic constitution, demographic
characteristics (e.g., age, race, sex), and exposures to
other substances. Such risk modifiers can act either to
enhance risk, such as the capacity ofcigarette smoking
to multiply the risk of lung cancer associated with as-
bestos exposure, or to reduce risk, such as the recently
emerging evidence that certain dietary factors may in-
hibit the carcinogenic process. Epidemiological data are
particularly-and often uniquely-relevant to these is-
sues. Because ofthis, analyses ofrisk among subgroups
of an exposed population are particularly germane to
regulatory agencies. At the same time, these types of
analyses are challenging to interpret, since variation
between groups can easily occur due to chance or the
differential operation of some type of bias.
Because ofthe central importance ofepidemiology in
cancer risk assessment, it is important to develop and
strengthen programs ofepidemiological research and to
ensure the conduct of studies to look for and measure
(if detected) health effects whenever relevant human
exposure has occurred. Collaborative studies among
Federal agencies and other groups are needed to eval-
uate urgent issues involving scientific, regulatory or
public policy concerns, as well as to stimulate the epi-
demiological application oftechnical and data resources
that are used by the government and other institutions
for different purposes. Because ofthe international pe-
culiarities in cancer occurrence, collaborative studies
with investigators in othercountries should also receive
greater emphasis to pursue a wide variety of etiologic
leads. These national and international collaborative
studies can occasionally profitably include intelligent
combined analysis of data already obtained from exist-
ing studies. In addition, further statistical investigation
is needed to develop and test multicause and multistage
models ofcarcinogenesis and to clarify the many issues
involved in extrapolating results from experimental
testing to the human experience.
Summary
Epidemiological investigations comprise one of the
majorstrategies increatingthescientificbasenecessary
for regulatory decisionmaking. Descriptive epidemiol-
ogical studies, including ecological or correlational ap-
proaches, are useful in generating and refining hy-
potheses about potential cancer risk factors. Well
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designed, well conducted, and well evaluated analytical
epidemiological studies ofeither the case-control or co-
hort variety can test such hypotheses and provide the
basis for causal inferences that are especially useful for
public health decisions. The strengths of these studies
lie in their capacity to assess directly the carcinogenic
risks ofenvironmental agents in humans (often withthe
dose levels and manners of exposure that are most rel-
evant) and in their ability to provide insights into mech-
anisms of human carcinogenesis that can assist in ex-
trapolation of risk estimates to dose levels or similar
agents not yet studied. The lack ofevidence ofa hazard
from an epidemiological investigation can also be useful
in that, within the scope ofthe study, a likely range can
be determined for the estimates of risk, as well as an
estimation ofthe statistical power ofthe study to have
detected an effect, ifone were really present. However,
the epidemiological method is often hampered by the
long latent period that exists between exposure to a
carcinogenic agent and the development of cancer, by
the inability to control for the confounding influences of
unknown risk factors, by problems in assessing specific
agents when the human exposures are to mixtures, by
the frequent absence of appropriate groups for study,
and by a variety ofdifficulties associated with accurate
and unbiased historical exposure assessment or disease
ascertainment. In addition, the epidemiological method
shares in the difficulties encountered by experimental
studies in the direct detection of relatively low-level
risks. In general, the strengths and weaknesses of the
epidemiologicalmethod formausefulcomplement tothe
strengths and weaknesses of laboratory approaches to
carcinogenesis. This, coupled with the direct assess-
ments of risks and the results of interventions allowed
by epidemiology, makes a strong argument for the con-
duct of epidemiological studies and inclusion of their
results in regulatory decision-making, whenever rel-
evant exposure has occurred in human populations.
Chemical Exposure Assessment*
Introduction
For the purpose of this document, a chemical expo-
sure assessment is that process which seeks to define
the quantity of a chemical which comes into contact, or
may come into contact, with human populations.
This information then can be coupled with toxicity
data to allow estimates ofthe potential risk from a car-
cinogen. Exposure assessments may also be used to
identify and predict the effects of prospective control
options or to measure the effectiveness ofintervention
activities designed to limit exposure. An assessment
may address sources ofhuman exposure, the intensity,
routes and conditions of exposure, the frequency and
duration of exposure, and the segments of population
exposed. Incertainsimple situations an assessmentmay
*Although the full committee participated in the framing of this
section, primary responsibility was assumed by Dr. P. White, Mr. C.
Church, and Dr. P. Preuss.
only need to consider well defined individual exposures
that can be measured directly. In more complicated cir-
cumstances, broad systematic surveys and extensive
mathematical computations may prove necessary (561-
563). Exposure assessment is often the most resource-
demanding portion of the evaluations of chemical risks
performed by the various Federal agencies.
The great diversity ofdifferent sources and routes of
chemical exposure complicates a review of this area.
"Many authorities agree that the weakest link in our
understanding of the environmental health studies is
ourknowledge ofhumanexposure" (564). Inthe Federal
Government, the source ofa specific chemical exposure
has served as a guiding principle in defining the re-
sponsibilities ofdifferent regulatory agencies. Separate
responsibilities exist for exposure to chemicals through
the ambient environment (air, water, and waste sites),
food, drugs, consumer products, and the workplace en-
vironment. In each area an array of specialized esti-
mating techniques, data sources, and expertise have
been developed. The hundreds ofthousands ofpossible
combinations of factors which might be included in a
specific exposure assessment make it extremely un-
likely that any two exposure assessments of the same
chemical will be identical. Each Federal agency tends
to focus on those aspects ofexposure which are relevant
to the laws which it administers (565-585). This section
addresses some ofthe common considerations in meth-
odology, as well as the broad issues and difficulties that
are relevant to exposure assessments. Three append-
ices provide more detail on aspects of exposure assess-
ments dealing with food, consumer products, and po-
tential carcinogens in the environment.
Despite the overall grouping according to source of
exposure, it is important to recognize that the path that
a chemical follows from its source to the exposed target
can be quite complex and may involve a number of dif-
ferent media: for example: (a) chemicals released into
one medium (e.g., the air) may later transfer to other
media (e.g., soil or water); (b) low ambient levels of a
compound may be magnified through bioaccumulation
of the compound through the food chain; (c) chemicals
may be degraded and new compounds formed during
environmental transport and disposition; (d) a chemical
used in an article may be released into the environment
years laterwhenthe article is disposed ofaswaste; and,
(e) workers may carry a chemical home on their work
clothing leading to a continuing exposure of their fam-
ilies.
Methodology ofExposure Assessment
There is a diversity of procedures for estimating ex-
posure (586). Although exposure estimating techniques
are becoming more sophisticated at this time, there is
no universally accepted minimum set of specifications
for the reliable estimation of exposure (587). Exposure
assessment is rapidly developing as a technical spe-
cialty, and evenrecentmajorreports onriskassessment
only mention exposure briefly (1,588-591). There are,
however, a number ofgeneral approaches discussed be-
low which may be applicable to the conduct of most
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exposure assessments.
As a useful simplification, exposure assessment stud-
ies can be divided between those that rely more heavily
on direct measurement of chemical exposure and those
where exposure is predicted, or "modeled."
MONITORING STUDIES. The direct monitoring ap-
proach is exemplified by the development of practical
personal monitors which measure directly concentra-
tions of chemicals in the air which individuals breathe
(592,593). An exposure assessment can be based on the
range of personal exposure data generated by these
monitors when used with an appropriate study group.
However, it should be noted that the detection limits
attained by personal monitors may pose limits in some
studies and that most personal monitoring techniques
currently provide information on average exposure but
not on the time course or peak levels of exposure.
Monitoringofpollutants inthe airand waterhasprob-
ably generated the greatest quantity of data among all
exposure study approaches. Carbon monoxide exposure
has been examined extensively using personal and pop-
ulation monitoring (594-601). Air pollution in the city
of St. Louis was studied for several years (602,603),
producing over one million data points per day during
much of the program. The plume from a power plant
(604) was studied intensively to define the transport and
chemical transformation of the emissions from a single
point source. Other techniques have been used to mon-
itor emissions from entire cities to refine our under-
standing ofthe atmospheric transport ofchemicals over
large geographic distances (605). Significant monitoring
studies have also been conducted for a wide range or
organic andinorganic compounds inmarine, freshwater,
and surface environments (606-619). Extensive studies
have been conducted to determine the levels of bioac-
cumulated pesticides and other chlorinated compounds
in edible fish and shellfish.
In the workplace, monitoring is the principle meth-
odology for determining the levels of exposure to spe-
cific chemicals. The monitoring is usually site-specific,
and generally is not used to estimate the total exposure
of the entire workforce. The Occupational Safety and
Health Administration (OSHA) and the National Insti-
tute of Occupational Safety and Health (NIOSH) have
established data management systems for assimilating
and aggregating data from workplace measurements.
At times, these two agencies collaborate in the prepa-
ration and publication of occupational health surveys
that describe exposures in certain chemicals across
broad segments of an industry or occupation.
There is no monitoring system in place for determin-
ing the levels of exposure to substances in consumer
products. Exposure estimates are generally based on
ad hoc short-term surveys, laboratory studies and
mathematical modeling. For example, monitoring sys-
tems have provided for many years extensive infor-
mation, on the levels of pollutants in the ambient air
from the combustion of fossil fuel. No such parallel ex-
ists for these same pollutants generated from the com-
bustion of fuel indoors. However, several monitoring
studies ofindoorairpollutants have nowgenerated data
on exposures to combustion products from gas or ker-
osene appliances in the home (620-622).
Chemical contaminants in the U.S. food supply are
monitored through the FDA's Total Diet Studies, an
annual program which involves purchase and analysis
ofapproximately 200 foods in grocery stores across the
United States. Other monitoring systems used to mea-
sure exposure to chemicals in food are described in Ap-
pendix A.
Chemicals are also monitored in humans as a means
of exposure evaluation (623-635). In a national pro-
gram, humantissuehasbeen analyzed onaregularbasis
to monitor selected, persistent chemicals such as DDT
and PCBs (634,635). Tissue, secreta, or excreta, or any
combination ofthese, can be assessed and compared to
an appropriate reference (636). Such data can be used
not only as a measure of overall individual exposure,
but also as a measure ofthe effectiveness ofregulatory
actionswhenthemonitoringis conductedforsufficiently
long times to reveal trends. Chemicals or classes of
substances for which there is some evidence that bio-
logical monitoring may be useful for detecting evidence
of a substantial internal dose on an individual or group
basis include: inorganic and organometallic substances,
aliphatic, alicyclic, and aromatic hydrocarbons, aro-
matic amines, ketones, aldehydes, phenols, and pesti-
cides (636-639). In summary, monitoring can provide
estimates ofindividual exposure and data to define the
connection between the sources of a chemical and ex-
posure to humans. Monitoring activities can encompass
studies of the sources of chemicals, the ambient envi-
ronment, thehumanenvironment ofthehomeandwork-
place, the food and waterconsumed, as well asthe doses
absorbed and retained by the human body.
MODELING. Modeling is a second broad approach
utilized in exposure assessment. Here the term "mod-
eling" is used broadly to describe the construction of a
methodology through which diverse data on different
factors can be combined to predict levels of human ex-
posure in the absence of complete monitoring data.
Models are predictive tools used when direct measure-
ment of exposure would be prohibitively time-consum-
ing and expensive and when the relationship between
the sources of a chemical and the eventual exposure is
complex. A model may be constructed both to allow
interpolation between experimental observations andto
make predictions of exposure and circumstances that
have not yet been experimentally studied.
Models often begin as an effort to describe and gen-
eralize theoretically a phenomenon observed in the lab-
oratory or field. Monitoring data bases are used to con-
struct mathematical relationships among variables of
concern (e.g., meteorological parameters and the tem-
poral/spatial distribution of chemicals emitted from a
source). For example, the air monitoring data from the
St. Louis and the powerplantplume studies cited above
have been used to build and refine modeling tools for
predicting population exposure to contaminants in the
air.
249CHEMICAL CARCINOGENS
Giventhewidevariety ofpossiblesituationsrequiring
exposure assessment, it is not surprising that many
different models have been developed. A recent cata-
logue of the models available for use in regulatory de-
cision-making identified 156 models, most ofwhich can
beapplied toexposure assessments (640-642). Areview
ofthese models is beyond the scope ofthis section, but
descriptions ofvarious types ofmodels are informative
and can be found in the references (577,587,619,643-
670).
In general, models are most helpful when average,
or idealized estimates of exposure are satisfactory.
Even though the level of sophistication of a particular
model may be high, the predictions may still be crude,
because any model is a simplified description ofthe nat-
ural phenomenon it depicts. There is a need for more
research to validate most models, since the accuracy of
their predictions is often unknown or only roughly
known. In addition, the accuracy of the exposure esti-
mates made by models can be no betterthan the quality
ofthe input data used. The use ofmodels does not com-
pensate for poor data, and in certain instances, may
obscure the uncertainty inherent in the exposure pre-
dictions. The use of scientific judgment in interpreting
results is essential.
MICROCOSMS. The use of microcosms to study pol-
lutant behaviorprovides an approachthat combines fea-
tures of both monitoring and modeling studies. The
transport and transformation processes which occurbe-
tween the source ofa chemical and the eventual human
exposure can be difficult and expensive to study in na-
ture, and in the absence of data on these processes,
models cannot be constructed. Microcosms, which at-
tempt to recreate portions of the environment in the
laboratory, can provide an alternate means for defining
these processes. They have the added advantage that
many variables can be controlled. Ideally, a microcosm,
when properly validated, faithfully mimics the pro-
cesses occurringin nature. Byaddingachemical to such
a system, its subsequent partitioning among the com-
ponents of the environment, together with the associ-
ated chemical and biological conversions, can be studied
in a single integrated experiment.
Marine, freshwater, terrestrial, subsurface or aqui-
fer, and atmospheric microcosms have been studied
(643,671-689). For example, the laboratory microcosm
concept has received increasing attention recently in
studies which seek to predict residential exposure to
products ofcombustion or airpollutants (690,691). Lim-
ited validation ofpredicted, versus measured, levels of
products of combustion in a residence has shown such
predictions to be useful in assessing exposure (688,689).
HUMAN FACTORS. In exposure studies using mon-
itoring, modeling, or a combination of approaches, the
actual behavior of the human population under study
must be taken into consideration. Some examples illus-
trate this: (1) the amount of time that an individual
spends indoors compared with outdoors will affect the
risks associated with either outdoor or indoor air pol-
lution; (2) failure of workers to wear protective equip-
ment can increase their occupational exposure to haz-
ardous compounds; and (3) consumerexposuretovapors
during the use of various products will decrease pro-
portionally with increases in the amount of ventilation
provided in the home.
Human behavior is often evaluated by using infor-
mation-gathering techniques somewhat similar to opin-
ion polls or marketing studies. In such a study, a ran-
domly selected population is asked a series ofquestions
that define aspects of their behavior that can affect
chemical exposure. On an occupational setting, "time-
motion" studies ofthe periods ofemployee contact with
varying work environments can contribute to an ex-
posure assessment.
The exposure to direct and indirect food additives is
monitored by the FDA by using a number of complex
studies ofhuman eatinghabits. Surveys offood additive
use have been undertaken since 1973 with the help of
the National Academy of Sciences, as have studies of
the migration of chemicals from packaging materials
into foods (575,579,583,585). Other related work has
determined the frequency of consumption of individual
foods and individual food serving sizes, with the data
compiled in such a way as to be compatible with the
population data found in the U.S. Census (582). These
surveys and studies have produced a complex array of
information which then is converted by the FDA into
estimates of population exposure to direct and indirect
additives in humanfood (576,584,694). Some ofthe same
data are used by EPA in setting tolerances forpesticide
residues in food crops (574).
STRUCTURE-ACTIVITY RELATIONSHIPS. Data now
exist on the chemical, physical, and toxicological char-
acteristics of a large number of chemicals, as does in-
formation on their transport, transformation, and en-
vironmental fate. Thus, some correlations now can be
made between the structures of certain chemicals and
the properties they exhibit, a process called structure-
activity analysis. Underfavorable conditions, these cor-
relations allow rough predictions to be made ofthe char-
acteristics of chemicals which have not been studied,
reducing the amount of testing necessary to make at
least an initial judgment of the risks which they may
pose (658,695-702). Structure-activity relationships
can be used to delineate the general properties of in-
terest, butthey are not generally asubstitute for actual
measurements.
The use ofstructure-activity relationships may allow
preliminary exposure estimates to be made even when
there is a scarcity ofdata on a specific chemical. Struc-
ture-activity analysis is a relatively new field, and the
available tools are still crude. The user must exercise
scientific judgment in interpreting the results, because
substantial work remains to be done in refining and
validating these techniques.
INTEGRATED EXPOSURE ASSESSMENTS. Most as-
sessmentsperformed insupportofrule-makingconsider
only a single source or route of exposure. Such assess-
ments are appropriate in the case when only one source
or route of exposure is significant. However, certain
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recent exposure assessments onchemicals withmultiple
routes of exposure have considered all routes simulta-
neously (703). In a pilot effort, an exposure assessment
has been prepared which considers six related halogen-
ated solvents and all routes ofexposure simultaneously
(704,705). This assessment, in combination with hazard
data, attempts to provide a risk assessment data base
for all six solvents and all routes of exposure. Using
this approach, all regulatory options and combinations
of options may be considered in seeking the most ef-
fective means ofreducing risk.
The preparation of such integrated exposure assess-
ments for widely used chemicals is very difficult and
resourceintensive andrequires thecontributions ofspe-
cialists in many disciplines. The difficulty and expense
of integrated assessments may limit the broad appli-
cation of these valuable tools.
Monitoring ofthe levels ofchemical contamination in
human tissue, blood and urine, as discussed above, can
provide a second method of assessing the total human
exposure to certain chemicals depending on metabolism
and persistence in the body.
DATA BASES AND DATA MANAGEMENT. Research
by the Federal regulatory agencies on human exposure
has produced a large body ofdata which can be used in
performing assessments. One recent index identified
319 data bases, many of which could be of value in ex-
posure assessment (641). Forexample, monitoring data
are reported regularly for National Pollution Discharge
Elimination System (NPDES) permits, issued under
the Clean Water Act, thereby affording information on
133,000 sources of chemicals found in surface waters
(706). Monitoring data on air emissions from many
sources and ambient air quality data from over 4,000
active air monitoring sites across the country are in-
cluded in the Aerometric and Emissions Reporting Sys-
tem (AEROS) (707). In addition, many major research
efforts (e.g., the St. Louis air pollution study) generate
large data bases useful in exposure assessment
(602,603).
Many data bases which do not deal directly with
chemicals are also useful. The data ofthe U.S. Census
provide information helpful to determine populations at
risk. The National Climatic Center maintains detailed
weather records, while the U.S. Geological Survey has
a massive data base on water on a regional and state
basis (708,709). The EPA has been constructing a com-
prehensive data base on organic chemical manufactur-
ing.
As the number ofdata bases and models available for
exposure assessment grows, it will become increasingly
difficult to access and manipulate the large quantities
ofinformationandbroad assortment oftechniques with-
out computer systems. Preliminary exposure assess-
ments, reviews of the relative effectiveness of regula-
tory control options, and many other assessment-
related tasks, which in the past required substantial
effort, can be accomplished rapidly with limited accu-
racy at a computer terminal, calling upon data bases
and models as needed (710-714).
Broad Issues Affecting Exposure Assessments
EXTRAPOLATION AND NONREPRESENTATIVE SYS-
TEMS. Exposure assessments, in a manner often anal-
ogous to risk assessments, may require extrapolation
from a limited number of sites, to a large population.
Such extrapolations carry with them uncertainties that
need to be reflected in the final assessment.
In some cases, the exposure measured may not cor-
relate well with the actual experience ofthe larger pop-
ulations. In such cases, the nonrepresentative nature
of the exposure measurement may give rise to an as-
sessment that is inaccurate. Such errors can arise es-
pecially when microcosmmeasurements and models are
used instead of extensive monitoring networks.
QUALITY ASSURANCE. Measurements of chemicals
at the trace levels of concern, as needed for many ex-
posure assessments, are difficult exercises in analytical
chemistryandcanleadtoerrorsanduncertaintieswhich
should be considered in preparing an assessment. Until
recently, extensive quality assurance information was
not a routine part of most research, testing, and mon-
itoringprograms. Toimprovethis situation, some agen-
cies have instituted quality assurance procedures which
require that records be maintained on the accuracy and
reliability of every chemical measurement associated
with research, monitoring, and compliance enforcement
(715,716). Two examples of such state-of-the-science
projects are the EPA-Chemical Manufacturers Asso-
ciationJoint Study on watertreatment systems and the
Love Canal Monitoring Study (717,718).
The quality assurance portion ofthe Love Canal Mon-
itoring Study provided information on the accuracy and
reliability ofthe analyses ofchemicals at trace levels in
air, water, and soil. The results demonstrated the lim-
itations inherent in the measurement of complex mix-
tures in a variety ofmatrices. The overall results in the
Love Canal studies suggest that the most advanced an-
alytical techniques correctly identify trace levels of an
organic chemical in complex environmental mixtures
with approximately 70% certainty.
To date, the major efforts on quality assurance have
been devoted to chemicalanalyses ofenvironmental ma-
terials. As discussed, other data contribute to the ex-
posure assessment, e.g. information generated through
microcosmstudies, humanbehavior, ormodeling. There
is a need for further validation of such tools to assure
their accuracy and reliability in estimating exposure
(719-722).
HIGH RISK POPULATIONS. Subgroups of the popu-
lation may be particularly at risk from exposure to a
chemical. These groups may be exposed to unusually
high levels of a chemical or may be especially sensitive
to the toxic properties ofa compound. The existence of
subgroups ofeither type could lead to a compound pro-
ducing a substantial risk even though the average ex-
posed individual may experience little, if any, risk. A
thorough exposure assessment needs to consider the
possibility that high riskpopulations or situations exist.
Many, or most, current exposure assessments do not
have enough data to allow an evaluation of the effects
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of a chemical on high risk populations.
REFINEMENT OF ASSESSMENTS. At the initial con-
sideration of a chemical, only crude data relating to
exposure will generally exist. Such crude data may al-
low arough estimate oflikely exposure; thispreliminary
estimate may be useful to decision makers in assigning
priorities and resources. It is also possible that crude
datamayallow anestimate ofthemaximumorminimum
exposure that may be expected to occur. Such an analy-
sis may effectively rule out, or indicate the presence of,
a significant risk. Specifically, a "worst case" estimate,
where all assumptions are chosen so as not to under-
estimate the possible exposure, may indicate that little
risk exists if significant exposures are not predicted.
As more resources are devoted to an exposure as-
sessment and more studies conducted, a refined as-
sessment is generated. Often there will be several
stages of refinement of an assessment, and the degree
of refinement and accuracy finally required will be re-
latedtothe certaintyneeded to enable riskmanagement
decisions.
RELATIONSHIPS TO BIOLOGICAL DOSE. The data
generated in an exposure estimate must ultimately be
coupled with biological data on the hazards presented
by a chemical in order to determine the actual risk pre-
sented by the exposure. In order to achieve this cou-
pling, the estimated human dose must be related to the
doses received in the human or experimental studies
that generated the information on the biological hazard.
The type ofexposure data needed can vary for different
risk estimation procedures. For example, for risk es-
timation using a dose-response relationship that is not
linear in the range of human exposure, information on
the frequency distribution of different exposure levels
in the population is needed, instead of simply an esti-
mate of the average exposure.
This comparison can be complicated by differences in
the frequency, duration, intensity, and route by which
the two doses were received. This is particularly rel-
evant since human exposures to a single chemical may
follow many different patterns ranging from a high sin-
gle exposure to a low level lifetime exposure. Humans
will also often be exposedthrough severalroutes: inges-
tion, inhalation and dermal. Because ofthe diversity of
human exposures, frequently there will not be toxico-
logical data available which were obtained under the
same exposure conditions. In those cases, careful re-
view and expert judgment enter into the application of
the exposure data.
Recently, there has been considerable interest in the
possibility ofrelating human chemical exposures to haz-
ard studies by utilizing biological indices of the effects
ofthe different exposures. Specifically, it has been sug-
gested that the quantity of a carcinogen reaching and
interacting with DNA be directly compared in exposure
and hazard studies. This topic receives fuller discussion
in other sections of this document. It should be noted
that at the present time, data to allow such comparisons
are generally not available, and considerable research
still is needed in order to assess the practical applica-
bility of this approach.
OVERALL LIMITATIONS OF EXPOSURE ASSESS-
MENTS. Many exposure assessments are unable to dis-
tinguish all of the parameters that are important in
determining possible health effects. These include var-
iations of exposure with time, including, peak versus
average exposures, and annual versus daily exposures.
In addition, exposure assessments rarely, if ever, are
able to estimate the dose that actually reaches a bio-
logical site where an effect may occur. As a conse-
quence, some information is often available about the
magnitude, frequency, or duration of exposure, but
rarely is information available that is adequate to ac-
curately determine allthree. In addition, the population
whose exposure is being assessed will often be exposed
by more than one route from a number of different
sources. As aresult, estimates addressing single routes
orsources ofexposure are ofteninadequate torepresent
what is actually occurring. Environmental monitoring
data, models, and microcosms may sometimes be in-
adequate, and oflimited value, and may lead to a false
sense of security if broadly applied without considera-
tion and enumeration of their limitations.
Finally, there are a number offactors that are a part
of both a hazard assessment and an exposure assess-
ment which usually are not completely determined.
These factors includethe age distribution oftheexposed
population, special subpopulations that may be partic-
ularly sensitive to low doses, cumulative exposures, la-
tency, host factors, or populations which may be ex-
posed to particularly high concentrations. As a result,
there are generally unknown data and uncertainties as-
sociated with exposure assessments at many points. It
is important that the assessor describe the data that
are missing, the associated uncertainties at each step
ofthe assessment, and the assumptions made when fill-
ing the gaps.
At present, therefore, there is a great deal that can
be improved in carrying out exposure assessments. In-
formed decision-making often requires consideration of
a complex array of information, rather than a single
numerical estimate ofexposure. To the extent possible,
the ultimate use of the data should be defined and the
exposure assessment tailored accordingly. The limits of
the assessment, both conceptual and methodological,
need to be described, and all the uncertainties enum-
erated. Quality assurance programs and efforts should
be included as well as a description of efforts made to
validate laboratory studies and mathematical modeling;
in general, careful scientific review ofall elements ofan
exposure assessment should be stressed.
Summary
Exposure assessment is a co-equal component, along
with hazard assessment, in the evaluation of human
risk. The assessment ofexposure to chemicals by direct
routes (e.g., breathing emissions from an industrial
stack) and indirect routes (e.g., pollutants accumulating
through the food chain) depends upon analytical chem-
ical monitoring data, results ofmodeling estimates, and
assumptions needed to fill in data gaps. The field of
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exposure assessment is rapidly developing and only re-
cently have attempts been made to develop systematic
approaches totheproblem. Although currenteffortsare
often associated with considerable uncertainty, the in-
creasing sophistication being brought to bear on the
issue holds the promise of greater confidence in these
estimates in the future.
Methodologies can be broken up into two broad cat-
egories: monitoring studies, which depend more on the
measurement ofexposure, and mathematical modeling,
which use analysis to define the exposure. Microcosms,
as samples of the environment, provide data for both
approaches. Human factors, however, are important
and must be considered.
An important part of the assessment process is the
marshaling of the appropriate data bases, and some of
the data bases used by three regulatory agencies are
listed in appendices.
Broad issues affecting assessments include the ques-
tion of extrapolation from representative systems to
large populations, quality assurance, the question of
high-risk populations; and the approach ofcoupling ex-
posure data to actual biological dose to improvement
assessments, are emphasized, with a discussion of the
limitations of assessment as it is being done today.
Utilizing Scientific Data in Assessing
Human Cancer Risk Associated with
Chemical Exposure*
Introduction
Assessment of human cancer risk associated with
some specified chemical exposure is a complicated sci-
entific endeavor that requires careful review ofall per-
tinent information by appropriately trained individuals.
This process relies heavily on information derived from
epidemiological, clinical, and long-term animal studies.
Short-term test results and information on structure-
activity relationships, comparative metabolism, phar-
macokinetics and mechanisms ofaction also contribute,
in varying degrees, to the assessment.
While there is general agreement within the scientific
community about the steps involved in the risk assess-
ment process, a number of specific issues related to
these various steps are still unresolved; e.g., the meth-
odology for combining positive and negative data when
evaluating carcinogenic potential and the selection of a
dose-response model for making low-dose risk projec-
tions. The execution of any given risk assessment may
also be hampered by the existence ofcritical gaps in the
data underlying the assessment. Because these issues
and data gaps can be pivotal in the process, it may be
necessary to make judgments about these unresolved
issues and assumptions to adjust for deficiencies in the
underlying data base that will permit risk assessments
to be completed. These judgments and assumptions
*Although the full committee participated in the framing of this
section, primary responsibility was assumed by Drs. M. Hogan and
D. Hoel.
should be plausible and, to the extent possible, be based
on the specific information on hand. However, the va-
lidity ofthese judgments and assumptions often cannot
be conclusively established, so the risk assessment pro-
cess should not be viewed as strictly "scientific" in the
usual sense of the word. Instead, risk assessment in-
volves a complex blend of current scientific data, rea-
sonable assumptions and scientific judgments that per-
mit decisions to be made in the absence of complete
information.
With the passage of time the scientific data base
grows, information gaps are filled, and perceptions
change. Thisprocessofevolutionandmaturationresults
in a need for periodic reformulations and restatements
of the appropriate guidelines for risk assessment.
This section describes the basic framework for car-
cinogenic risk assessment and attempts to reflect what
general agreement currently exists within the scientific
community. It is intended to provide a bridge between
the scientific data base on carcinogenicity developed in
previous chapters and the various Federal regulatory
agencies that are charged with the responsibility ofpro-
tecting the general public from exposures to carcino-
genic agents.
Steps in the Assessment Process
There are four steps or components that are typically
involved in carcinogenic risk assessment. The first,
which is often referred to as hazard identification, en-
tails a qualitative evaluation of both the data bearing
on an agent's ability to produce carcinogenic effects and
therelevance ofthisinformation tohumans. The second,
exposure assessment, is concerned with the number of
individuals who are likely to be exposed and with the
types, magnitudes, and durations of their anticipated
exposures. The third component, hazard or dose-re-
sponse assessment, uses the information on carcinogen-
icity from the hazard identification phase together with
mathematical modelingtechniques to estimate the mag-
nitude or an upper bound on the magnitude of the car-
cinogenic effect at any given dose level. Finally, one
may combine the information from the first three com-
ponents or steps to characterize the carcinogenic risk
associated with the expected human exposure to the
compound of interest.
HAZARD IDENTIFICATION. Due to the lack of com-
plete information, there may be some uncertainty in-
volved in determining whether or not an agent poses a
carcinogenic hazard to humaas. While information on
human exposures and effects is particularly valuable,
toooften suchdataeitherdo notexist orareinadequate,
and one must rely primarily on information from long-
term animal bioassays in assessing the potential for car-
cinogenic response in humans. In reviewing data, each
relevant study must be evaluated as to the limits of
inference implied by the experimental design, the re-
sults, and the conclusions. Although strict criteria for
evaluating carcinogenicity data have not been devel-
oped forallcircumstances, there seems tobereasonably
good agreement among scientific groups as to the gen-
eral elements to be included as a part of qualitative
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carcinogenic assessments (309,483,489,531,588,723,
724).
Epidemiological studies can, under certain circum-
stances, provide direct measures ofcarcinogenic effects
in humans. For example, some epidemiological inves-
tigations are able to associate cancer incidence or mor-
talitywith exposure tospecificchemicals, industrialpro-
cesses, or components of an individual's life style.
Analytical studies, i.e., case control and cohort studies,
are especially important indicators of possible human
carcinogenic risk, but case reports and descriptive stud-
ies may also be supportive. Consistent results in inde-
pendent studies, freedom from bias and confounding
factors, reliable exposure data, reasonable follow-up
time, dose-related responses and high levels of statis-
tical significance are among the factors leading to in-
creased confidence in a conclusion of carcinogenicity.
Even if an epidemiological investigation fails to dem-
onstrate an increased incidence of carcinogenicity
among the exposed study members, upper and lower
confidence limits on the risk measure used in the study
can indicate a range of probable risk that could be in-
curred by a similarly composed segment (i.e., in terms
of age, race, sex, etc.) of the general population.
Evidence from long-term animal bioassays consti-
tutes the second major class of information bearing on
the carcinogenicity of chemicals. The primary factors
that are considered in the evaluation ofcarcinogenicity
are higher tumor incidence and shorter latency in
treated groups relative to controls. Findings arae
strengthened bytheexistence ofpositive effectsinmore
than onetreated group orsex. Additional support comes
from positive results observed with different routes of
exposure, in replicated experiments, in different ani-
mals strains and species, and in multiple organs or tis-
sues. Attention is also given to the magnitude oftumor
increase in treated animals, the existence of dose-re-
lated trends, the degree and extent ofmalignancy at a
given site as a function ofdose and time, the evaluation
of concurrent nonneoplastic pathology in treated ani-
mals, and the finding of even a limited number of rare
tumors in the exposed group(s). In addition the simi-
larity, orlackofit, betweencontemporaryandhistorical
control tumor rates can affect the carcinogenicity eval-
uation.
Beyond these two majortypes ofevidence, additional
information bearing on the qualitative identification of
carcinogenic potential may be gained from short-term
test results, including testing by genetic toxicity, ma-
cromolecular bindingand invitrotransformation; short-
term in vivo tests such as skin painting experiments;
comparative metabolism studies among species; review
of known physiological, pharmacological, biochemical
and toxicological properties ofthe chemical; evaluations
ofcontaminants, degradation products and metabolites
of the chemical under study; and consideration of the
carcinogenic potential of structurally related com-
pounds. At the present time these latter categories of
information will often play a supporting orconfirmatory
role in the process of human cancer hazard identifica-
tion. However, when specific information on compara-
tive metabolic and kinetic data, exposure route-depen-
dent responses, etc. is available, and its relevance
demonstrated, it may be useful in determining the like-
lihood of possible human cancer hazard.
The relevant data discussed above are reviewed and
assessed to determine if the chemical is likely to be
carcinogenic in humans. The greater the consistency of
the information, the greater the confidence that the
agent poses or does not pose a carcinogenic hazard for
humans.
EXPOSURE ASSESSMENT. Without exposure, there
obviously is no riskto the human population, regardless
of the potency of the carcinogen under consideration.
Thus, exposure evaluation is a critical component ofthe
risk assessment process. One of the most frequently
encounteredproblemswhenattemptingtouseepidemio-
logical data in cancer risk assessment is the lack of ap-
propriate historical exposure information.
In an exposure analysis, a group or groups of indi-
vidualsareidentified and described withrespecttotheir
population size and composition, and the route (e.g.,
inhalation, dermal, ingestion), magnitude, frequency,
and duration of their exposures. In addition, consider-
ationmustbegiventobothdirectexposures(e.g., drugs
or occupation) and indirect exposures (e.g., food or air)
thatresults from achemical's transport through various
environmental compartments before impacting on hu-
mans.
For a given exposure source the concentration or
amount of the chemical in that medium is determined
by measurement, estimated by modeling, calculated
fromphysical-chemicalpropertiesandotherinformation
onthe agent, orprojected from data on surrogate chem-
icals. Common values might include ambient airborne
concentrations given as parts of chemical per million
parts of air or the the number of milligrams of a drug
perdose. Measurements, estimates orassumptionsthen
need to be made concerning the exposure ofhumans to
the chemical through a given medium; e.g., the fre-
quency of consumption of a specific food containing a
pesticide residue or the frequency, pattern, duration
and conditions of use of a consumer product containing
a cleaning solvent. Next, assimilation of the chemical
into the body is considered; again there is reliance on
whatever pharmacokinetic data or estimates are avail-
able. Values may be expressed in a number of ways
such as the percentage of dose absorbed from the gas-
trointestinal tract, the movement of so many micro-
grams of chemical across a given area of skin over a
certain time period, or the percent of the inhaled ma-
terial absorbed in the respiratory tract.
All the above information, i.e., population identifi-
cation and characterization, chemical concentration in a
given medium, the nature and pattern ofexposure and
finally the assimilation ofthe chemical into the body, is
assembled and analyzed. Information on multiple
sources ofexposure may then be combined into a single
measure of overall exposure.
In some instances, it may not be possible to identify
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or isolate the particular chemical or chemicals in a com-
plex mixture or manufacturing process that are likely
to pose a carcinogenic risk to humans, and so detailed
exposure quantitation becomes difficult. Furthermore,
tremendous variability in exposure exists among mem-
bers of a population. People change jobs or place of
residence, convert from well water to municipal water,
occasionally take prescription/non-prescription drugs,
etc. Each of these differences among persons contrib-
utes to the uncertainty associated with any exposure
value. To the extent possible, the degree ofuncertainty
in exposures should be discussed and estimated. Char-
acterization of uncertainty may involve calculation of a
"worst-case" exposure or upper bound on exposures,
consideration of a range of likely or possible exposure
values, or even the computation of confidence bounds
associated with a specific model-based exposure esti-
mate.
HAZARD OR DOSE-RESPONSE ASSESSMENT.
Hazard ordose-response assessment is a quantitative
exercise that attempts to describe the expected human
response to any given level of a carcinogenic exposure.
The response is typically characterized in terms of
either a specific estimate or an upper bound on the un-
derlying risk. This step in the risk assessment process
relies heavily on data from exposed humans and on ob-
servations of animals employed in long-term cancer
studies. Long-term animal screening studies have tra-
ditionally focused on the detection of carcinogenic po-
tential. As aresult, they are usually based on exposures
at or near the test animal's maximum tolerated dose
level. Since these doses are often orders of magnitude
higher than those encountered by humans, some form
ofmathematical low-dose extrapolation procedure is re-
quired to estimate the expected response at the expo-
sure levels typically of concern in the environment. In
addition, a species extrapolation orscaling factoris usu-
ally employed when estimating anticipated human can-
cer risk from experimental data. Low-dose extrapola-
tion may also be an important consideration for
epidemiologically-based assessments, since the avail-
able human data may often involve relatively high level
occupational exposures.
Low-Dose Extrapolation. Low-dose carcinogenic
risk estimation is based on mathematical modeling that
attempts to characterize explicitly the unknown, un-
derlying relationship between exposure and response
or to place an upper bound on the dose-response rela-
tionship.
Linear extrapolation procedures are often employed
forestimating the low-dose risk. In the absence ofback-
ground response a commonly used approach is to draw
a straight line from an upper (binomial) confidence limit
on the observed response rate at the study exposure
level to the origin. If background is present, the pro-
cedure can be modified by making specific assumptions
aboutthe nature ofbackgroundinordertotakeitseffect
into account (725,726). Two of the more appealing fea-
tures of this procedure are that it is easy to apply and
that it will generate an upper bound on the unknown,
underlying cancer risk in most instances. The most fre-
quent criticisms directed against it are that it may be
unduly conservative and that it fails to utilize all ofthe
study data ifseveral exposure levels are employed. Re-
cently, an interesting modification ofthe linear extrap-
olation procedure has been proposed by a number of
investigators (727,728). They suggested that some type
of mathematical dose-response model should be fit to
the experimental data, that the estimated response and
associated model-based confidence limit for a prese-
lected level ofexposure should be determined, and that
linear extrapolation should then be used to determine
anupperbound onriskforthelow-dose level ofinterest.
When low-dose extrapolation is based on an attempt
to characterize the underlying dose-response relation-
ship, one of three general classes of models (i.e., tol-
erance distribution models, mechanistic models, or
time-to-tumor models) is usually employed.
The tolerance distribution models assume that each
member of a population has a threshold or tolerance
level below which that individual will not respond to
the exposure in question. It is also presumed that the
variability among individual threshold levels can be de-
scribed in terms of a probability distribution. For this
class of models the probability that a particular indi-
vidual will exhibit a carcinogenic response when ex-
posed at dose level d is the same as the probability that
the individual's tolerance level is less than d. The fa-
miliar probit, logit, and Weibull dose-response models
can all be generated by adopting different probability
distributions to describe the population's tolerance var-
iability (729). The best known of the low-dose extrap-
olation techniques based on tolerance distribution
models is the Mantel-Bryan procedure (730,731), which
employs a probit model. Although the Mantel-Bryan
procedure was originally regarded as a conservative
approach to the estimation oflow-dose risk since it em-
ploys afixed, presumably conservative estimate ofslope
and extrapolates from an upper confidence limit on the
observed experimental response, subsequent research
(732) has shown that in the low-dose region the probit
model tends to produce relatively high "safe-dose" es-
timates when compared to other extrapolation proce-
dures. As a result of this characteristic and other crit-
icisms that have been raised agianst the Mantel-Bryan
procedure (732), its use in quantitative risk assessment
has markedly declined.
Theclass ofmechanistic models, i.e., the one-hit, mul-
tistage, and multi-hit models, derives its name from the
presumed mechanism ofcarcinogenesis upon which the
models in the class are based. Each of these models
reflects the assumption that a tumor originates from a
single cell thathas beendamaged by eitherthe chemical
or one of its metabolites.
The simplest ofthe mechanistic models is the one-hit
model (729) which assumes that damage to the target
cell sufficient to cause a tumor results from a single
"chemical hit." This model is essentially linear in the
low-dose region. Since it has only a single parameter
other than background, it will not always provide an
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adequate fit to the experimental observations.
The multistage model, developed by Armitage-Doll
(733), is perhaps the most frequently employed of all
low-dose extrapolation models currently in use. It re-
flects the observation that a developing tumor goes
through several different stages, which can be affected
by the carcinogen in question, before it is clinically de-
tectable. The multistage model will often be approxi-
mately linear in the low-dose region, and so its risk
estimates are sometimes regarded as being relatively
conservative. Furthermore, the procedures most com-
monly used to generate upper confidence bounds forthe
multistage model lead to estimates that are linear at
low doses (734).
The multihit model (729,735) assumes that the target
cell must absorb at least k chemical hits before the cell
achieves its carcinogenic potential. Some investigators
regard the generalized multihit model, where k can be
any nonnegative value, as being more flexible than the
multistage model; and its use in risk assessment has
been recommended (497). However, there are research
results (736) that indicate a number ofimportant, prac-
tical problems associated with its application, such as
the fact that model hyperlinearity may produce ex-
tremely conservative estimates of safe dose levels, or
that the multihit model can also indicate a "safe dose"
at levels higher than some doses that actually produced
deleterious effects.
The last class of models employed in low-dose ex-
trapolation is the time-to-tumor models. These models,
which attempt to describe the complex relationship be-
tween dose, tumor latency, and cancer risk, include the
lognormal distribution (725), the Weibull distribution
(737), and the Armitage-Doll (733) and the Hartley-
Sielken (738) models. While time-to-tumor models can
lead in many instances to a more complete characteri-
zation ofthe underlying carcinogenic process, the qual-
ity oftheavailable datamay notpermittheirapplication
or, at the very least, is often not sufficient to allow any
discrimination among such models using goodness-of-fit
criteria. Furthermore, a recent analysis (739) of a sim-
ulated data base containing information on a time-to-
tumor occurrence indicated that low-dose riskestimates
generated by a variety ofextrapolation procedures oc-
casionally differed from the actualriskbythree ormore
orders of magnitude even when this additional infor-
mation was included in the modeling process. It also
appeared that, on the whole, incorporation of time-to-
tumor data did not substantially increase the precision
of low-dose risk estimation relative to modeling based
only on quantal response information.
When data on the time of tumor occurrence or de-
tection are available, some investigators have proposed
that alternative measures or risk based on the concept
oftime-to-tumor, such as the "mean-free" dose or "late-
risk" dose (740), be used in the cancer assessment pro-
cess. However, a detailed evaluation ofthese measures
(741) indicated that they suffer from a number ofshort-
comings and are probably most meaningful when used
in combination with the more traditional measures, like
the lifetime probability of tumor.
As the preceding discussion has indicated, uncertain-
ties are involved in the use of any of the commonly
employed extrapolation models. Furthermore, good-
ness-of-fit to the experimental observations is not an
effective means of discriminating among models (493).
Thus, no single low-dose extrapolation procedure has
yet gained universal acceptance within the scientific
community.
Model selection is further complicated when back-
ground tumor incidence is present and presumed to be
induced by a mechanism or mechanisms distinct from
that associated with the chemical under study. In this
instance the various mathematical models may fit the
observable data equally well and still generate low-dose
risk estimates that may differ by many orders of mag-
nitude. On the other hand, if background additivity is
assumed, i.e., ifit is presumed that there is a common
mechanism of tumor induction, then all models are es-
sentiallylinearinthe low-doseregion (734). Evenifonly
asmallportionofthebackground incidence is associated
with the same mechanistic process as the study chem-
ical, linearity will tend to prevail at sufficiently low
doses (742).
All ofthe preceding discussion has implicitly assumed
that the carcinogenic dose-response relationship of in-
terest is that which associates the probability oftumor
onset with the administered dose or exposure levels.
However, in the case of experimentally-derived data,
saturation ofcritical enzyme systems may occur at high
dose levels, and so the real dose ofinterest may be the
biologically effective dose that reaches the actual target
site. Since the relationship between the effective dose
and the administered dose may be non-linear, phar-
macokinetic considerations can significantly modify low-
dose risk estimates regardless of the model employed
(519,520,743,744). Incorporation of mechanistic and
pharmacokinetic data as well as information on target
organ dose, when it is available, may, therefore, sig-
nificantly enhance the usefulness ofmathematical mod-
eling procedures. In addition, consideration ofany data
on dose-dependent changes and differences in metabo-
lism and repair, and appropriate adjustment for partial
lifetime and intermittent exposure and competing risks
mightalsoreduceuncertainty associated withthe math-
ematical modeling process.
Other Estimation Procedures. Traditionally, the
approach to quantitative hazard evaluation for noncar-
cinogenic, toxicological endpoints has been based on the
use of safety factors. With a safety factor approach, an
"acceptable" exposure level is determined by dividing
the no-observed-effect-level (NOEL) from laboratory-
based chronic toxicity tests by an appropriately chosen
safetyfactor. Intheory, the safetyfactorthatisselected
attempts to reflect both the possibility of an increased
sensitivity ofhumans relative to laboratory animals and
the variation in susceptibility within the human popu-
lation.
In spite of its common use, there are a number of
potential problems associated with the safety factor ap-
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proach. The observation ofno treatment-related effects
at a given dose level may depend, at least in part, on
the number ofanimals exposed at that particular level.
Furthermore, the determination ofa NOEL ignores the
shape ofthe dose-response curve, even though it would
seem that a curve that has a shallow slope in the ex-
perimental NOEL region potentially represents a
greater toxicological hazard than one that rises steeply
in this region. In addition, there is no biological justi-
fication for the general use ofany specific safety factor.
Another important consideration that would argue
against the use of a safety factor approach in cancer
risk assessment is the fact that this approach assumes
the existence ofatrue populationthreshold belowwhich
no adverse effects can occur. Even if the concept of
individual thresholds could be supported, the well-rec-
ognized genetic variability in the human population
would effectively prevent the estimation of a general
population threshold value. Moreover, given the high
level of background cancer present in the human en-
vironment, it seems unlikely that one could rule out the
possibility that a new chemical exposure, however lim-
ited, might augment an already ongoing mechanistic
process and thereby produce a collective or additive
exposure that exceeds the unknown threshold level
(745). While recent attempts to categorize carcinogens
as acting directly or indirectly on the genome have re-
newed interest in the possible use of the safety factor
approach, most scientists believe that there is not suf-
ficient biological understanding of these processes to
make such classifications for the carcinogenic effect of
an agent onthe total organism atthe presenttime (746).
Even if this distinction is made, however, the imple-
mentation of a safety factor approach would still be
problematical because of the various limitations of this
procedure that have been discussed above.
Anothermeasure thatisoccasionallyproposed foruse
in cancer hazard evaluation is the relative potency in-
dex. Relative potency calculations are based on stan-
dard measures oftoxicity, such as the effective dose for
50% of the tested group (ED50). Such measures are
limited from an extrapolation viewpoint in that they
attempt to compress an entire dose-response curve into
a single number suitable for comparative purposes.
Therefore, dependingupon which toxicological measure
underlies its derivation, a relative potency index may
offer little insight into the relative risk in the low-dose
region.
Extrapolation ofLow-Dose Risk Estimates to Target
Populations. Low-dose risk estimates derived from
laboratory animal data still must be extrapolated to the
human population. This process is complicated by a va-
riety offactors that differ among species and potentially
affect the response to carcinogenic exposures. Included
among these factors are differences between humans
and experimental test animals with respect to life span,
body size, genetic variability or population homogene-
ity, existence of concurrent disease, pharmacokinetic
effects such as metabolism and excretion patterns and
exposure regimen.
The traditional approach to the species extrapolation
issue has been to use some standardized baseline for
making interspecies comparisons. Commonly employed
standardized dosage scales include mg/kg (body
weight)-day, ppm in the diet or water, mg/m2 (body
surface area)-day, and mg/kg (body weight)-lifetime.
The choice of a particular dosage scale will obviously
affectthemagnitude ofthe projected risk. Forexample,
calculating average daily dose on a body weight rather
than a surface area basis can reduce the estimated hu-
manriskbyapproximately 6-foldwhenratdataareused
for modeling human response and up to 14-fold for
mouse data (588). A number of studies (747-749) have
used the few epidemiologic and laboratory data sets
available in the literature involving comparable carcin-
ogenic exposures to evaluate the relative reliability of
these various scales for animal-to-human extrapolation.
While no single scale emerged as the clear choice in all
cases, it does appear that the best agreement between
observed and predicted human cancer risk is often ob-
tained when a mg/kg-day or a mg/m2-day dosage scale
is employed (748,749). However, it must be emphasized
that experience in this area is very limited and that the
use of any standardized dosage scale for species scale-
up is only a crude approximation to a more detailed
adjustment that considers the spectrum of factors that
can lead to differential speciesresponses. Furthermore,
recent research (750) into this issue has indicated that
the previously observed (749) strong quantitative cor-
relation ofvarious agents'carcinogenicpotenciesinmice
and rats may be explained by a corresponding corre-
lation ofmaximum tolerated dose levels for these same
agents. Thegeneralimplications ofthisfindingforquan-
titative species extrapolation are not fully understood
at this time.
In addition to the empirical comparisons discussed
above, there are a number ofbiological issues that bear
onthechoice ofaparticulardosage scaleinspecies scale-
up. For example, it may be important to know whether
the parent compound, one or more of its metabolites,
or some combination of the two, is responsible for the
observed carcinogenic activity. Similarly, the nature of
the biochemical target site and the various factors de-
termining the rate, duration, and extent of the toxico-
logic reaction may be relevant to the selection process.
However, while any meaningful information on the un-
derlying carcinogenic mechanism(s) should, if possible,
be taken into account when choosing a dosage scale,
such specific information often will not be available.
While no extrapolation across species is involved
when epidemiological data are used in risk estimation,
the marked variability in human sensitivity must be
taken into account. Furthermore, there are a number
of other problems that may be encountered with at-
tempting to use epidemiological data to construct esti-
mates of lifetime risk for a subset of the general pop-
ulation. In the absence of specific knowledge about the
synergistic or antagonistic potential of the exposure of
interest, additivity ofeffects is often assumed. This as-
sumption can lead to either an under or over estimation
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ofthe true carcinogenic risk presented by the exposure
under consideration.
Epidemiological investigations are often conducted
for only a limited period of time, and failure to adjust
properly for incomplete follow-up of subjects can sig-
nificantly affect the estimation of life-time risk. Simi-
larly, estimation of lifetime cancer risks is also compli-
cated if the available epidemiologic data involve
exposures that fall far short of a normal lifespan. For
example, if a multistage mechanism is assumed, then
the effect of early termination of exposure will be de-
pendent on the stages of the carcinogenic process that
are influenced by the exposure (553,751).
RISK CHARACTERIZATION. The final step intherisk
assessment process, risk characterization, typically in-
volves amultidisciplinary evaluation ofallrelevant data
including the qualitative evidence regarding the likeli-
hood thatthe chemical inquestion poses ahumancancer
hazard, available information on potential or actual hu-
man exposure, and the quantitative results of dose re-
sponse and species extrapolation modeling. The
strengths and weaknesses, the biologicalrelevance, and
the quality of all data used to develop the characteri-
zation of the human cancer risk associated with antici-
pated or known exposures should be considered, and an
attempt to qualify or quantify the various uncertainties
in the characterization of risk should be made when
possible.
As discussed earlier, the qualitative evidence is eval-
uated by a weight-of-the-evidence approach. Uncer-
tainties in the data are resolved using best scientific
judgment. While no overall measure can be given ofthe
uncertainty, the decision-maker needs to be aware of
the strengths and limitations ofthe qualitative data in-
volved in the risk characterization process. The results
of a total risk assessment should be expressed in such
a way that there is a clear distinction drawn between
a chemical for which the qualitative evidence is over-
whelming and a chemical for which the qualitative evi-
dence is only marginally persuasive.
As developed in the section on chemical exposure as-
sessment, the exposure assessment may contain nu-
merous uncertainties. For example, the assessment
may reflect inherent limitations, such as those associ-
ated with analytical monitoring ormodelingtechniques.
Further, assumptions are sometimes necessary in the
absence ofdatainordertogenerate anassessment; e.g.,
the amount of soil ingested by a child. In many such
instances, "worst case" assumptions are made in an at-
tempt to err on the side ofpublic safety. The exposure
assessment shouldbeexpressed insuch awaythatthese
uncertainties and assumptions are evident to the deci-
sion-maker.
Description of uncertainty is also important in the
development of the quantitative estimates from dose-
response and species extrapolation modeling. Unfor-
tunately, the description of uncertainty in this step of
the assessment process has often been limited to a de-
scription of the statistical uncertainty involved in low-
dose extrapolation as expressed through the calculation
of confidence limits for risk estimates.
As has already been noted, the choice ofa particular
low-dose extrapolation model can have a pronounced
influence on the estimated low-dose risk. Therefore, it
has been proposed (752) that an indication of the vari-
ability introduced by model selection be obtained by
consideringthe range in the magnitude oflow-dose risk
estimates associated withthemore commonly employed
models.
Furthermore, if laboratory data are utilized in esti-
mating low-dose risk, some attempt can be made to
describe the biological variability associated with the
process of species scale-up by contrasting estimates
based on different dosage scales and animal test sys-
tems.
Finally, it is important in the characterization of hu-
man cancer risk to summarize briefly anyjudgments or
assumptions that may have entered into the risk as-
sessment process to insure that they are clearly differ-
entiated from scientific fact (1).
Emerging Areas ofScience Expected to Impact on
Regulatory Actions*
Although no one can predict with certainty what and
when major breakthroughs will occur in science, many
emerging areas of science can be expected to signifi-
cantly affect cancer risk assessment and related regu-
latory decisions in the future.
Greater knowledge of the metabolic pathways of
chemical compounds and the pharmacokinetics of such
agents in various animal species should help regulatory
agencies to ascertain better whether carcinogenicity
tests have been performed in an animal assay system
which is relevant to man. Information on metabolic
pathways for activation ofa chemical carcinogen known
to be important in humans but not present in the animal
assay system used willinfluencethe dataevaluation and
interpretation forhumanriskestimation. Similarly, fac-
tors such as diet, age, stress, sex, hormonal status, etc.
can influence the metabolic conversion of chemicals to
ultimate carcinogens and may be important in hazard
evaluations conducted on proposed compounds.
DNA adducts remaining in organs in vivo, in the ab-
sence oftumors in a test animal species, may be innoc-
uous; may indicate physiological peculiarities in the test
system that prevent progression to overt tumors; or
may suggest that overt manifestation to neoplasm has
yet to take place. Such inhibitory factors may or may
not be present in other assay systems or in man. Al-
ternatively, failure to demonstrate tumor formation
may indicate the need for promoter activity or inter-
action with other modifying agents. Substantial adduct
formation without resulting biological manifestations
may suggest either that the lesions induced are innoc-
uous or dictate that more testing is needed to access
the human exposure experience (i.e., multiple exposure
factors, promoting agents, nutrition, etc.). In any
*Although the full committee participated in the framing of this
subsection, primary responsibility was assumed by Drs. R. W. Hart
and A. Turturro.
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event, it is evident that additional research is required
to define more precisely what DNA adduct formation
means in term of human risk.
Most prescreen assays for chemical carcinogens pres-
ently rely primarily on chemical interaction with DNA
(point mutation assays, DNA damage and repair). This
approach may be inadequate, since certain chemicals
may not induce cancer by direct interaction with the
DNA. New assays for carcinogenicity are being devel-
oped to include animal models where these factors can
be taken into consideration inthe evaluation ofchemical
agents.
Since tumor induction is generally considered to be a
multistage process, each stage may be under indepen-
dent genetic control. Test systems are being developed
and used that are based on animals believed to be de-
fective in genetic factors similar to those defects that
predispose humans to cancer induction. Such test sys-
tems may also be used to screen sensitivity to selected
carcinogens for subpopulations of humans with similar
genetic characteristics.
A relationship seems to exist between altered DNA
and carcinogenesis. The presence ofcarcinogen-altered
DNA is being explored as a possible test system to
detect persistent damage at the molecular level after
exposure to suspect carcinogenic chemicals. Such a sys-
tem could be used to screen exposed human populations
for altered DNA bases using monoclonally derived spe-
cific antibodies to modified bases. Such assays may also
help place in perspective effects on the DNA arising
fromendogenous vs. exogenous DNAdamagingagents.
This screening would be an example ofusing a marker
for altered cells important to the carcinogenic process.
Additional bio-markers should be developed for cells in
all stages of carcinogenesis. Such tests might be ex-
pected to identify the carcinogenic potential of suspect
agents and the population(s) at risk for possible future
development of cancers.
Certain DNA base alterations may occur in regions
of the genome that currently seem to be unimportant
for carcinogenesis. It is important to know which al-
terations are necessary for initiation ofa tumor cell and
which are masked or not expressed. Information is
being assimilated on types of alterations in "control"
regions and the relationship of the number of altered
bases in these regions to tumor formation. These data
shouldprovideinformationneededtodifferentiatethose
insults to DNA that are critical from those that are not.
Ifmulticritical sites must be altered in aparticular man-
ner, this approach may be used to examine multistage
phenomena of cancer. The measurement of risk from
particular carcinogens at the cellular level would then
be based on a more selective effect than the level of
total DNA adducts.
Other areas of research that may in time have an
effect on regulatory decisions include the development
of model systems to assay for compounds influencing
promotion and progression ofinitiated populations, elu-
cidation of factors controlling cellular differentiation,
and tests for chromosomal rearrangements and onco-
gene activities and the development ofcomputer-based
techniques for both the identification ofthe portions of
molecules that are important in carcinogenesis and the
modeling of animal (the "computer mouse") and human
response to tumor induction. Each of these areas of
study will not only expand our knowledge of mecha-
nisms but may also permit a more realistic assessment
of risk. Besides improving assessment, increased
knowledge of mechanism may also result in a greater
ability to render carcinogenic agents biologically innoc-
uous, removing hazards.
Summary
The assessment ofhuman cancer risk associated with
different chemical exposures is seen to be a complex
mixture of currently available scientific data, assump-
tions and judgments based on prevailing scientific
thought, and policy decisions. The process involves the
identification ofpotentialhumancancerhazards, usually
based on epidemiological, clinical, and long-term animal
studies, the determination ofpotential human exposure
profiles, the estimation ofthe unknown, underlying re-
lationship between exposure and response, and, finally,
the combination ofthe results ofthese exercises to char-
acterize the expected human cancer risk. Some degree
of uncertainty is involved in all phases of this process,
and as a result, no simple, standardized format has yet
been developed for evaluating human cancer risk, even
though a number of basic principles have emerged. It
is apparent that human cancer risk assessment is still
in an evolutionary state and that a number ofemerging
areaas of science will impact on this process in the fu-
ture.
Appendices
Appendix A: FDA Information Sources for
Exposure Estimates
Survey, epidemiological, toxicological, and analytical
data used by the FDA in determining the human health
consequences of exposure to many of the categorical
agents which the agency regulates are derived from a
variety of sources. For example, NIOSH and OSHA
provide data on occupational exposure and CDC pro-
vides data for a variety of exposure sources. The sci-
entific literature and various reports provide a wide
variety ofanimal and human data. In addition, data are
obtained on types and amounts of foods eaten, concen-
tration offood contaminants and human health effects.
Food Consumption
Some principal sources of food consumption data in-
clude: the U.S. Department ofAgriculture (USDA) Na-
tionwide Food Consumption Survey (NFCS); the Na-
tional Health and Nutrition Examination Survey
(NHANES); and the Market Research Corporation of
America (MRCA) survey data. Sources of food compo-
sition data include: USDA: Handbook 456, Handbook
8, National Nutrient Data Bank file; NHANES: Model
Gram and Nutrient Composition files; and MRCA: Lead
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content of foods and methylxanthine content of foods
(based on data from Total Diet Study and industry).
Additional information on some ofthese sources is pro-
vided in the following discussions.
NATIONWIDE FOOD CONSUMPTION SURVEY. The
results of the Nationwide Food Consumption Survey
(NFCS), 1977-78, provide data on the kinds and quan-
tities offoods and nutritive values of diets ingested by
men, women and children ofdifferent ages classified by
various household characteristics. Dietary information
obtained for individuals included the kind and amount
of each food eaten; the time the food was eaten, the
type of service, and the cost. Individuals were also
asked if the day's intake was typical and if they were
on a special diet, were vegetarians, or took vitamins,
minerals, or other supplements. Reported are average
intakes per day and per eating occasion for foods most
commonly eaten by individuals who participated for 3
days in the NFCS conducted by the U.S. Department
of Agriculture.
NATIONAL HEALTH AND NUTRITION EXAMINATION
SURVEY. Data were collected for NHANES II
through response to questionnaires on medical history,
food consumption, and health-related behavior. Data
also were collected through direct medical examination.
NHANES II was conducted onanationwide probability
sample ofapproximately 20,000 persons ages 6 months
to 74 years from the civilian non-institutionalized pop-
ulation ofthe United States. Food consumption data is
ofthe formofquantities offoodconsumed andfrequency
of eating in a 24-hr recall period.
MARKET RESEARCH CORPORATION OF AMERICA
SURVEYS. One of the largest proprietary surveys of
food intake is one conducted by the Market Research
Corporation ofAmerica (MRCA). This corporation con-
ducts the Menu Census survey which is designed to
collect detailed information for one year on the ultimate
disposition of all food products in terms of their con-
sumption by individuals or their use in preparation of
other dishes consumed by the individuals. Only infor-
mation on frequency ofeating is reported; that is, quan-
tities are not included. Each Menu Census consists of
4000 households. Each household reports all food prep-
aration and consumption at home and away from home
for 14 consecutive days in daily diaries. Brands and food
packaging materials are also described. The sample is
balanced within each quarter as closely as possible to
the U.S. Census by various demographic characteris-
tics, includingregion, household size, householdincome,
and other socioeconomic variables. Pertinent compari-
sons among these three data sources are given in Table
A-1.
The Total Diet Studies monitorlevels ofchemical con-
taminants and essentialminerals intablereadyfood and
consider dietary intake of these substances by various
age-sex groups. The Total Diet Study is an annual pro-
gram which involves the purchase ofapproximately 200
foods in grocery stores across the United States and
the analysis ofthese foods for essential minerals, toxic
elements, radionuclides, industrial chemicals and pes-
ticides. The food list and diets, beginning in April 1982,
were revised to reflect the present food supply and the
current food consumption habits. The number of age-
sex groups was increased to eight (infants, young chil-
dren, male and female teenagers, male and female
adults, and male and female older persons) in order to
expand the coverage ofthe U.S. population. Foods were
analyzedindividually, ratherthanincommoditygroups,
to obtain information on the contribution of specific
foods to the daily intake ofminerals and contaminants.
The diets are based on data from the 1977-78 USDA
NFCS and the NHANES II carried outby the National
Center for Health Statistics in 1976-80. Two hundred
and thirty-four foods are collected from fourgeographic
regions (northeast, south, west, and north central) and
analyzed by the Kansas City Field Office Laboratory
for 11 essential minerals and more than 120 chemical
contaminants. The essential minerals analyzed for are:
copper, iron, magnesium, manganese, potassium, phos-
phorus, calcium, sodium, iodine, selenium, andzinc. The
daily intake by weight of these 234 foods has been
weighted to represent 100% of the usual diet for the
eight age-sex groups. These estimated food intakes are
used to assess daily contaminant and mineral intake.
FoodAdditives
There are two major data bases. The National Acad-
emy ofScience (NAS) Surveys provide the agency with
a data base for the concentration of additives used in
food. To ensure confidentiality, the NAS maintains the
raw data from the surveys. These data have been ob-
tained from mailed questionnaires that have been sent
to over 2000 firms with approximately 1100 responding.
The values obtained from the NAS are used as the sub-
stance concentration value in estimating intakes.
The surveys approach the question of usage of food
additives from two directions: how much poundage is
used annually and what is the level ofuse in each ofthe
firms' products.
TheBureauofFoods'databaseforfoodadditives com-
prises food additive safety information for substances
added directly to food inthe United States. Nearly 1600
items (over 1300 synthetic flavoring substances, nearly
300 direct additives, and some 70 color additives and
color diluents) supply data on human exposure levels,
chemical structure, and toxicological parameters. The
computer database is searchable by software programs
that permit sorting of the data on many parameters,
including lowest effect levels, test animal species, tox-
icological effects and organ sites, as well as exposure
and chemical structure categories.
This database comprises one module ofthe Bureau's
SIREN (Scientific Information Retrieval and Exchange
Network) system, the othertwo beingthe food additive
information system (FAIS) and the new animal drug
informationsystem (NADIS) containingover 1/2million
indexed records across two FDA bureaus.
Census Data
Census data on the count and characteristics of the
population are obtained from the Bureau ofthe Census.
The agency has census files for 1960 and 1970 for the
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Table A-i. National food consumption surveys.
MCRA Menu Census VI
Characteristic USDA NFCS 1977-78 NHANES II 1976-80 1977-78
Sample size 30,770 20,332 11,150
Length of dietary survey 3 days 1 day 14 days
Dietary methodology 24-hr recall (one-day) 24-hr/recall Daily diary
records (two days)
Collection methodology Recall: interviewers record: Interviewer Self-administered via mail
self-administered
Reporter Individual subject Individual subject Main food preparer
Place of recording Home Mobile exam center Home
Food quantities Yes Yes No
Drinking water Yes No No
Processing/packaging No No Yes
information
Other surveys in this series 1965-66 1971-74 1957-75
total population counts for each U.S. county or county
equivalent, such as independent city, and within each
county equivalent by sex, race, and 5-year age interval.
These data are used in calculating rates in the popula-
tion. Population estimates for the years 1971-1978 are
available.
Fish Intake Data
Fish intake data are important to FDA in regulating
food safety and has been used in evaluating the hazard
ofmercury, dioxins, and othercontaminants offish. The
sources ofnational fish production data are the National
Marine Fisheries Service (NMFS) and the USDA.
NMFS calculates an annual estimate of the per capita
consumption of seafood from data on the total catch of
commercial seafood. The estimate does not include com-
mercial fresh water fish, i.e., recreationally caught fish
sold at roadside stands. The NMFS also supplies a da-
tabase on the mercury content found in fish. The USDA
calculates annual per capita fish intake by adding an
estimate ofrecreationally caught fish and the othertype
ofdatatothecommercial seafoodproduction tocalculate
the total fish consumption.
Natural Toxicants
A computerized natural toxicants literature file is
maintained which contains reprints of articles relative
to the occurrence and health effects of mycotoxins, in-
cluding plant and marine toxins. In addition, informa-
tion is maintained on the level ofmycotoxins in various
commodities in the U.S.
ElementalAnalyses
Data from the U.S. Geological Survey on elemental
analysis of soils, waters, and vegetation provide back-
ground information on geographic differences in ele-
ments likely to be in the human diet.
Special Studies
Consumer interview surveys are conducted periodi-
cally on topics of special interest, which may grow out
of immediate or potential health risks to the public or
the need forinformation not currently available in areas
of regulatory concern to the agency. The studies are
designed internally, executed under extramural con-
tract and the data are delivered on computer tape for
internal tabulation and analysis.
Literature
A bibliography file of articles written by FDA em-
ployees is maintained. This file together with a com-
puterized cross index contains articles on such subjects
as analytical methods and food contaminant levels.
Appendix B: Exposure Assessment at EPA
Introduction
An exposure assessment is that process which seeks
to define the quantity of a chemical which comes into
contact, or may come into contact, with human popu-
lations. This integral portion of the risk assessment is
a growing technical speciality whose complexity has
long been noted but has only recently been addressed
using the sophisticated scientific tools available
(588,589).
The process involves consideration ofthe magnitude,
frequency and duration of encounters between individ-
uals and the chemical in question. In some instances
(e.g., prescribed dosing with drugs), the information is
ratherpreciselyknown. Inthe case ofexposuretochem-
icals of environmental concern, however, the assess-
ment process is often associated with a dearth of data
and assumptions/approximations must be made to fill in
the gaps. For example, while some data may be avail-
able on the "direct exposure" from the emissionsof a
manufacturing plant, estimates of the "indirect expo-
sure" resulting from potential bioaccumulation in the
food chain may be less precisely known.
In recent years, data bases have been compiled, com-
puter models developed, laboratory/field measurement
taken and "standard operating procedures" adopted
(1,590,591) that have narrowed the uncertainty asso-
ciated with some of these estimates.
Defining the Exposure
Before beginning an exposure assessment, it is nec-
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essary to define clearly the product needed in terms of
purpose, breadth, depth and approach. This conceptual
scheme is being developed in detail by the EPA
(586,587).
Depending on the answers provided to these ques-
tions, different resources are available to construct the
exposure assessment. Some of the more important re-
sources are discussed below.
Monitoring
In many cases, site-specific monitoring is performed
in order to generate qualitative or quantitative data for
an exposure assessment, e.g., more than 5000 water,
soil, and sediments samples have been analyzed for the
presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the
state of Missouri; groundwater and vertical soil cores
have been analyzed for ethylene dibromide in Hawaii,
California, and Georgia; and stack emissions have been
sampled for heavy metals.
In addition to site-specific information, qualitative
and quantitative exposure information is available from
the various monitoring networks which have operated
over the years to collect data on chemicals in different
environmental media. For example, the Mussel Watch
Program (612,618) has analyzed shellfish in the U.S.
estu-arine waters for a variety of pollutants. Shellfish
are filter feeders and are generally efficient bioconcen-
trators of water contaminants; the residues in these
organisms serve as sensitive markers for upstream pol-
lution of waters which feed the estuaries.
In addition, great quantities of analytical chemical
information on U.S. waters can be accessed through the
computer data base, STORET. These data represent
information gathered over the past years from every
major watershed in the U.S.
Increasingly, the problem of groundwater contami-
nation is of concern. Little systematically collected in-
formation on this environmental compartment is avail-
able atthistime, although moreeffortisbeingexpended
to identify and quantitate levels of certain chemicals
such as aldicarb and ethylene dibromide at selected
sites.
EPA has gathered information on atmospheric pol-
lutants for many years. As part of the national efforts
to the quality of the ambient air, innumerable mea-
surements have been made at various times and loca-
tions on certain pollutants, namely carbon monoxide,
sulfur oxides, nitrogen oxides, particulates, hydrocar-
bons, and photochemical oxidants. Much of this infor-
mation is available in computer files maintained by
EPA, Office of Air Programs, in Research Triangle
Park, NC.
In a broader perspective of"monitoring"-where the
chemical is in the environment-EPA's Office of Toxic
Substances maintains and has access to files which iden-
tify chemical substances which are manufactured in or
imported into the U.S. Some types ofgeototal produc-
tion figures are generally available, along with graphic
information on the location ofproduction sites. This in-
formation is useful in generating a "material balance"
ofa chemical (a complete accounting ofsources and dis-
position of a chemical in the environment).
EPA often relies on data generated by other Federal
agencies (e.g., FDA, NIOSH and the Department of
Labor) to estimate the exposures likely to be encoun-
tered from eating food or being in the workplace.
Increasingly, interest is expressed in determining
more direct mreasurement of human exposure to en-
vironmental pollutants. Foryears, EPAhas maintained
the National Human Adipose Tissue Network which
collects adipose tissue from selected cadavers in such a
wayastoobtain arigorous statistical sample ofthe U.S.
population. These tissue samples are analyzed for a va-
riety of organic chemical residues so that trends and
potential problem chemicals can be identified. Further,
the Agency publishes a summary ofstudies, onresidues
in humans, which have appeared in the scientific liter-
ature on residues in humans.
An ambitious program underway at the EPA, called
the Total Exposure Assessment Methodology (TEAM)
study (625-630), combines personal monitor results
(593) with analyses of food, beverages, water, human
blood plasma and serum, urine, breath and mothers'
milktocharacterizetheindividualexposure oflargetest
populations to a variety of organic chemicals over ex-
tended periods oftime. Such data also will be useful in
determining what portion of a particular chemical is
actually absorbed by the body and how absorption var-
ies from one individual to another at different exposure
levels. The actual dose of a chemical which determines
the health outcome from the exposure is often different
from the apparent exposure level (753). The goal ofthe
TEAM program is to develop an individual exposure
monitoring methodology for use in estimating popula-
tion exposures, includinganalytical chemicaltechniques
ofprovenaccuracyandreliability, toolsforconveniently
collecting detailed information on the activities of in-
dividuals on a24-hr aday basis, and tools formanaging,
analyzing, and interpreting the data produced by such
studies.
In sum, the Agency has broad environmental moni-
toring data on a number ofchemical substances in var-
ious media. The information too often is not sufficient
in depth, detail, and validation to provide precise data
in a given exposure situation. Furtheruncertainties are
introduced when attempts are made to extrapolate
these data to absorbed dose. Therefore, while the
Agency is indeed building an exposure data base, the
range of uncertainty surrounding any exposure situa-
tion can be significant.
Modeling
The questions of "indirect exposure" often center on
the transformation, transport, and ultimate fate of a
chemical once itis released into the environment. While
direct monitoring can provide some data in this regard,
important detailed questions of chemical kinetics, dis-
tribution between media, potential uptake by biological
organisms, and the like cannot easily be derived from
such information.
Two approaches to filling this gap are through the
use ofmicrocosms and through the use ofmathematical
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modeling.
MICROCOSMS. A microcosm is a recreation ofa por-
tion of the environment in the laboratory-a physical
model ofnature. Ideally, the nmicrocosm faithfully mim-
ics the processes occurringinnature. Byaddingachem-
ical to such a system, its subsequent partitioning
amongst the components of the environment, together
with the associated chemical and biological conversion,
can be studied in a single integrated experiment.
Marine, freshwater, terrestrial, atmospheric, and
subsurface oraquifermicrocosms are available and have
demonstrated utility. Much of our knowledge of the
chemistrywhich occurs inthe atmosphere has beengen-
erated using smog chambers (639,671), i.e., atmosphere
microcosms. Marine microcosms are now being used to
understand the complex processes which affect the fate
of a chemical in the ocean where it can be transformed
by the benthate community, and eventually concen-
trated up the food chain leading to human food (672-
675). Terrestrial microcosms are being used to define
more precisely the fate of a chemical on soil-plant-
water systems (676-678). Subsurface or aquifer micro-
cosms have been created using special drilling tech-
niques which allow a column ofmaterial to be removed
from an aquifer in an undisturbed and uncontaminated
state (689). Such columns are then used to study the
chemical and biological conversions underground.
One of the continuing questions raised about micro-
cosms is how well do their results actually mimic what
would occur in the "real" environment itself. In recent
years, increased effort has been aimed at validating
these systems and gaining an appreciation of the limi-
tations of their data. At this time, however, the risk
assessor must recognize this inherent potential source
of error.
MATHEMATICAL MODELING. One of the most fre-
quently used tools in exposure assessment is mathe-
matical modeling. Most such models begin as an effort
to describe theoretically the phenomena observed inthe
laboratory or field. Large monitoring data bases are
used to construct mathematical relationships between
variables of concern (e.g., meteorological parameters
and the temporal/spacial distribution ofchemicals emit-
ted from a source). These relationships constitute the
model which, because ofthe inherent complexity, often
requires a computer for its use. Models are predictive
tools used when direct measurement ofexposure would
be prohibitively time consuming and/or expensive and
whenthe relationship between the sources ofa chemical
and the eventual exposure is complex.
Giventhewidevarietyofpossible situationsrequiring
exposure assessments, it is not surprising that many
different models have been developed. A recent catalog
of the models available for use in regulatory decision-
making (640) identified 156 models, most of which can
be applied to exposure assessments (641,642). A de-
scription of the general features of some advanced
models is informative (644).
Ambient air modeling has reached the highest level
of complexity with a capability for considering numer-
ous point, line, and area emission sources simultane-
ously (645-647). Several models (643) predict the com-
plex chemical conversions occurring in air during
transport of pollutants. One model allows prediction of
the half-life and reaction products for an organic chem-
ical in air (648). Models currently under development
address the problems of predicting exposure on a re-
gional basis (649) and in areas with rough terrain (650).
The Handbookfor Performing Exposure Assessments
(754) lists a number of routinely used air models avail-
able through NTIS.
Models are also available for the indoor air environ-
ment. The-breadth and complexity of such modeling
varies in proportion to the complexity of the environ-
ment being modeled. Even a single room or residence
model may become quite complex when considerations
of air filter efficiencies, particulate agglomeration/plat-
ing-out, nonspecific heterogeneous decay of reactive
pollutants, multiple sources, sinks and varying source-
strengths are encountered. Additional difficulties ofas-
sessing infiltration rates, and the partitioning of ven-
tilation rates amongdiscrete volumes in abuilding have
led to the use ofcompartmented models (651). The con-
tribution of varying levels of ambient pollutants to the
indoor environment has been evaluated by a time-seg-
mented model which has undergone limited field vali-
dation (693).
As a result of the Great Lakes research program
(652-656) and research into the environmental fate of
pesticides (657,658), models are available which de-
scribe the movement ofchemicals in fresh wateraquatic
environments. Studies on the ocean disposal of munic-
ipal wastes have led to models for chemicals in coastal
waters (659-661). Recent work on terrestrial micro-
cosms has provided input data for a terrestrial model
(662) which includes consideration of plant uptake. A
number ofmodels are available which describe leaching
and runoff of chemicals to streams (640). The newest
areas ofmodeling are ground water (619,663-667), hu-
man microenvironments and activity patterns (668-
670), food consumption (576), and multimedia environ-
mental partitioning (755,756).
As models increase in complexity, the ability to pre-
dict exposure generally becomes more accurate. This
additional accuracy, however, is purchased at the price
ofadditionalinputdata(694). Thechoice ofmodelsavail-
able for a particular assessment may be reduced by a
limited data base.
In general, models are most helpful when rough es-
timates ofexposure arerequired. Eventhoughthe level
ofsophistication ofa particular model may be high, the
predictions are still crude because anymodelis an over-
simplified description ofthe natural phenomenon it de-
picts. There is aneedformoreresearch tovalidatemost
models, since the accuracy of the exposure estimates
made by models can be no betterthan the quality ofthe
input data: The use of models does not compensate for
poor input data, but in certain instances may obscure
the true uncertainty inherent in the exposure predic-
tions. In sum, the modeling as well as in monitoringthe
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Agency can obtain valuable information. At the same
time it needs to be recognized that this information
might be accompanied by potential significant uncer-
tainties. Nevertheless, the use ofscientific judgment in
interpreting results is essential.
Appendix C: Chemical Exposure
Assessment for Consumer Products
Assessing human exposure to toxic chemicals from
consumer products is a vital part of CPSC's chemical
hazard work and is the element which most distin-
guishes CPSC's efforts from the activities ofother Fed-
eral agencies. The range ofuses ofchemical compounds
in consumer products is great and the ways that con-
sumers utilize a single product may vary considerably.
For example, the techniques required for assessing ex-
posure to a gas that may be emitted from building ma-
terials into home air and for a dye or other agent con-
tained in cloth that may contact the skin have little in
common. Most experience in exposure assessment from
products has been gained over the past few years. Be-
cause of this, CPSC approaches exposure assessments
on a case-by-case basis with each study in general re-
quiring original experimental or theoretical work.
Nonetheless, the general activity of exposure assess-
ment can be described as a four step process:
(1) Determine the fact of the release of a compound
from products and estimate the quantity ofrelease. The
degree of difficulty of this step can vary greatly. For
example, it is straightforward if the compound of in-
terest is contained in an aerosol product. It mayrequire
extensive experimental study if the compound is con-
tained in a plastic matrix that is subjected to a variety
ofuses. More often than not in CPSC's experience, ex-
perimental studies are required. The presence ofa com-
pound in aconsumerproduct does notimplythatrelease
actually occurs.
(2) Relate the quantity of release with the level of
human exposure (to the outside of the body) from use
of the products. A series of analyses are required for
this step. First, use patterns for the products must be
determined; both the most typical use patterns and
those that could lead to lower or higher degrees of ex-
posure must be considered. Experience of staff, infor-
mation from industry, and consumer surveys can pro-
vide this information. Then, for each specific use, the
data on chemical release must be used to estimate the
actual amount ofcontact the user has with the chemical.
Forachemicalemittedintothehomeair, dataonrelease
rate, use patterns, home volume, and air exchange rate
can be combined in a mathematical model to estimate
the average and peak levels in the air. On the other
hand, an experimental study couldbe conducted tomea-
sure actual air levels from a certain product use. As
another example the quantity ofaliquid that comes into
contact with skin can be measured.
(3) Determine the entry ofthe material into the body.
This step can be straightforward if the toxicity infor-
mation on a chemical was obtained by a route of ex-
posure comparable with consumer use. On the other
hand, particularly in the case ofdermal exposures, data
on entry of a compound into the body are frequently
lacking. In that case experimental studies, such as
painting the skin of an experimental animal with a ra-
diolabeled quantity of the compound of interest, may
be conducted.
(4) Combine the data in steps (1) through (3) for a
complete estimate of human exposure to a compound.
This estimate can then be combined with health hazard
information (toxicity) in evaluating human risks; it can
serve as the basis required for a mathematical esti-
mation of risk.
These steps are presented as one sequence, however,
exposure estimation is often an interactive procedure.
One uses available, limited information to make prelim-
inary estimates of risk that may (if sufficiently con-
servative) eliminate concern about an exposure or may
be successively refined by gathering data where it is
most needed.
Inaddition, incertain studies, some oftheabove steps
may be combined rather than considered separately.
For example, a chemically treated cloth may be placed
in contact with the skin of an experimental animal and
the amount of uptake of the chemical by the animal
measured. This experiment provides information that
could separately be obtained by measuring both quan-
tities released from the cloth and rates of penetration
of the chemical through the skin. In another example,
personal air monitoring can take into account both re-
lease rates from products and patterns of product use.
Exposure assessmentforchemicalsinconsumerprod-
ucts is a developing science which makes innovative use
of standard physical and chemical data, demands de-
velopment of new experimental procedures, and com-
bines relatively "hard" experimental data with "soft"
data onwidely varying human behavior patterns. While
each exposure assessment is now a new undertaking,
certain basic techniques (such as air level modeling) are
finding repeated application. In the next several years
the knowledge now being gained should lead to more
readily standardized and more easily performed expo-
sure assessments.
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